<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>gff10k_030215.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: black 1.1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>UNITED STATES</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>SECURITIES AND EXCHANGE
COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Washington,&nbsp;D.C. 20549</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin: 1pt 227.4pt"><DIV STYLE="font-size: 1pt; border-top: black 1.1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center; text-indent: 0in"><B>Form
10-K</B><BR> &nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin: 1pt 227.4pt"><DIV STYLE="font-size: 1pt; border-top: black 1.1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 14pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 4%; text-indent: 0in; font-size: 10pt"><font style="font: 10pt Wingdings">x</font></td>
    <td style="width: 96%; text-indent: 0in; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center; text-indent: 0in"><B>For the fiscal year
ended December&nbsp;31, 2014</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center; text-indent: 0in"><B>OR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 4%; text-indent: 0in; font-size: 10pt"><font style="font: 10pt Wingdings">&uml;</font></td>
    <td style="width: 96%; text-indent: 0in; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.</b></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center; text-indent: 0in"><B>For the transition
period from&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center; text-indent: 0in"><B>Commission File
Number 000-23186</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center; text-indent: 0in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin: 1pt 227.4pt"><DIV STYLE="font-size: 1pt; border-top: black 1.1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center; text-indent: 0in"><B>BIOCRYST PHARMACEUTICALS,
INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>(Exact name of registrant
as specified in its charter)</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin: 1pt 227.4pt"><DIV STYLE="font-size: 1pt; border-top: black 1.1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 51%; text-indent: 0in; font-size: 10pt">&nbsp;</td>
    <td style="vertical-align: bottom; width: 1%; text-indent: 0in; font-size: 10pt">&nbsp;</td>
    <td style="width: 48%; text-indent: 0in; font-size: 10pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; text-align: center; text-indent: 0in; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>DELAWARE</b></font></td>
    <td style="vertical-align: bottom; text-indent: 0in; font-size: 10pt">&nbsp;</td>
    <td style="vertical-align: top; text-align: center; text-indent: 0in; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>62-1413174</b></font></td></tr>
<tr>
    <td style="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-align: center; text-indent: 0in"><b>(State of other
        jurisdiction of</b></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-align: center; text-indent: 0in"><b>incorporation
        or organization)</b></P></td>
    <td style="vertical-align: bottom; text-indent: 0in; font-size: 10pt">&nbsp;</td>
    <td style="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-align: center; text-indent: 0in"><b>(I.R.S. employer</b></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-align: center; text-indent: 0in"><b>identification
        no.)</b></P></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center; text-indent: 0in"><B>4505 Emperor Blvd.,
Suite&nbsp;200, Durham, North Carolina 27703</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>(Address of principal executive
offices)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center; text-indent: 0in"><B>(919)&nbsp;859-1302</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>(Registrant&rsquo;s telephone
number, including area code)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center; text-indent: 0in"><B>Securities registered
pursuant to Section&nbsp;12(b) of the Act:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 51%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: bottom; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="width: 48%; text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td>
        <P STYLE="text-align: center"><B><U>Title of Each Class</U></B></P></td>
    <td style="text-indent: 0in">&nbsp;</td>
    <td>
        <P STYLE="text-align: center"><B><U>Name of Each Exchange on Which Registered</U></B></P></td></tr>
<tr>
    <td style="vertical-align: top; text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif"><b>Common Stock, $.01&nbsp;Par Value</b></font></td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif"><b>The NASDAQ Global Select Market</b></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center; text-indent: 0in"><B>Securities registered
pursuant to Section&nbsp;12(g) of the Act:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center; text-indent: 0in"><B>Title of class</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>None</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin: 1pt 227.4pt"><DIV STYLE="font-size: 1pt; border-top: black 1.1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by a check mark if the registrant is a well-known seasoned issuer, as defined in Rule&nbsp;405 of the Securities Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Wingdings">x</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> &nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by a check mark if the registrant is not required to file reports pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> &nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-right: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by a check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12&nbsp;months (or for such shorter period that the registrant was required to file such
reports), and (2)&nbsp;has been subject to such filing requirements for the past 90&nbsp;days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Wingdings">x</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> &nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by a check mark whether the registrant submitted electronically and posted on its corporate Website, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule&nbsp;405 of Regulation&nbsp;S-T (Section&nbsp;232.405 of this chapter)
during the preceding 12&nbsp;months (or for such shorter period that the registrant was required to submit and post such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Wingdings">x</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> &nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if disclosure of delinquent filers pursuant to Item&nbsp;405 of Regulation&nbsp;S-K (Section&nbsp;229.405 of this
chapter) is not contained herein, and will not be contained, to the best of registrant&rsquo;s knowledge, in definitive proxy or
information statements incorporated by reference in Part&nbsp;III of this Form&nbsp;10-K or any amendment to this Form&nbsp;10-K.&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 0in; text-align: justify">Indicate by check
mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting
company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting
company&rdquo; in Rule&nbsp;12b-2 of the Exchange Act. (Check one):</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 22%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: bottom; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="width: 48%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: bottom; width: 2%; text-indent: 0in">&nbsp;</td>
    <td style="width: 24%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: bottom; width: 2%; text-indent: 0in">&nbsp;</td>
    <td style="width: 1%; text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">Large&nbsp;accelerated&nbsp;filer</font></td>
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in"><font style="font: 10pt Wingdings">x</font></td>
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">Accelerated&nbsp;filer</font></td>
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in"><font style="font: 10pt Wingdings">&uml;</font></td></tr>
<tr>
    <td style="text-indent: 0in">&nbsp;</td>
    <td colspan="2" style="text-indent: 0in">&nbsp;</td>
    <td colspan="2" style="text-indent: 0in">&nbsp;</td>
    <td colspan="2" style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">Non-accelerated filer</font></td>
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in"><font style="font: 10pt Wingdings">&uml;</font><font style="font: 10pt Times New Roman, Times, Serif"> &nbsp;&nbsp;(Do not check if a smaller reporting company)</font></td>
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">Smaller&nbsp;reporting&nbsp;company</font></td>
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in"><font style="font: 10pt Wingdings">&uml;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by a check mark whether the registrant is a shell company (as defined in Exchange Act Rule&nbsp;12b-2).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> &nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Wingdings">x</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> .</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 0in">The Registrant estimates that the aggregate
market value of the Common Stock on June&nbsp;30, 2014 (based upon the closing price shown on the NASDAQ Global Select Market on
June&nbsp;30, 2014)&nbsp;held by non-affiliates was $903,002,038.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 0in">The number of shares of Common Stock, par
value $.01, of the Registrant outstanding as of January&nbsp;31, 2015 was 72,320,136 shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center; text-indent: 0in"><B>DOCUMENTS INCORPORATED
BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 0in">Portions of the Registrant&rsquo;s definitive
Proxy Statement to be filed in connection with the solicitation of proxies for its 2015 Annual Meeting of Stockholders are incorporated
by reference into Items&nbsp;10, 11, 12, 13 and 14 under Part&nbsp;III hereof.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center; text-indent: 0in"><B><U>TABLE OF CONTENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="vertical-align: top; text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif"><b>PART&nbsp;I</b></font></td>
    <td style="vertical-align: top; text-indent: 0in">&nbsp;</td>
    </tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: left"><A HREF="#p1i1"><font style="font: 10pt Times New Roman, Times, Serif">ITEM&nbsp;1. BUSINESS</font></A></td>
    <td style="vertical-align: bottom; text-align: right; text-indent: 0in"><A HREF="#p1i1"><font style="font: 10pt Times New Roman, Times, Serif">4</font></A></td>
    </tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: left"><A HREF="#p1i1a"><font style="font: 10pt Times New Roman, Times, Serif">ITEM&nbsp;1A. RISK FACTORS</font></A></td>
    <td style="vertical-align: bottom; text-align: right; text-indent: 0in"><A HREF="#p1i1a"><font style="font: 10pt Times New Roman, Times, Serif">16</font></A></td>
    </tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: left"><A HREF="#p1i1b"><font style="font: 10pt Times New Roman, Times, Serif">ITEM&nbsp;1B. UNRESOLVED STAFF COMMENTS</font></A></td>
    <td style="vertical-align: bottom; text-align: right; text-indent: 0in"><A HREF="#p1i1b"><font style="font: 10pt Times New Roman, Times, Serif">31</font></A></td>
    </tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: left"><A HREF="#p1i2"><font style="font: 10pt Times New Roman, Times, Serif">ITEM&nbsp;2. PROPERTIES</font></A></td>
    <td style="vertical-align: bottom; text-align: right; text-indent: 0in"><A HREF="#p1i2"><font style="font: 10pt Times New Roman, Times, Serif">31</font></A></td>
    </tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: left"><A HREF="#p1i3"><font style="font: 10pt Times New Roman, Times, Serif">ITEM&nbsp;3. LEGAL PROCEEDINGS</font></A></td>
    <td style="vertical-align: bottom; text-align: right; text-indent: 0in"><A HREF="#p1i3"><font style="font: 10pt Times New Roman, Times, Serif">31</font></A></td>
    </tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: left"><A HREF="#p1i4"><font style="font: 10pt Times New Roman, Times, Serif">ITEM&nbsp;4. MINE SAFETY DISCLOSURES</font></A></td>
    <td style="vertical-align: bottom; text-align: right; text-indent: 0in"><A HREF="#p1i4"><font style="font: 10pt Times New Roman, Times, Serif">31</font></A></td>
    </tr>
<tr>
    <td style="text-indent: 0in">&nbsp;</td>
    <td colspan="4" style="text-indent: 0in">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif"><b>PART&nbsp;II</b></font></td>
    <td style="vertical-align: top; text-indent: 0in">&nbsp;</td>
    </tr>
<tr>
    <td style="text-indent: 0in">&nbsp;</td>
    <td colspan="4" style="text-indent: 0in">&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: left; padding-left: 10pt; text-indent: -10pt"><A HREF="#i5"><font style="font: 10pt Times New Roman, Times, Serif">ITEM&nbsp; 5. MARKET FOR REGISTRANT&rsquo;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</font></A></td>
    <td style="vertical-align: bottom; text-align: right; text-indent: 0in"><A HREF="#i5"><font style="font: 10pt Times New Roman, Times, Serif">31</font></A></td>
    </tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: left"><A HREF="#i6"><font style="font: 10pt Times New Roman, Times, Serif">ITEM&nbsp;6. SELECTED FINANCIAL DATA</font></A></td>
    <td style="vertical-align: bottom; text-align: right; text-indent: 0in"><A HREF="#i6"><font style="font: 10pt Times New Roman, Times, Serif">33</font></A></td>
    </tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: left"><A HREF="#i7"><font style="font: 10pt Times New Roman, Times, Serif">ITEM&nbsp;7. MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></A></td>
    <td style="vertical-align: bottom; text-align: right; text-indent: 0in"><A HREF="#i7"><font style="font: 10pt Times New Roman, Times, Serif">33</font></A></td>
    </tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: left"><A HREF="#i7a"><font style="font: 10pt Times New Roman, Times, Serif">ITEM&nbsp;7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</font></A></td>
    <td style="vertical-align: bottom; text-align: right; text-indent: 0in"><A HREF="#i7a"><font style="font: 10pt Times New Roman, Times, Serif">43</font></A></td>
    </tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: left"><A HREF="#i8"><font style="font: 10pt Times New Roman, Times, Serif">ITEM&nbsp;8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</font></A></td>
    <td style="vertical-align: bottom; text-align: right; text-indent: 0in"><A HREF="#i8"><font style="font: 10pt Times New Roman, Times, Serif">44</font></A></td>
    </tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: left; padding-left: 10pt; text-indent: -10pt"><A HREF="#i9"><font style="font: 10pt Times New Roman, Times, Serif">ITEM&nbsp;9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</font></A></td>
    <td style="vertical-align: bottom; text-align: right; text-indent: 0in"><A HREF="#i9"><font style="font: 10pt Times New Roman, Times, Serif">68</font></A></td>
    </tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: left"><A HREF="#i9a"><font style="font: 10pt Times New Roman, Times, Serif">ITEM&nbsp;9A. CONTROLS AND PROCEDURES</font></A></td>
    <td style="vertical-align: bottom; text-align: right; text-indent: 0in"><A HREF="#i9a"><font style="font: 10pt Times New Roman, Times, Serif">68</font></A></td>
    </tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: left"><A HREF="#i9b"><font style="font: 10pt Times New Roman, Times, Serif">ITEM&nbsp;9B. OTHER INFORMATION</font></A></td>
    <td style="vertical-align: bottom; text-align: right; text-indent: 0in"><A HREF="#i9b"><font style="font: 10pt Times New Roman, Times, Serif">68</font></A></td>
    </tr>
<tr>
    <td style="text-indent: 0in">&nbsp;</td>
    <td colspan="4" style="text-indent: 0in">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif"><b>PART&nbsp;III</b></font></td>
    <td style="vertical-align: top; text-indent: 0in">&nbsp;</td>
    </tr>
<tr>
    <td style="text-indent: 0in">&nbsp;</td>
    <td colspan="4" style="text-indent: 0in">&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: left"><A HREF="#i10"><font style="font: 10pt Times New Roman, Times, Serif">ITEM&nbsp;10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</font></A></td>
    <td style="vertical-align: bottom; text-align: right; text-indent: 0in"><A HREF="#i10"><font style="font: 10pt Times New Roman, Times, Serif">69</font></A></td>
    </tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: left"><A HREF="#i11"><font style="font: 10pt Times New Roman, Times, Serif">ITEM&nbsp;11. EXECUTIVE COMPENSATION</font></A></td>
    <td style="vertical-align: bottom; text-align: right; text-indent: 0in"><A HREF="#i11"><font style="font: 10pt Times New Roman, Times, Serif">69</font></A></td>
    </tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: left; padding-left: 10pt; text-indent: -10pt"><A HREF="#i12"><font style="font: 10pt Times New Roman, Times, Serif">ITEM&nbsp;12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</font></A></td>
    <td style="vertical-align: bottom; text-align: right; text-indent: 0in"><A HREF="#i12"><font style="font: 10pt Times New Roman, Times, Serif">69</font></A></td>
    </tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: left"><A HREF="#i13"><font style="font: 10pt Times New Roman, Times, Serif">ITEM&nbsp;13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</font></A></td>
    <td style="vertical-align: bottom; text-align: right; text-indent: 0in"><A HREF="#i13"><font style="font: 10pt Times New Roman, Times, Serif">69</font></A></td>
    </tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: left"><A HREF="#i14"><font style="font: 10pt Times New Roman, Times, Serif">ITEM&nbsp;14. PRINCIPAL ACCOUNTING FEES AND SERVICES</font></A></td>
    <td style="vertical-align: bottom; text-align: right; text-indent: 0in"><A HREF="#i14"><font style="font: 10pt Times New Roman, Times, Serif">69</font></A></td>
    </tr>
<tr>
    <td style="text-indent: 0in">&nbsp;</td>
    <td colspan="4" style="text-indent: 0in">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif"><b>PART&nbsp;IV</b></font></td>
    <td style="vertical-align: top; text-indent: 0in">&nbsp;</td>
    </tr>
<tr>
    <td style="text-indent: 0in">&nbsp;</td>
    <td colspan="4" style="text-indent: 0in">&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: left"><A HREF="#i15"><font style="font: 10pt Times New Roman, Times, Serif">ITEM&nbsp;15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES</font></A></td>
    <td style="vertical-align: bottom; text-align: right; text-indent: 0in"><A HREF="#i15"><font style="font: 10pt Times New Roman, Times, Serif">70</font></A></td>
    </tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: left"><A HREF="#sign"><font style="font: 10pt Times New Roman, Times, Serif">SIGNATURES</font></A></td>
    <td style="vertical-align: bottom; text-align: right; text-indent: 0in"><A HREF="#sign"><font style="font: 10pt Times New Roman, Times, Serif">71</font></A></td>
    </tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: left"><A HREF="#exh"><font style="font: 10pt Times New Roman, Times, Serif">INDEX TO EXHIBITS</font></A></td>
    <td style="vertical-align: bottom; text-align: right; text-indent: 0in"><A HREF="#exh"><font style="font: 10pt Times New Roman, Times, Serif">72</font></A></td>
    </tr>
<TR>
    <TD STYLE="vertical-align: top; text-align: left; padding-left: 10pt">EX-10.7</TD>
    <TD STYLE="vertical-align: bottom; text-indent: 0in">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: left; padding-left: 10pt">EX-10.8</TD>
    <TD STYLE="vertical-align: bottom; text-indent: 0in">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: left; padding-left: 10pt">EX-10.16</TD>
    <TD STYLE="vertical-align: bottom; text-indent: 0in">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: left; padding-left: 10pt">EX-10.42</TD>
    <TD STYLE="vertical-align: bottom; text-indent: 0in">&nbsp;</TD></TR>
<tr>
    <TD STYLE="vertical-align: top; text-align: left; padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">EX-21</font></td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    </tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: left; padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">EX-23</font></td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    </tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: left; padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">EX-31.1</font></td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    </tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: left; padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">EX-31.2</font></td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    </tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: left; padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">EX-32.1</font></td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    </tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: left; padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">EX-32.2</font></td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    </tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: left; padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">EX-101</font></td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    </tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-bottom: 0; margin-left: 0; text-align: center; text-indent: 0in"><B>PART
I</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 9%; text-indent: 0in"><A NAME="p1i1"></A><font style="font: 10pt Times New Roman, Times, Serif"><b>ITEM&nbsp;1.</b></font></td>
    <td style="width: 91%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>BUSINESS</i></b></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 0in"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">This report includes forward-looking statements
within the meaning of Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, which are subject to the &ldquo;safe
harbor&rdquo; created in Section&nbsp;21E. In particular, statements about our expectations, beliefs, plans, objectives or assumptions
of future events or performance are contained or incorporated by reference in this report. All statements other than statements
of historical facts contained herein are forward-looking statements. We have based these forward-looking statements on our current
expectations about future events. While we believe these expectations are reasonable, forward-looking statements are inherently
subject to risks and uncertainties, many of which are beyond our control. Our actual results may differ materially from those
suggested by these forward-looking statements for various reasons, including those discussed in this report under the heading
&ldquo;Risk Factors.&rdquo; Given these risks and uncertainties, you are cautioned not to place undue reliance on our forward-looking
statements. The forward-looking statements included in this report are made only as of the date hereof. We do not undertake, and
specifically decline, any obligation to update any of these statements or to publicly announce the results of any revisions to
any forward-looking statements to reflect future events or developments. When used in the report, unless otherwise indicated,
&ldquo;we&rdquo;, &ldquo;our&rdquo;, &ldquo;us&rdquo;, the &ldquo;Company&rdquo; and &ldquo;BioCryst&rdquo; refer to BioCryst
Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"><B>Our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">We are a biotechnology company that designs,
optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. We focus on
the treatment of rare diseases in which significant unmet medical needs exist and align with our capabilities and expertise. We
integrate the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small
molecule pharmaceuticals through the process known as structure-guided drug design. Structure-guided drug design is a drug discovery
approach by which we design synthetic compounds from detailed structural knowledge of the active sites of enzyme targets associated
with particular diseases. We use X-ray crystallography, computer modeling of molecular structures and advanced chemistry techniques
to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
Enzymes are proteins that act as catalysts for many vital biological reactions. Our goal generally is to design a compound that
will fit in the active site of an enzyme and thereby prevent its catalytic activity. Molecules from our discovery efforts which
are commercially available or that are in development are summarized in the table below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.1pt solid">
        <P STYLE="text-align: left">Drug/Drug Candidate</P></td>
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">Drug Class</font></td>
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">Therapeutic</font><br>
<font style="font: 10pt Times New Roman, Times, Serif">Area(s)</font></td>
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">Phase</font></td>
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">Rights</font></td></tr>
<tr>
    <td style="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-indent: 0in">RAPIVAB<sup>TM</sup></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-indent: 0in">(peramivir injection)</P>
        <P STYLE="vertical-align: top; text-indent: 0in">&nbsp;</P></td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">Intravenous Neuraminidase Inhibitor</font></td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">Acute uncomplicated Influenza</font></td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-indent: 0in">Approved</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-indent: 0in">(US)</P></td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">BioCryst (worldwide, except Japan, Taiwan, Korea and Israel)</font></td></tr>
<tr>
    <td style="vertical-align: top; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-indent: 0in">RAPIACTA<sup>&reg;</sup></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-indent: 0in">(peramivir injection)</P></td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">Intravenous Neuraminidase Inhibitor</font></td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">Uncomplicated seasonal influenza </font></td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-indent: 0in">Approved</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-indent: 0in">(Japan)</P></td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-indent: 0in">Shionogi</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-indent: 0in">(Japan &amp; Taiwan)</P></td></tr>
<tr>
    <td style="vertical-align: top; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-indent: 0in">PERAMIFLU<sup>&reg;</sup></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-indent: 0in">(peramivir injection)</P></td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">Intravenous Neuraminidase Inhibitor</font></td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">Uncomplicated seasonal influenza </font></td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-indent: 0in">Approved</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-indent: 0in">(Korea)</P></td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-indent: 0in">Green Cross</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-indent: 0in">(Korea)</P></td></tr>
<tr>
    <td style="vertical-align: top; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">BCX4161</font></td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">Oral Serine Protease Inhibitor Targeting Kallikrein</font></td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">Hereditary angioedema (&ldquo;HAE&rdquo;)</font></td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">Phase 2</font></td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-indent: 0in">BioCryst</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-indent: 0in">(worldwide)</P></td></tr>
<tr>
    <td style="text-indent: 0in">&nbsp;</td>
    <td colspan="2" style="text-indent: 0in">&nbsp;</td>
    <td colspan="2" style="text-indent: 0in">&nbsp;</td>
    <td colspan="2" style="text-indent: 0in">&nbsp;</td>
    <td colspan="2" style="text-indent: 0in">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">BCX7353 and other 2<sup>nd</sup> generation&nbsp;HAE compounds</font></td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">Oral Serine Protease Inhibitors Targeting Kallikrein (intended to be &nbsp;once-daily treatments)</font></td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">HAE</font></td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">Preclinical</font></td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-indent: 0in">BioCryst</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-indent: 0in">(worldwide)</P></td></tr>
<tr>
    <td style="text-indent: 0in">&nbsp;</td>
    <td colspan="2" style="text-indent: 0in">&nbsp;</td>
    <td colspan="2" style="text-indent: 0in">&nbsp;</td>
    <td colspan="2" style="text-indent: 0in">&nbsp;</td>
    <td colspan="2" style="text-indent: 0in">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">BCX4430</font></td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">RNA dependent-RNA Polymerase Inhibitor</font></td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">Filoviruses, including Ebola and Marburg viruses</font></td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">Phase 1</font></td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-indent: 0in">BioCryst</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-indent: 0in">(worldwide)</P></td></tr>
<tr>
    <td style="text-indent: 0in">&nbsp;</td>
    <td colspan="2" style="text-indent: 0in">&nbsp;</td>
    <td colspan="2" style="text-indent: 0in">&nbsp;</td>
    <td colspan="2" style="text-indent: 0in">&nbsp;</td>
    <td colspan="2" style="text-indent: 0in">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">Forodesine</font></td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">Oral Purine Nucleoside Phosphorylase Inhibitor</font></td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">Oncology</font></td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">Phase 2</font></td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-indent: 0in">Mundipharma</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-indent: 0in">(worldwide)</P></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0"><B>Business Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">Our business strategy is to create shareholder
value by focusing our discovery and development efforts on oral drugs for rare diseases for which a significant unmet medical
need exists. We select disease targets and product candidates in which a small molecule would offer a significant benefit over
existing products or would be the first to market. We strive to advance our product candidate portfolio from discovery to commercial
markets efficiently by utilizing a small group of talented and highly-skilled employees working in conjunction with strategic
outsource partners. BioCryst is unique in its approach to treat orphan diseases with small molecules utilizing crystallography
and structure-guided drug design. The principal elements of our strategy are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif"><i>Focusing on High Value-Added Structure-Guided Drug Design Technologies.</i> We utilize structure-guided drug design in order to most efficiently develop new therapeutic candidates. Structure-guided drug design is a process by which we design a product candidate through detailed analysis of the enzyme target, which the product candidate must inhibit in order to stop the progression of the disease or disorder. We believe that structure-guided drug design is a powerful tool for the efficient development of small-molecule product candidates that have the potential to be safe and effective. Our structure-guided drug design technologies typically allow us to design and synthesize multiple product candidates that inhibit the same enzyme target, with the goal of establishing broad patent protection and formulating compounds with competitive advantages.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><P STYLE="margin: 0pt 0"><I>Selecting Inhibitors that are Promising
                                         Product Candidates.</I><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> We start
                                         by selecting disease targets with well-understood biology and characteristics that fit
                                         with our ability to utilize structure-guided drug design capabilities to build potent
                                         and specific enzyme inhibitors. Next, we narrow our selection of these product candidates
                                         based on product characteristics, such as initial indications of safety and biologic
                                         activity on the target.</FONT></P>


</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><P STYLE="margin: 0pt 0"><I>Developing our Product Candidates
                                         Efficiently.</I> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">An important
                                         element of our business strategy is to efficiently progress our product candidates through
                                         the development process. In order to accomplish this, we strive for disease targets with
                                         a defined clinical and regulatory pathway for approval. In addition, we control fixed
                                         costs and overhead by outsourcing with strategic partners and contractors or entering
                                         into license agreements with third parties, including the U.S. Government. We maintain
                                         a streamlined corporate infrastructure that focuses our expertise. By contracting with
                                         the U.S. Government and outsourcing certain aspects of our operations, we are able to
                                         control overhead costs and focus financial resources directly where they provide the
                                         most benefit and reduce our business risk.</FONT></P></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">We are a Delaware corporation originally
founded in 1986. Our corporate headquarters is located at 4505 Emperor Blvd., Suite&nbsp;200, Durham, North Carolina 27703 and
the corporate telephone number is (919)&nbsp;859-1302. For more information about us, please visit our website at www.biocryst.com.
The information on our website is not incorporated into this Form&nbsp;10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"><B>RAPIVAB (peramivir injection)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23.05pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.05pt">Peramivir is an intravenous neuraminidase
inhibitor approved in multiple countries for the treatment of patients with influenza, most recently in the United States as RAPIVAB.
Influenza is a seasonal virus with the highest infection rates generally observed in colder months.&nbsp;Intravenous (&ldquo;i.v.&rdquo;)
peramivir injection has also been approved in Japan (RAPIACTA<SUP>&reg;</SUP>) and Korea (PERAMIFLU<SUP>&reg;</SUP>). In the countries
for which peramivir is commercially available, influenza occurs primarily during the September to April timeframe.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">RAPIVAB
was approved by the U.S. Food and Drug Administration (&ldquo;FDA&rdquo;) on December 19, 2014</FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">for
the treatment of acute uncomplicated influenza in patients 18 years and older who have been symptomatic for no more than two days.
In December 2013, we submitted a New Drug Application (&ldquo;NDA&rdquo;) which contained data from over 2,700 subjects treated
with peramivir in 27 clinical trials. We have made RAPIVAB available for commercial sale through agreements with specialty distributorships
during the 2014-2015 influenza season. Our current focus is to obtain a stock-piling procurement contract with the U.S. Government
to realize the strategic value of this program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">RAPIVAB was developed under a $234.8 million
contract from the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human
Services (&ldquo;BARDA/HHS&rdquo;), which expired on June 30, 2014. See &ldquo;Collaborations and In-License Relationships&mdash;BARDA/HHS&rdquo;
below for a further discussion of this development contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 22.5pt">In January 2010, our partner Shionogi&nbsp;&amp;
Co., Ltd. (&ldquo;Shionogi&rdquo;) received the first approval for peramivir injection and launched it in Japan under the commercial
name RAPIACTA<SUP>&reg;</SUP>. It was initially approved for the treatment of adults with uncomplicated seasonal influenza, as
well as those at high-risk for complications associated with influenza. In October 2010, Shionogi received approval for an additional
indication to treat children and infants with influenza in Japan. In August 2010, Green Cross Corporation (&ldquo;Green Cross&rdquo;)
received marketing and manufacturing approval from the Korean Food&nbsp;&amp; Drug Administration under the commercial name PERAMIFLU<SUP>&reg;</SUP>
to treat patients with influenza A &amp; B viruses, including pandemic H1N1 and avian influenza. In addition, we have a regional
collaboration for the development and commercialization of peramivir in Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 5; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-bottom: 0; margin-left: 0; text-indent: 0in"><B>Hereditary Angioedema Drug Candidates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.05pt"><I><U>BCX4161</U>:</I> BCX4161 is our
most advanced HAE product candidate in a suite of molecules being developed as oral treatments for the prevention of hereditary
angioedema (&ldquo;HAE&rdquo;) attacks. BCX4161 is positioned to be the first oral prophylactic kallikrein inhibitor  for the
prevention of HAE attacks. BCX4161 is a novel, selective inhibitor of plasma kallikrein in development as an orally-administered
treatment for the prevention of attacks in patients with HAE. By inhibiting plasma kallikrein, BCX4161 suppresses bradykinin production.
Bradykinin is the mediator of acute swelling attacks in HAE patients. HAE is a rare, severely debilitating and potentially fatal
genetic condition that occurs in approximately 1 in 50,000 people. HAE symptoms include recurrent episodes of edema in various
locations, including the hands, feet, face, genitalia and airway. Airway swelling is particularly dangerous and can lead to death
by asphyxiation. In addition, patients often have bouts of excruciating abdominal pain, nausea and vomiting caused by swelling
in the intestinal wall.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.05pt">In December 2014, and January 2015,
the FDA granted BCX4161 &ldquo;Orphan Drug&rdquo; designation and &ldquo;Fast Track&rdquo; designation for the treatment of HAE.
Orphan drug designation is granted by the FDA Office of Orphan Products Development to novel drugs intended for the safe and effective
treatment of a rare disease or condition that affects fewer than 200,000 patients in the U.S. This designation provides certain
incentives, including federal grants, tax credits, waiver of Prescription Drug User Fee Act (&ldquo;PDUFA&rdquo;) filing fees,
and a seven-year marketing exclusivity period against competition once the product candidate is approved. The Fast Track designation
process of the FDA is designed to facilitate the development and expedite the review and approval of drugs intended to treat serious
or life threatening conditions and that address unmet medical needs. A drug that receives Fast Track designation is usually eligible
for more frequent written communication and meetings with the FDA to discuss the drug's development plan and the collection of
appropriate data supporting drug approval. In addition, the Committee for Orphan Medicinal Products (&ldquo;COMP&rdquo;) of the
European Medicines Agency (&ldquo;EMA&rdquo;) issued a positive opinion on the application for orphan drug designation for BCX4161
for the treatment of patients with HAE and the European Commission recently affirmed this designation. Orphan drug designation
by the EMA provides regulatory and financial incentives for companies to develop and market therapies that treat a life-threatening
or chronically debilitating condition affecting no more than five in 10,000 persons in the European Union (&ldquo;EU&rdquo;).<BR></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 22.5pt">On December 18, 2014, we announced the dosing
of the first patient in OPuS-2 (<B>O</B>ral <B>P</B>rophylaxi<B>S-2</B>), a blinded, randomized, placebo-controlled clinical trial
of orally-administered BCX4161 in patients with HAE. OPuS-2 is a 12-week, three-arm, parallel cohort design trial to evaluate the
efficacy and safety of two doses of BCX4161, 300 mg and 500 mg, administered three-times daily compared with placebo. This trial
is being conducted in the U.S. and select European countries and is expected to enroll approximately 100 HAE patients. The primary
efficacy endpoint for the trial will be the mean angioedema attack rate for each BCX4161 dose group compared to placebo.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
May 27, 2014, we announced positive results from a proof of concept Phase 2a clinical trial in patients with HAE (&ldquo;OPuS-1&rdquo;
i.e., <B>O</B>ral <B>P</B>rophylaxi<B>S-1</B>). This clinical trial evaluated 400 mg of BCX4161 administered three-times daily
for 28 days in a randomized, placebo-controlled, two-period cross-over design. Twenty-four HAE patients who had a high frequency
of attacks (more than one per week) were enrolled. This study was designed to provide proof of concept for oral kallikrein inhibition
as a treatment strategy for HAE. The primary goals of the trial were to estimate the degree of efficacy of BCX4161 in reducing
the frequency of angioedema attacks and to evaluate the safety and tolerability of 28 days of BCX4161 treatment. The OPuS-1 trial
met its primary efficacy endpoint, several secondary endpoints as well as other objectives established for the clinical trial.
Each of the twenty-four patients dosed completed the trial. The primary efficacy endpoint for the trial was the mean angioedema
attack rate. Treatment with BCX4161 demonstrated a statistically significant mean attack rate reduction of 0.45 attacks per week
versus placebo, p&lt; 0.001. The mean attack rate per week was 0.82 on BCX4161 treatment, compared to 1.27 on placebo.</FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">Oral
administration of BCX4161 was generally safe and well-tolerated, with an adverse event profile similar to that observed for placebo.
Patient dosing compliance in this trial was 98 percent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt"><I><U>2nd generation HAE compounds:</U></I>
The goal of our second generation HAE discovery program is to discover and develop oral molecules for the prevention of HAE attacks
which have a superior selectivity and bioavailability profile while maintaining similar potency as compared to BCX4161. In December
2013, we announced the selection of two optimized plasma kallikrein inhibitors to advance into preclinical development as potential
once-daily, oral prophylactic treatments for HAE. Based on early preclinical development studies, these structurally different
molecules have a similar mechanism of action as BCX4161 and have achieved the principal goal of improved bioavailability. Both
compounds had roughly five times better bioavailability than BCX4161. These compounds demonstrated sub-nanomolar potency on the
isolated enzyme and single digit nanomolar potency in suppressing kallikrein activity in an ex-vivo activated normal human plasma
kallikrein inhibition (&ldquo;aPKI&rdquo;) assay. Plasma concentrations of each of the optimized compounds exceeded the aPKI assay
EC80 concentration at 24 hours after a single oral dose of 10 mg/kg in rats, indicating potential for once-daily dosing. Based
upon the product profile and its stage of preclinical development, we expect to start Phase 1 development of BCX7353, one of these
two advanced second generation molecules, in the second quarter of 2015. Given the other advanced second generation molecule&rsquo;s
inferior profile and similar molecular composition to BCX7353,  we have chosen
only to advance BCX7353. In addition to BCX7353, we continue to work on and advance other second generation compounds
that are at an earlier stage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"><B>BCX4430</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 22.5pt">BCX4430 is a broad-spectrum antiviral
(&ldquo;BSAV&rdquo;) research program and is currently being developed under a contract with the National Institute of Allergy
and Infectious Diseases (&ldquo;NIAID/HHS&rdquo;). The objective of our BSAV program is to develop BCX4430 as a broad-spectrum
therapeutic for viruses that pose a threat to national health and security. The primary focus of the program is treatment of hemorrhagic
fever viruses. NIAID/HHS funding has supported BCX4430&rsquo;s development as a treatment for Marburg virus and Ebola virus. In
March 2014, BCX4430 was featured in an online <I>Nature</I> publication depicting successful efficacy results in animal models
of infection with Marburg virus and Ebola virus.&nbsp;BCX4430 completely protected cynomolgus macaques from Marburg virus infection
when administered by intramuscular injection 48 hours post-infection.&nbsp;Post-exposure intramuscular administration of BCX4430
also protected rodents against Marburg virus and Ebola virus infections.&nbsp;In addition, BCX4430 was shown to be active in vitro
against a broad range of other RNA viruses, including the emerging viral pathogen Middle East Respiratory Syndrome Coronavirus
(&ldquo;MERS-CoV&rdquo;).&nbsp;The publication, which reported the protection of non-human primates from filovirus disease by BCX4430,
describes efficacy results generated from an ongoing collaboration between scientists in the U.S. Army Medical Research Institute
of Infection Diseases (&ldquo;USAMRIID&rdquo;) and us.&nbsp;BCX4430 has been shown to be active against more than 20 RNA viruses
in nine different families, including filoviruses, togaviruses, bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and
flaviviruses.&nbsp;In tests conducted at USAMRIID, BCX4430 protected animals against parenteral exposures to Marburg, Ebola and
Rift Valley Fever viruses and from exposures to aerosolized Marburg virus, an experimental condition designed to mimic an exposure
scenario that could result during a bioterrorist attack.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt"></P>

<!-- Field: Page; Sequence: 6; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">On December 23, 2014, we announced results
from a successful proof-of-concept study of BCX4430 for the treatment of experimental Ebola virus infection in Rhesus macaques,
conducted at USAMRIID. The primary goal of the study was to assess the effect of BCX4430 treatment on survival through Day 41
in animals infected with Ebola virus. Dosing of&nbsp;placebo or BCX4430 by intramuscular (&ldquo;i.m.&rdquo;) injection was initiated
30-120 minutes after virus challenge and continued twice a day (&ldquo;BID&rdquo;) for 14 days. Animals were dosed with either
placebo, 16 mg/kg of BCX4430 BID or 25 mg/kg of BCX4430 BID. Survival at day 41 in the 16 mg/kg BID group of BCX4430 treated animals
was 4 of 6 (66.7%, p &lt; 0.001 compared to 0% survival in controls) and 6 of 6 in the 25 mg/kg BID group (100%, p &lt; 0.001
compared to controls). The overall survival rate for BCX4430 treated animals at day 41 was 10 of 12 (83%, p &lt; 0.001 compared
to controls). Preliminary evaluation of the quantity of virus in the blood showed an approximate 3-log reduction in Ebola virus
RNA copies/mL of plasma, compared with control animals. This Rhesus macaque study was conducted following the completion, in November
2014, of a dose-ranging study of BCX4430 for the experimental treatment of cynomolgus macaques infected with Ebola virus. The
cynomolgus macaque study was designed to evaluate whether BCX4430 showed a meaningful benefit for survival in Ebola virus non-human
primate (&ldquo;NHP&rdquo;) disease models and explore a dose range. In this study BCX4430 demonstrated a statistically significant
prolongation of survival for the animals at the highest dose regimen tested, but no animals survived beyond 21 days. On December
15, 2014, we announced the dosing of the first subject in a randomized, placebo-controlled Phase 1 clinical trial to evaluate
i.m. administration of BCX4430 in healthy volunteers. The main goals of this first-in-human study are to evaluate the safety,
tolerability and pharmacokinetics of escalating doses of BCX4430 administered via i.m. injection in healthy subjects. In part
one of the study, subjects will receive a single dose of BCX4430; and then subjects will receive BCX4430 for seven days in the
second part of the study. Up to six single-dose cohorts and four multiple-dose cohorts will be evaluated, with a total of up to
88 volunteers participating.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">In September 2013, NIAID/HHS contracted
with BioCryst for the development of BCX4430 as a treatment for Marburg virus disease, and subsequently Ebola virus disease. NIAID/HHS,
part of the National Institutes of Health, made an initial award of $5.0 million to us. On February 12, 2015, NIAID/HHS exercised
an additional option under the contract, which provides $2.7 million to us for i.v. BCX4430 investigational new drug (&ldquo;IND&rdquo;)
enablement and submission. $25.0 million of option funding has been awarded under the NIAID/HHS contract to date and total available
funding under the contract is $29.1 million, if all contract options are exercised. The goals of this contract, including amendments,
are to file IND applications for i.v. and i.m. BCX4430 for the treatment of Marburg virus disease, to conduct an initial Phase
1 human clinical trial, as well as to study BCX4430 as a treatment for Ebola virus disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 0in"><B>Forodesine</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 22.5pt">Forodesine is a Purine Nucleoside Phosphorylase
(&ldquo;PNP&rdquo;) inhibitor in development by Mundipharma as a treatment for cancer under a world-wide license agreement. PNP
is a purine salvage pathway enzyme. High doses of PNP inhibitors could be useful in the treatment of hematological malignancies.
In January 2013, Mundipharma&rsquo;s Japanese subsidiary, Mundipharma K.K., initiated enrollment in a phase 1/2 clinical trial
of forodesine in recurrent/refractory peripheral T-cell lymphoma patients. The objective of the Phase 1 portion is to confirm
safety and tolerability in recurrent/refractory peripheral T-cell lymphoma patients during repeated oral administration of forodesine
300 mg twice-daily for 28 days, to evaluate pharmacokinetics, and to determine the recommended dose for Phase 2. The goal of the
Phase 2 portion is to evaluate the efficacy, safety, and pharmacokinetics of the recommended dosage regimen determined in the
Phase 1 portion. The primary efficacy endpoint shall be objective response rate (&ldquo;ORR&rdquo;) based on evaluation by an
image assessment committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23.05pt">On November&nbsp;11, 2011, we entered
into an Amended and Restated License and Development Agreement (the &ldquo;Amended and Restated Agreement&rdquo;) with Mundipharma,
amending and restating the February&nbsp;1, 2006 exclusive, royalty-bearing Development and License Agreement for the development
and commercialization of forodesine for use in the field of oncology. Under the terms of the Amended and Restated Agreement, Mundipharma
obtained worldwide rights to forodesine, so Mundipharma controls the worldwide development and commercialization of forodesine
and assumes all future development and commercialization costs. The Amended and Restated Agreement is a multiple element arrangement
for accounting purposes in which we were required to deliver to Mundipharma both the worldwide rights to forodesine and the transfer
of product data and know-how to permit Mundipharma to develop and commercialize forodesine (the &ldquo;Knowledge Transfer&rdquo;).
The world-wide license rights were granted to Mundipharma upon execution of Amended and Restated Agreement and the Knowledge Transfer
was completed in the first quarter of 2012. We have accounted for these elements as a combined unit of accounting as neither one
has stand-alone value to Mundipharma. Upon completion of the Knowledge Transfer, the unamortized deferred revenue and deferred
expense of $7.8 million and $1.9 million, respectively, were recognized in our Statements of Comprehensive Loss in the quarter
ended March&nbsp;31, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 22.5pt">We have licensed the PNP technology
from Albert Einstein College of Medicine of Yeshiva University (&ldquo;AECOM&rdquo;) and Industrial Research, Ltd. (&ldquo;IRL&rdquo;)
and will owe sublicense payments to AECOM/IRL based on the future milestone payments and royalties received by us from Mundipharma
and any other partners for which we out-license our PNP inhibitors. On November&nbsp;17, 2011, we amended our agreement with AECOM/IRL
whereby AECOM/IRL agreed to accept a reduction of one-half of the percentage of Net Proceeds (as defined in the license agreement)
received by us under our Amended and Restated Agreement with Mundipharma. This reduction does not apply to royalty payments made
as a result of sales of licensed products by our sub licensees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"><B></B></P>

<!-- Field: Page; Sequence: 7; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-bottom: 0; margin-left: 0; text-indent: 0in"><B>Corporate restructuring</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 22.5pt">On December&nbsp;7, 2012, we announced a corporate restructuring intended to significantly reduce our cost
structure and to implement a focused strategy to advance our HAE and antiviral programs. The corporate restructuring included a
workforce reduction of approximately 50% of our headcount, or 38 positions. We restructured our operations and implemented a focused
R&amp;D strategy in order to have sufficient liquidity to advance our HAE and antiviral programs to reach near-term value milestones.
The restructuring and R&amp;D focus significantly reduced our cost structure. We recorded a restructuring charge of $1.8 million
in the fourth quarter of 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 0in"><B>Collaborations and In-License Relationships</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 22.5pt"><I><U>U.S.&nbsp;Department of
Health and Human Services (&ldquo;BARDA/HHS&rdquo;)</U>.</I> In January 2007, BARDA/HHS awarded us a $102.6 million contract
for the advanced development of peramivir for the treatment of influenza. During 2009, peramivir clinical development shifted
to focus on intravenous delivery and the treatment of hospitalized patients. To support this focus, a September 2009 contract
modification was awarded to increase funding by $77.2 million. On February&nbsp;24, 2011, we announced that BARDA/HHS had
awarded us a $55.0 million contract modification, intended to fund completion of the Phase 3 development of intravenous
(&ldquo;i.v.&rdquo;) peramivir for the treatment of patients hospitalized with influenza. This contract modification brought
the total award from BARDA/HHS to $234.8 million and provided funding to support the filing of an NDA to seek regulatory approval for i.v. peramivir in the U.S. The contract expired on June 30, 2014
according to its terms. In December 2014, the FDA approved RAPIVAB (peramivir injection) for treatment of uncomplicated
influenza in patients 18 years and older who have been symptomatic for no more than two days, and we made RAPIVAB available
for commercial sale through our specialty distributors on December 26, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 27.35pt"><I><U>National Institute of Allergy
and Infectious Diseases (&ldquo;NIAID/HHS&rdquo;)</U>.&nbsp;</I>In September 2013, NIAID/HHS contracted with us for the development
of BCX4430 as a treatment for Marburg, and subsequently, Ebola virus disease. NIAID/HHS, part of the National Institutes of Health,
made an initial award of $5.0 million to us. On February 12, 2015, NIAID/HHS exercised an additional option under the contract,
which provides $2.7 million to us for i.v. BCX4430 IND enablement and submission. $25.0 million of option funding has been awarded
under the NIAID/HHS contract to date and total funding under the contract could be up to $29.1 million, if all contract options are
exercised. The goals of this contract, including amendments, are to file IND applications for i.v. and i.m. BCX4430 for the treatment
of Marburg virus disease, to conduct an initial Phase 1 human clinical trial, as well as to study BCX4430 as a treatment for Ebola
virus disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 22.5pt">The contract with NIAID/HHS is a cost-plus-fixed-fee
contract. That is, we are entitled to receive reimbursement for all costs incurred in accordance with the contract&rsquo;s provisions
that are related to the development of BCX4430 plus a fixed fee, or profit. NIAID/HHS will make periodic assessments of progress,
and the continuation of the contract is based on our performance, the timeliness and quality of deliverables, and other factors.
The government has rights under certain contract clauses to terminate this contract. This contract is terminable by the government
at any time for breach or without cause.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 22.5pt"><I><U>Shionogi&nbsp;&amp; Co., Ltd.
(&ldquo;Shionogi&rdquo;).</U></I> On February&nbsp;28, 2007, we entered into a License, Development and Commercialization Agreement
(as amended, supplemented or otherwise modified, the &ldquo;Shionogi Agreement&rdquo;), an exclusive license agreement with Shionogi
to develop and commercialize peramivir in Japan for the treatment of seasonal and potentially life-threatening human influenza.
In October 2008, we and Shionogi amended the Shionogi Agreement to expand the territory covered by the agreement to include Taiwan
and to provide rights for Shionogi to perform a Phase 3 clinical trial in Hong Kong. Under the terms of the Shionogi Agreement,
Shionogi obtained rights to injectable formulations of peramivir in Japan in exchange for a $14.0&nbsp;million upfront payment.
The license provided for development milestone payments (up to $21.0&nbsp;million), which have all been paid, and for commercial
milestone payments (up to $95.0&nbsp;million) in addition to double-digit (between 10% and 20%) royalty payments on product sales
of peramivir.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 22.5pt">Generally, all payments under the Shionogi
Agreement are non-refundable and non-creditable, but they are subject to audit. Shionogi is responsible for all development, regulatory,
and marketing costs in Japan. The term of the Shionogi Agreement is from February&nbsp;28, 2007 until terminated. Either party
may terminate in the event of an uncured breach. Shionogi has the right of termination without cause. In the event of termination,
all license and rights granted to Shionogi shall terminate and shall revert back to us. We developed peramivir under a license
from the University of Alabama Birmingham (&ldquo;UAB&rdquo;) and have paid sublicense payments to UAB on the upfront payments
and will owe sublicense payments on any future event payments and/or royalties received by us from Shionogi.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"><I><U>Shionogi Royalty Monetization and Non-Recourse
Notes Payable</U></I>. On March&nbsp;9, 2011, we completed a $30.0 million&nbsp;financing transaction to monetize certain future
royalty and milestone payments under the Shionogi Agreement, pursuant to which JPR Royalty Sub LLC (&ldquo;Royalty Sub&rdquo;)
a wholly-owned subsidiary of BioCryst, issued the PhaRMA Notes discussed below. We received net proceeds of $22.7 million&nbsp;from
this transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">As part of the transaction, we entered into
a purchase and sale agreement dated as of March&nbsp;9, 2011 with Royalty Sub, whereby we transferred to Royalty Sub, among other
things, (i)&nbsp;its rights to receive certain royalty and milestone payments from Shionogi arising under the Shionogi Agreement,
and (ii)&nbsp;the right to receive payments under a Japanese yen/US dollar foreign currency hedge arrangement (as further described
below, the &ldquo;Currency Hedge Agreement&rdquo;) put into place by us in connection with the transaction. Royalty payments will
be paid by Shionogi in Japanese yen and milestone payments will be paid in U.S. dollars. Our collaboration with Shionogi was not
impacted by this transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">On March 9, 2011, Royalty Sub
completed a private placement to institutional investors of $30.0 million in aggregate principal amount of its PhaRMA Senior
Secured 14.0% Notes due 2020 (the &ldquo;PhaRMA Notes&rdquo;). The PhaRMA Notes were issued by Royalty Sub under an
Indenture, dated as of March&nbsp;9, 2011 (the &ldquo;Indenture&rdquo;), by and between Royalty Sub and U.S. Bank National
Association, as Trustee. Principal and interest on the PhaRMA Notes issued are payable from, and are secured by, the rights
to royalty and milestone payments under the Shionogi Agreement transferred by us to Royalty Sub and payments, if any, made to
Royalty Sub under the Currency Hedge Agreement. The PhaRMA Notes bear interest at 14%&nbsp;per annum, payable annually in
arrears on September&nbsp;1st of each year (the &ldquo;Payment Date&rdquo;). We remain entitled to receive any royalties and
milestone payments related to sales of peramivir by Shionogi following repayment by Royalty Sub of the PhaRMA
Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 22.5pt">Royalty Sub&rsquo;s obligations to
pay principal and interest on the PhaRMA Notes are obligations solely of Royalty Sub and are without recourse to any other person,
including the Company, except to the extent of our pledge of its equity interests in Royalty Sub in support of the PhaRMA Notes.
We may, but are not obligated to, make capital contributions to a capital account that may be used to redeem, or on up to one
occasion pay any interest shortfall on, the PhaRMA Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 22.5pt">In September&nbsp;2013, Royalty Sub
paid $1.8 million of interest on the PhaRMA Notes from royalty payments received from RAPIACTA&reg; sales from the preceding four
calendar quarters. This payment resulted in an obligation shortfall of approximately $2.4 million associated with accrued interest
due September&nbsp;3, 2013. As stipulated under the PhaRMA Notes Indenture, if the amount available for payment on any Payment
Date is insufficient to pay all of the interest due on a Payment Date, the shortfall in interest will accrue interest at the interest
rate applicable to the PhaRMA Notes compounded annually. Accordingly, commencing in September&nbsp;2013, interest began to accrue
at 14%&nbsp;per annum on the interest shortfall of $2.4 million. In March, June and August of 2014, Royalty Sub paid additional
interest of $446,000, $1.9 million and $70,000, respectively, bringing the shortfall down to $222,000 as of September 30, 2014.
Under the terms of the Indenture, Royalty Sub&rsquo;s inability to pay the full amount of interest payable in September&nbsp;2013
by the next succeeding Payment Date for the PhaRMA Notes, which was September&nbsp;1, 2014, constituted an event of default. Accordingly,
we have classified the PhaRMA Notes and related accrued interest as current liabilities on our balance sheet. As a result of the
event of default under the PhaRMA Notes, the holders of the PhaRMA Notes may pursue acceleration of the PhaRMA Notes, may foreclose
on the collateral securing the PhaRMA Notes and the equity interest in Royalty Sub and exercise other remedies available to them
under the Indenture in respect of the PhaRMA Notes. In such event, we may not realize the benefit of future royalty payments that
might otherwise accrue to us following repayment of the PhaRMA Notes and we might otherwise be adversely affected. Due to the
non-recourse nature of the PhaRMA Notes, in the event of any potential acceleration or foreclosure, we believe the primary impact
to us would be the loss of future royalty payments from Shionogi and legal costs associated with retiring the PhaRMA Notes. In
addition, we may incur costs associated with liquidating the related Currency Hedge Agreement, which would no longer be required
in the event of foreclosure or if the PhaRMA Notes cease to be outstanding. As the PhaRMA Notes are the obligation of Royalty
Sub, we do not currently expect the event of default on the PhaRMA Notes to have a significant impact on our future results of
operations or cash flows. In addition to the 2013 interest shortfall, Royalty Sub was unable to make the 2014 interest payment
of $4.2 million on the September 1, 2014 Payment Date. Accordingly, commencing in September&nbsp;2014, we began accruing interest
at 14%&nbsp;per annum on the 2014 interest shortfall of $4.2 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 22.5pt">The Indenture does not contain
any financial covenants. The Indenture includes customary representations and warranties of Royalty Sub, affirmative and
negative covenants of Royalty Sub, Events of Default and related remedies, and provisions regarding the duties of the
Trustee, indemnification of the Trustee, and other matters typical for indentures used in structured financings of this type.
The PhaRMA Notes are redeemable at the option of Royalty Sub at any time at a redemption price equal to 100% of the
outstanding principal balance of the PhaRMA Notes being redeemed, plus accrued and unpaid interest through the redemption
date on the PhaRMA Notes being redeemed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 22.5pt">&nbsp; <I><U>Foreign Currency Hedge.
</U></I>In connection with the issuance by Royalty Sub of the PhaRMA Notes, we entered into a Currency Hedge Agreement to hedge
certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. Under the Currency Hedge Agreement,
we have the right to purchase dollars and sell yen at a rate of 100 yen per dollar for which we may be required to pay a premium
in each year from 2015 through 2020, provided the Currency Hedge Agreement remains in effect. A payment of $2.0 million&nbsp;will
be required if, on May&nbsp;18 of the relevant year, the U.S. dollar is worth 100 yen or less, as determined in accordance with
the Currency Hedge Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">The Currency Hedge Agreement does not qualify
for hedge accounting treatment; therefore, mark-to-market adjustments are recognized in our Consolidated Statement of Comprehensive
Loss. Cumulative mark-to-market adjustments resulted in gains of $5.5 million, $5.3 million, and a loss of $749,000 for the twelve
months ended December&nbsp;30, 2014, 2013 and 2012, respectively. We are also required to post collateral in connection with the
mark-to-market adjustments based on defined thresholds. As of December 31, 2014, no collateral was posted under the Currency Hedge
Agreement. We will not be required at any time to post collateral exceeding the maximum premium payments remaining payable under
the Currency Hedge Agreement. The maximum amount of hedge collateral we would be required to post is $11.7 million. We are required
to maintain a foreign currency hedge at 100 yen per dollar under the agreements governing the PhaRMA Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 22.5pt"><I><U>Green Cross</U>.</I> In June 2006, we entered into an agreement with Green Cross to develop and commercialize peramivir in Korea.
Under the terms of the agreement, Green Cross is responsible for all development, regulatory, and commercialization costs in Korea.
We received a one-time license fee of $250,000. The license provides that we will share in profits resulting from the sale of peramivir in Korea, including the
sale of peramivir to the Korean government for stockpiling purposes. Furthermore, Green Cross will pay us a premium over its cost
to supply peramivir for development and any future marketing of peramivir products in Korea. Both parties have the right to terminate
in the event of an uncured material breach. In the event of termination, all rights, data, materials, products and other information
would be transferred to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt"></P>

<!-- Field: Page; Sequence: 9; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 22.5pt">In August 2010, we announced that Green
Cross had received marketing and manufacturing approval from the Korean Food&nbsp;&amp; Drug Administration for i.v. peramivir,
under the commercial name PERAMIFLU<SUP>&reg;</SUP>. PERAMIFLU is intended to treat patients with influenza A&nbsp;&amp; B viruses,
including pandemic H1N1 and avian influenza. Green Cross received the indication of single dose administration of 300&nbsp;mg i.v.
peramivir. Since PERAMIFLU&rsquo;s approval, Green Cross has been in pricing discussions with the Korean National Health Insurance
Corporation and has yet to agree to a formulary price. PERAMIFLU&rsquo;s distribution to date has been limited to a case-by-case
basis and significant sales have not occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt"><I><U>Other Peramivir Collaborations.</U></I> In addition to our
collaborations with Shionogi and Green Cross, in March 2011 we entered into an arrangement with Neopharm Scientific Limited, granting
certain commercial and distribution rights for peramivir in Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 22.5pt"><I><U>Mundipharma</U>.</I> In February
2006, we entered into an exclusive, royalty bearing right and license agreement with Mundipharma for the development and commercialization
of forodesine, a PNP inhibitor, for use in oncology (the &ldquo;Original Agreement&rdquo;). Under the terms of the Original Agreement,
Mundipharma obtained rights to forodesine in markets across Europe, Asia, and Australasia in exchange for a $10.0&nbsp;million
up-front payment. In addition, Mundipharma contributed $10.0&nbsp;million of the documented out-of-pocket development costs incurred
by us in respect of the current and planned trials as of the effective date of the agreement, and Mundipharma would conduct additional
clinical trials at their own cost up to a maximum of $15.0&nbsp;million. The Original Agreement provided for the possibility of
future event payments totaling $155.0&nbsp;million for achieving specified development, regulatory and commercial events (including
certain sales level amounts following a product&rsquo;s launch) for certain indications. In addition, the Original Agreement provided
that we would receive royalties (ranging from single digits to mid teens) based on a percentage of net product sales, which varies
depending upon when certain indications receive NDA approval in a major market country and can vary by country depending on the
patent coverage or sales of generic compounds in a particular country. Generally, all payments under the Original Agreement were
nonrefundable and non-creditable, but they are subject to audit. We licensed forodesine and other PNP inhibitors from AECOM/IRL
and will owe sublicense payments to AECOM/IRL on all milestone payments and royalties received by us from Mundipharma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 22.5pt">On November&nbsp;11, 2011, we entered
into the Amended and Restated Agreement with Mundipharma. Under the terms of this Amended and Restated Agreement, Mundipharma
obtained worldwide rights to forodesine in the field of oncology. Mundipharma will control the development and commercialization
of forodesine and assume all future development and commercialization costs. The Amended and Restated Agreement provides for the
possibility of future event payments totaling $15.0&nbsp;million for achieving specified regulatory events for certain indications.
In addition, the Amended and Restated Agreement provides that we will receive tiered royalties ranging from mid- to high-single
digit percentages of net product sales in each country where forodesine is sold by Mundipharma. These royalties are subject to
downward adjustments based on the then-existing patent coverage and/or the availability of generic compounds in each country.
Generally, all payments under the Amended and Restated Agreement are nonrefundable and non-creditable, but they are subject to
audit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 22.5pt">Mundipharma will also have a right
of exclusive negotiations with us for a limited period of time if they initiate negotiations for a specified backup PNP inhibitor.
Otherwise, they will be able to participate in the same negotiations process we enter into with another company for the backup
PNP inhibitor. The Amended and Restated Agreement will continue for the commercial life of the licensed products, but may be terminated
by either party following an uncured material breach by the other party or in the event the pre-existing third party license with
AECOM/IRL expires. It may be terminated by Mundipharma upon 60&nbsp;days written notice without cause or under certain other conditions
as specified in the Amended and Restated Agreement. If Mundipharma terminates the Amended and Restated Agreement, Mundipharma
would no longer have any rights in forodesine and the rights would revert back to us; provided, however, that in the event the
we determine to subsequently use the data developed under the Amended and Restated Agreement for development and commercialization
of forodesine in the field of oncology, then we would have to pay Mundipharma 150% of the cost of such data for such use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 22.5pt"><I><U>Albert Einstein College of Medicine
of Yeshiva University and Industrial Research, Ltd. (&ldquo;AECOM&rdquo; and &ldquo;IRL&rdquo; respectively)</U>.&nbsp;</I>In
June 2000, we licensed a series of potent inhibitors of PNP from AECOM and IRL, (collectively, the &ldquo;Licensors&rdquo;). The
lead product candidates from this collaboration are forodesine and ulodesine. We have obtained worldwide exclusive rights to develop
and ultimately distribute these, or any other, product candidates that might arise from research on these inhibitors. We have the option to expand our license agreement with the Licensors to include other inventions in the field
made by the investigators or employees of the Licensors. We agreed to use commercially reasonable efforts to develop these drugs.
In addition, we have agreed to pay certain milestone payments for each licensed product (which range in the aggregate from $1.4
million to almost $4.0 million&nbsp;per indication) for future development of these inhibitors, single digit royalties on net sales
of any resulting product made by us, and to share approximately one quarter of future payments received from other third-party
partners, if any. In addition, we have agreed to pay annual license fees, which can range from $150,000 to $500,000, that are creditable
against actual royalties and other payments due to the Licensors. This agreement may be terminated by us at any time by giving
60&nbsp;days advance notice or in the event of material uncured breach by the Licensors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 22.5pt">In May 2010, we amended the license
agreement through which we obtained worldwide exclusive rights to develop and ultimately distribute any product candidates that
might arise from research on a series of PNP inhibitors, including forodesine and ulodesine. Under the terms of the amendment,
the Licensors agreed to accept a reduction of one-half in the percentage of future payments received from third-party sub licensees
of the licensed PNP inhibitors that must be paid to the Licensors. This reduction does not apply to (i)&nbsp;any milestone payments
we may receive in the future under our license agreement with Mundipharma and (ii)&nbsp;royalties received from its sub licensees
in connection with the sale of licensed products, for which the original payment rate will remain in effect. The rate of royalty
payments to the Licensors based on net sales of any resulting product made by us remains unchanged.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 22.5pt">In consideration for these modifications in 2010,
we issued to the Licensors shares of our common stock with an aggregate value of $5.9 million and paid the Licensors $90,000 in
cash. Additionally, at our sole option and subject to certain agreed upon conditions, any future non-royalty payments due to be
paid by us to the Licensors under the license agreement may be made either in cash, in shares of our common stock, or in a combination
of cash and shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt"></P>

<!-- Field: Page; Sequence: 10; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">On November&nbsp;17, 2011, we further amended
our agreements with the Licensors whereby the Licensors agreed to accept a reduction of one-half in the percentage of Net Proceeds
(as defined in the license agreement) received by us under our Amended and Restated Agreement with Mundipharma that will be paid
to AECOM/IRL. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">On June&nbsp;19, 2012, we further amended our
agreements with the Licensors whereby the parties clarified the definition of the field with respect to PNP inhibition and the
Licensors agreed to grant an exclusive worldwide license of BCX4430 to us for any antiviral use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt"><I>The University of Alabama at Birmingham (&ldquo;UAB&rdquo;).&nbsp;</I>We
currently have agreements with UAB for influenza neuraminidase and complement inhibitors. Under the terms of these agreements,
UAB performed specific research for us in return for research payments and license fees. UAB has granted us certain rights to any
discoveries in these areas resulting from research developed by UAB or jointly developed with us. We have agreed to pay single
digit royalties on sales of any resulting product and to share in future payments received from other third-party partners. We
have completed the research under the UAB agreements. These two agreements have initial 25-year terms, are automatically renewable
for five-year terms throughout the life of the last patent and are terminable by us upon three months&rsquo; notice and by UAB
under certain circumstances. Upon termination both parties shall cease using the other parties&rsquo; proprietary and confidential
information and materials, the parties shall jointly own joint inventions and UAB shall resume full ownership of all UAB licensed
products. There is currently no activity between us and UAB on these agreements, but when we license this technology, such as in
the case of the Shionogi and Green Cross agreements, or commercialize products related to these programs, we will owe sublicense
fees or royalties on amounts it receives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"><B>Government Contracts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">In January 2007, BARDA/HHS awarded us
a $102.6 million contract for the advanced development of peramivir for the treatment of influenza. During 2009, peramivir clinical
development shifted to focus on intravenous delivery and the treatment of hospitalized patients. To support this focus, a September
2009 contract modification was awarded to increase funding by $77.2 million. On February&nbsp;24, 2011, we announced that BARDA/HHS
had awarded us a contract modification of $55.0 million, intended to fund completion of the Phase 3 development of i.v. peramivir
for the treatment of patients hospitalized with influenza. This contract modification brought the total award from BARDA/HHS to
$234.8 million and provided funding to support the filing of an NDA to seek regulatory approval for i.v. peramivir in the U.S.
The contract expired on June 30, 2014 according to its terms. In December 2014, the FDA approved RAPIVAB (peramivir injection)
for treatment of uncomplicated influenza in patients 18 years and older who have been symptomatic for no more than two days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">Under the defined scope of work in the
contract with BARDA/HHS for the development of peramivir, a process was undertaken to validate a U.S.-based manufacturer and the
related method for producing commercial batches of peramivir active pharmaceutical ingredient (&ldquo;API&rdquo;). As a required
outcome of this validation process, large quantities of peramivir API were produced. In accordance with our accounting practices,
we recorded all costs associated with this validation process as research and development expenses in our Consolidated Statements
of Comprehensive Loss. Simultaneously, revenue from the BARDA/HHS contract was also recorded in our Consolidated Statements of
Comprehensive Loss in 2009. BARDA/HHS subsequently reimbursed us for these costs and upon reimbursement from BARDA/HHS, the associated
peramivir API became property of the U.S.&nbsp;Government.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">Under the terms of the contract, if we
determine the amount of peramivir API produced under the contract is in excess of what is necessary to complete the contract,
we can acquire any excess peramivir API at cost to use for our own purposes. We believe that as a result of the manufacturing
campaign described above, more peramivir API has been produced than what was required to support U.S.&nbsp;regulatory approval.
If we use any excess API for our other contracts or activities, we will need to reconcile through an appropriate acquisition process
with BARDA/HHS and to determine the appropriate acquisition process remuneration for this API.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">In September 2013, NIAID/HHS contracted
with us for the development of BCX4430 as a treatment for Marburg, and subsequently, Ebola virus disease. NIAID/HHS, part of the
National Institutes of Health, made an initial award of $5.0 million to us. On February 12, 2015, NIAID/HHS exercised an additional
option under the contract, which provides $2.7 million to us for i.v. BCX4430 IND enablement and submission. $25.0 million of option funding has been awarded under the NIAID/HHS contract to date and total funding under the contract
could be up to $29.1 million, if all contract options are exercised. The goals of this contract, including amendments, are to
file IND applications for i.v. and i.m. BCX4430 for the treatment of Marburg virus disease, to conduct an initial Phase 1 human
clinical trial, as well as to study BCX4430 as a treatment for Ebola virus disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 22.5pt">Our contract with NIAID/HHS is a cost-plus-fixed-fee
contract. That is, we are entitled to receive reimbursement for all costs incurred in accordance with the contract&rsquo;s provisions
that are related to the development of BCX4430 plus a fixed fee, or profit. NIAID/HHS will make periodic assessments of our progress,
and the continuation of the contract is based on our performance, the timeliness and quality of deliverables, and other factors.
The government has rights under certain contract clauses to terminate this contract. The contract is terminable by the government
at any time for breach or without cause. In addition, the government has the right to audit costs billed to them under the contracts
and routinely conducts audits on our contracts. Any findings associated with these routine audits are generally reflected prospectively
in our operating results upon the ultimate agreement and resolutions of the audit findings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"><B></B></P>

<!-- Field: Page; Sequence: 11; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"><B>Patents and Proprietary Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 22.5pt">Our success will depend in part on our
ability to obtain and enforce patent protection for our products, methods, processes and other proprietary technologies, preserve
our trade secrets, and operate without infringing on the proprietary rights of other parties, both in the United States and in
other countries. We own or have rights to certain proprietary information, proprietary technology, issued and allowed patents and
patent applications which relate to compounds we are developing. We actively seek, when appropriate, protection for our products,
proprietary technology and proprietary information by means of U.S.&nbsp;and foreign patents, trademarks and contractual arrangements.
In addition, we rely upon trade secrets and contractual arrangements to protect certain of our proprietary information, proprietary
technology and products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 22.5pt">The patent positions of companies like
ours are generally uncertain and involve complex legal and factual questions. Our ability to maintain and solidify our proprietary
position for our technology will depend on our success in obtaining effective patent claims and enforcing those claims once granted.
We do not know whether any of our patent applications or those patent applications that we license will result in the issuance
of any patents. Our issued patents and those that may issue in the future, or those licensed to us, may be challenged, invalidated,
rendered unenforceable or circumvented, which could limit our ability to stop competitors from marketing related products or the
length of term of patent protection that we may have for our products. In addition, the rights granted under any issued patents
may not provide us with competitive advantages against competitors with similar compounds or technology. Furthermore, our competitors
may independently develop similar technologies or duplicate any technology developed by us in a manner that does not infringe
our patents or other intellectual property. Because of the extensive time required for development, testing and regulatory review
of a potential product, it is possible that, before any of our product candidates or those developed by our partners can be commercialized,
any related patent may expire or remain in force for only a short period following commercialization, thereby reducing any advantage
of the patent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 22.5pt">As of December&nbsp;31, 2014, we
have been issued approximately 13 U.S.&nbsp;patents that expire between 2017 and 2030 and that relate to our HAE program
compounds, neuraminidase inhibitor compounds, BSAV and PNP compounds. We have licensed a number of compounds protected by
certain composition of matter patents from AECOM and IRL, plus additional manufacturing patents, totaling 16 additional U.S.
patents that expire between 2017 and 2027. Additionally, we have approximately 9 PCT or U.S.&nbsp;patent applications pending
related to HAE program compounds, neuraminidase inhibitor compounds, BSAV and PNP compounds. Our pending applications may not
result in issued patents, our patents may not cover the products of interest or may not be enforceable in all, or any
jurisdictions and our patents may not provide us with sufficient protection against competitive products or otherwise be
commercially viable. After expiration of composition of matter patents for our products and product candidates, we may rely on data
exclusivity, or in some cases, method of use patents. The enforceability of these patents varies from jurisdiction
to jurisdiction and may not be allowed or enforceable in some territories where we may seek approval. We may not have the
funds to continue patent prosecution or to defend all of our existing patents in our current patent estate and may
selectively abandon patents or patent families worldwide or in certain territories.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">Our success is also dependent upon the
skills, knowledge and experience of our scientific and technical personnel, none of which is patentable. To help protect our rights,
we require all employees, consultants, advisors and partners to enter into confidentiality agreements, which prohibit the disclosure
of confidential information to anyone outside of BioCryst and, where possible, require disclosure and assignment to us of their
ideas, developments, discoveries and inventions. These agreements may not provide adequate protection for our trade secrets, know-how
or other proprietary information in the event of any unauthorized use or disclosure or the lawful development by others of such
information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>Competition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">The pharmaceutical and biotechnology industries
are intensely competitive. Many companies, including biotechnology, chemical and pharmaceutical companies, are actively engaged
in activities similar to ours, including research and development of drugs for the treatment of rare medical conditions. Many of
these companies have substantially greater financial and other resources, larger research and development staffs, and more extensive
marketing and manufacturing organizations than we do. In addition, some of them have considerable experience in preclinical testing,
clinical trials and other regulatory approval procedures. In addition, there are also academic institutions, governmental agencies
and other research organizations that are conducting research in areas in which we are working. We expect to encounter significant
competition for any of the pharmaceutical products we plan to develop. Companies that successfully complete clinical trials, obtain
required regulatory approvals and commence commercial sales of their products may achieve a significant competitive advantage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt"><I>Antivirals:</I> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
pharmaceutical market for products that prevent or treat influenza is very competitive. Key competitive factors for RAPIVAB&trade;
(peramivir injection) include, among others, efficacy, ease of use, safety, price and cost-effectiveness, storage and handling
requirements and reimbursement. A number of neuraminidase inhibitors are currently available in the U.S.&nbsp;and/or other counties,
including Japan, for the prevention or treatment of influenza, including seasonal flu vaccines and F. Hoffmann-La Roche Ltd.&rsquo;s
(&ldquo;Roche&rdquo;) TAMIFLU&reg;, GlaxoSmithKline plc&rsquo;s (&ldquo;GSK&rdquo;) RELENZA&reg; and Daiichi Sankyo Co., Ltd.&rsquo;s
INAVIR&reg;. In addition, FUJIFIM Corporation&rsquo;s favipiravir, a polymerase inhibitor, is approved in Japan. Roche&rsquo;s neuraminidase
inhibitor is also approved for prophylaxis of influenza, and both Roche and GSK have i.v. formulations in clinical trial development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 22.5pt"></P>

<!-- Field: Page; Sequence: 12; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 22.5pt">In January 2011, GSK announced initiation
of a multi-country Phase 3 study of i.v. zanamivir (the same active ingredient as in RELENZA) in hospitalized patients with influenza.
The GSK study is expected to be fully enrolled in the 2014-2015 flu season. In addition to these companies with neuraminidase
inhibitors, there are other companies working to develop additional antiviral drugs to be used against various strains of influenza.
Currently, there are a number of other companies developing potential new influenza therapies. Various government entities throughout
the world are offering incentives, grants and contracts to encourage additional investment into preventative and therapeutic agents
against influenza, which may have the effect of further increasing the number of our competitors and/or providing advantages to
certain competitors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 22.5pt">BCX4430 is a product candidate in our
BSAV research program and is currently being developed under a contract with NIAID/HHS. The objective of our BSAV program is to
develop BCX4430 as a broad-spectrum therapeutic for viruses that pose a threat to national health and security. The U.S. Government
is investing in a number of programs intended to address gaps in its medical countermeasure plan. Due to the Ebola outbreak in
West Africa in 2014, investment in medical countermeasures has increased worldwide. Therapeutic products with potentially promising
data to treat Ebola include FUJIFILM Corporation&rsquo;s favipiravir (polymerase inhibitor), Tekmira Pharmaceuticals Corporation&rsquo;s
TKM-Ebola (RNAi interference based) and Mapp Biopharmaceutical, Inc.&rsquo;s ZMapp (antibody-based). Both TKM-Ebola and ZMapp
have been used in Ebola patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 23pt; margin-right: 0; margin-left: 0"><I><U>HAE</U>:</I> HAE is an autosomal dominant disease characterized by painful, unpredictable, recurrent attacks of inflammation
affecting the hands, feet, face, abdomen, urogenital tract, and the larynx. The inflammation can be disfiguring, debilitating,
or in the case of laryngeal attacks, life-threatening. Prevalence for HAE is uncertain but is estimated to be approximately 1 case per 50,000 persons without known
differences among ethnic groups and is caused by deficient (Type I) or dysfunctional (Type II) levels of C1- Inhibitor (&ldquo;C1-INH&rdquo;),
a naturally occurring molecule that is known to inhibit kallikrein, bradykinin, and other serine proteases in the blood. If left
untreated, HAE can result in a mortality rate as high as 40% primarily due to upper airway obstruction. There are a number of licensed
and developmental therapies for HAE, including the following:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">C1-INH therapy is available as an acute therapy (Beriner</FONT>t<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&reg;)
and as a prophylactic therapy (Cinryze&reg;). These therapies are available intravenously and work by replacing the missing or
malfunctioning C1-INH protein in patients.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Kallikrein Inhibition<B> - </B>Kablbitor&reg; is a specific recombinant
plasma kallikrein inhibitor that halts the production of bradykinin and can be dosed subcutaneously in an inpatient setting.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Bradykinin receptor antagonist <B>- </B>Firazyr&reg; (icatibant) is
a competitive antagonist of the bradykinin B2 receptor Firazyr is approved for the treatment of acute attacks and is administered
by subcutaneous administration. </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Other medications -<B> </B>Prophylactic administration of synthetic
attenuated androgens (generically available as danazol or stanozolol) has been utilized to reduce the frequency or severity of
attacks. However, long-term use of danazol or stanozolol may result in virilization and arterial hypertension. Six-month liver
function tests, annual lipid profiles, and biennial hepatic ultrasound are recommended because these medications increase production
of C1-INH in the liver.<B> </B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 22.5pt; margin-right: 0; margin-left: 0">In addition to
BCX4161, BCX7353 and our other second generation compounds, there are a number of other HAE therapies in development. These
include a prophylactic plasma derived C1-INH delivered by subcutaneous injection in Phase 3 (CSL Behring); DX-2930, a
monoclonal antibody administered by subcutaneous injection for prophylactic treatment of HAE in Phase 1b (Dyax Corp) and
ISIS-PKK<SUB>Rx</SUB>, a RNA-targeted antisense drug to inhibit prekallikrein for prophylactic treatment of HAE in Phase 1
(ISIS Pharmaceuticals, Inc.).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 22.5pt">In order to compete successfully in these and other therapeutic areas, we must develop proprietary positions
in patented drugs for therapeutic markets that have not been satisfactorily addressed by conventional research strategies and,
in the process, expand our expertise in structure-based drug design. Our product candidates, even if successfully tested and developed,
may not be adopted by physicians over other products and may not offer economically feasible alternatives to other therapies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 10pt"><B>Research and Development</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">We initiated our research and development
activities in 1986. We have assembled a scientific research staff with expertise in a broad base of advanced research technologies
including protein biochemistry, X-ray crystallography, chemistry and pharmacology. Our research facilities, located in Birmingham,
Alabama, include protein biochemistry and organic synthesis laboratories, testing facilities, X-ray crystallography, computer
and graphics equipment and facilities to make product candidates on a small scale for early stage clinical trials. During the
years ended December 31, 2014, 2013 and 2012, our research and development expenses were $51.8 million, $41.9 million and $49.2
million, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 6pt; text-align: left; margin-bottom: 0"><B>Compliance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">We conduct our business in an ethical,
fair, honest and lawful manner. We act responsibly, respectfully and with integrity in our relationships with patients, health
care professionals, collaborators, governments, regulatory entities, stockholders, suppliers and vendors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">In order to ensure compliance with applicable
laws and regulations, our Chief Financial Officer, General Counsel and Vice President of Human Resources oversee compliance training,
education, auditing and monitoring; enforce disciplinary guidelines for any infractions of our corporate polices; implement new
policies and procedures; respond to any detected issues; and undertake corrective action procedures. Our controls address compliance
with laws and regulations that govern public pharmaceutical companies including, but not limited to, the following: federal and
state law, such as the Sarbanes-Oxley Act of 2002 and the U.S. Foreign Corrupt Practices Act of 1977; NASDAQ listing requirements;
the regulations of the Financial Industry Regulatory Authority; the Securities and Exchange Commission; the FDA; and the United
States Department of Health and Human Services. Our standard operating procedures are designed to provide a framework for corporate
governance in accordance with ethical standards and best legal practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 13; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 0in"><B>Government Regulation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">The FDA regulates the pharmaceutical and
biotechnology industries in the U.S., and our product candidates are subject to extensive and rigorous domestic government regulations
prior to commercialization. The FDA regulates, among other things, the development, testing, manufacture, safety, efficacy, record-keeping,
labeling, storage, approval, advertising, promotion, sale and distribution of pharmaceutical products. In foreign countries, our
products are also subject to extensive regulation by foreign governments. These government regulations will be a significant factor
in the production and marketing of any pharmaceutical products that we develop. Failure to comply with applicable FDA and other
regulatory requirements at any stage during the regulatory process may subject us to sanctions, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">delays;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">warning letters;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">fines;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">product recalls or seizures;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">injunctions;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">penalties;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">refusal of the FDA to review pending market approval applications or supplements to approval applications;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">total or partial suspension of production;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">civil penalties;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">withdrawals of previously approved marketing applications;&nbsp;and</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">criminal prosecutions.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">The regulatory review and approval process
is lengthy, expensive and uncertain. Before obtaining regulatory approvals for the commercial sale of any products, we or our partners
must demonstrate that our product candidates are safe and effective for use in humans. The approval process takes many years, substantial
expenses may be incurred and significant time may be devoted to clinical development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">Before testing potential product candidates
in humans, we carry out laboratory and animal studies to determine safety and biological activity. After completing preclinical
trials, we must file an IND, including a proposal to begin clinical trials, with the FDA. Thirty days after filing an IND, a Phase
1 human clinical trial can start, unless the FDA places a hold on the trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">Clinical trials to support a NDA are typically
conducted in three sequential phases, but the phases may overlap.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">Phase 1&mdash;During Phase 1, the initial
introduction of the drug into healthy volunteers, the drug is tested to assess metabolism, pharmacokinetics and pharmacological
actions and safety, including side effects associated with increasing doses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">Phase 2&mdash;Phase 2 usually involves
trials in a limited patient population to: (1)&nbsp;assess the efficacy of the drug in specific, targeted indications; (2)&nbsp;assess
dosage tolerance and optimal dosage; and (3)&nbsp;identify possible adverse effects and safety risks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">Phase 3 (pivotal) &mdash;If a compound
is found to be potentially effective and to have an acceptable safety profile in Phase 2 evaluations, Phase 3 clinical trials,
also called pivotal studies, major studies or advanced clinical trials, are undertaken to further demonstrate clinical efficacy
and to further test for safety within an expanded patient population at geographically dispersed clinical trial sites. In general,
the FDA requires that at least two adequate and well-controlled Phase 3 clinical trials be conducted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">Initiation and completion of the clinical
trial phases are dependent on several factors including things that are beyond our control. For example, the clinical trials cannot
begin at a particular site until that site receives approval from its Institutional Review Board (&ldquo;IRB&rdquo;), which reviews
the protocol and related documents. This process can take from several weeks to several months. In addition, clinical trials are
dependent on patient enrollment, but the rate at which patients enroll in the study depends on:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">willingness of investigators to participate in a study;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">ability of clinical sites to obtain approval from their IRB;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">the availability of the required number of eligible subjects to be enrolled in a given trial;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">the availability of existing or other experimental drugs for the disease we intend to treat;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">the willingness of patients to participate;&nbsp;and</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 14; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">the patients meeting the eligibility criteria.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">Delays in planned patient enrollment may
result in increased expense and longer development timelines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">After successful completion of the required
clinical testing, generally an NDA is submitted. Upon receipt of the NDA, the FDA will review the application for completeness.
Within 60 days, the FDA will determine if the application is sufficiently complete to warrant full review and will consider the
application &ldquo;filed&rdquo; at that time. Also upon receipt of the application, the FDA will assign a review priority to the
application. Priority review applications are usually reviewed within 8 months; standard review applications are usually reviewed
within 12 months. The FDA will usually refer NDAs for new molecular entities to an appropriate advisory committee for review and
evaluation in regards to providing a recommendation as to whether the application should be approved. The FDA is not bound to follow
the recommendation of an advisory committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">Following the review of the application,
which may include requests for additional information from the sponsor and&nbsp;results from inspections of manufacturing and clinical
sites, the FDA will issue an &ldquo;action letter&rdquo; on the application. The action letter will either be an &ldquo;approval
letter,&rdquo; in which case the product may be lawfully marketed in the United States, or a &ldquo;complete response letter.&rdquo;
A complete response letter will state that the FDA cannot approve the NDA in its present form and, usually, will describe all of
the specific deficiencies that the FDA has identified in the application. The complete response letter, when possible, will include
the FDA&rsquo;s recommended actions to place the application in a condition for approval. Deficiencies can be minor (e.g., labeling
changes) or major (e.g., requiring additional clinical trials). A complete response letter may also be issued before the FDA conducts
the required facility inspection and/or reviews labeling, leaving the possibility that additional deficiencies in the original
NDA could be subsequently cited. An applicant receiving a complete response letter is permitted to resubmit the NDA addressing
the identified deficiencies (in which case a new two or six month review cycle will begin), or withdraw the NDA. The FDA may consider
a failure to take action within one year of a complete response letter to be a request to withdraw, unless the applicant has requested
an extension of time in which to resubmit. If the FDA approves an NDA, the marketing of the product will be limited to the particular
disease states and conditions of use that are described in the product label.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">We and all of our contract manufacturers
are also required to comply with the applicable FDA current Good Manufacturing Practice, or cGMP, regulations during clinical development
and to ensure that the product can be consistently manufactured to meet the specifications submitted in an NDA. The cGMP regulations
include requirements relating to product quality as well as the corresponding maintenance of records and documentation. Manufacturing
facilities must be approved by the FDA before they can be used to manufacture our products. Based on an inspection, the FDA determines
whether manufacturing facilities are in compliance with applicable regulations. Manufacturing facilities in non-United States countries
that are utilized to manufacture drugs for distribution into the United States are also subject to inspection by the FDA. Additionally,
failure to comply with local regulatory requirements could affect production and availability of product in relevant markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"><B>Human Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">As of January&nbsp;31, 2015, we had approximately
50&nbsp;employees, of whom approximately 35 were engaged in the research and development function of our operations. Our research
and development staff, 20 of whom hold Ph.D. or M.D. degrees, have diversified experience in biochemistry, pharmacology, X-ray
crystallography, synthetic organic chemistry, computational chemistry, medicinal chemistry, clinical development and regulatory
affairs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">Our employees are not represented by any
collective bargaining agreements, and we have never experienced a work stoppage. Employees are required to execute confidentiality
and assignment of intellectual property agreements. We consider our relations with our employees to be satisfactory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"><B>Available Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">We have available a website on the Internet.
Our address is www.biocryst.com. We make available, free of charge, at our website our Annual Reports on Form&nbsp;10-K, Quarterly
Reports on Form&nbsp;10-Q, Current Reports on Form&nbsp;8-K, and amendments to those reports filed or furnished pursuant to Section&nbsp;13(a)
or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file such material with, or furnish it to,
the SEC. We also make available at our website copies of our audit committee charter, compensation committee charter, corporate
governance and nominating committee charter and our code of business conduct, which applies to all our employees as well as the
members of our Board of Directors. Any amendment to, or waiver from, our code of business conduct will be posted on our website.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"><B>Financial Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">For information related to our revenues,
profits, net loss and total assets, in addition to other financial information, please refer to the Financial Statements and Notes
to Financial Statements contained in this Annual Report. Financial information about revenues derived from foreign countries is
included in Note&nbsp;1 to the Financial Statements contained in this Annual Report.</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0"></P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 9%; text-indent: 0in"><A NAME="p1i1a"></A><font style="font: 10pt Times New Roman, Times, Serif"><b>&nbsp;ITEM&nbsp;1A.</b></font></td>
    <td style="width: 91%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>RISK FACTORS</i></b></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt"><I>An investment in our stock involves
risks. You should carefully read this entire report and consider the following uncertainties and risks, which may adversely affect
our business, financial condition or results of operations, along with all of the other information included in our other filings
with the Securities and Exchange Commission, before deciding to buy our common stock.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"><B>Risks Relating to Our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in"><B><I>We have incurred losses since
our inception, expect to continue to incur such losses, and may never be profitable.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">Since our inception, we have not achieved profitability.
We expect to incur additional losses for the foreseeable future, and our losses could increase as our research and development
efforts progress. We expect that such losses will fluctuate from quarter to quarter and losses and fluctuations may be substantial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">To become profitable, we, or our collaborative
partners, must successfully manufacture and develop product candidates, receive regulatory approval, and successfully commercialize
and/or enter into profitable agreements with other parties. It could be several years, if ever, before we receive significant revenue
from any current or future license agreements or revenues directly from product sales.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">Because of the numerous risks and uncertainties
associated with developing our product candidates and their potential for commercialization, we are unable to predict the extent
of any future losses. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly
or annual basis. If we are unable to achieve and sustain profitability, the market value of our common stock will likely decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in"><B><I>Our success depends upon our
ability to advance our products through the various stages of development, especially through the clinical trial process.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23.05pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23.05pt">To receive the regulatory approvals
necessary for the sale of our product candidates, we or our partners must demonstrate through preclinical studies and clinical
trials that each product candidate is safe and effective. The development process is complex and uncertain. Because of the cost
and duration of clinical trials, we may decide to discontinue development of product candidates that are unlikely to show good
results in the clinical trials, unlikely to help advance a product to the point of a meaningful collaboration, or unlikely to
have a reasonable commercial potential. We may suffer significant setbacks in pivotal pre-clinical studies and clinical trials
(e.g. BCX4430, BCX4161 and our second generation HAE product candidates), even after earlier clinical trials show promising results.
Clinical trials may not be adequately designed or executed, which could affect the potential outcome and analysis of study results.
Any of our product candidates may produce undesirable side effects in humans. These side effects could cause us or regulatory
authorities to interrupt, delay or halt clinical trials of a product candidate. These side effects could also result in the FDA
or foreign regulatory authorities refusing to approve the product candidate for any targeted indications. We, our partners, the
FDA or foreign regulatory authorities may suspend or terminate clinical trials at any time if we or they believe the trial participants
face unacceptable health risks. Clinical trials may fail to demonstrate that our product candidates are safe or effective and
have acceptable commercial viability. Regulatory authorities may interrupt, delay or halt clinical trials for a product candidate
for any number of reasons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Our ability to successfully complete clinical
trials is dependent upon many factors, including but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 5%; text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="width: 95%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">our ability to find suitable clinical sites and investigators to enroll patients;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">the availability of and willingness of patients to participate in our clinical trials;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">the ability to maintain contact with patients to provide complete data after treatment;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">our product candidates may not prove to be either safe or effective;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">clinical protocols or study procedures may not be adequately designed or followed by the investigators;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">manufacturing or quality control problems
    could affect the supply of  product candidates for our trials; and</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">delays or changes in requirements by governmental agencies.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 22.5pt">Clinical trials are lengthy and expensive.
We or our partners incur substantial expense for, and devote significant time to, preclinical testing and clinical trials, yet
we cannot be certain that the tests and trials will ever result in the commercial sale of a product. For example, clinical trials
require adequate supplies of drug and sufficient patient enrollment. Lack of adequate drug supply or delays in patient enrollment,
including in our planned clinical trials for HAE, can result in increased costs and longer development times. Even if we or our
partners successfully complete clinical trials for our product candidates, we or our partners might not file the required regulatory
submissions in a timely manner and may not receive regulatory approval for the product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<!-- Field: Page; Sequence: 16; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in"><B><I>Our clinical trials may not adequately show that
our product candidates are safe or effective.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 27.35pt">Progression of our product candidates
through the clinical development process is dependent upon our trials indicating our product candidates have adequate safety and
efficacy in the patients being treated by achieving pre-determined safety and efficacy endpoints according to the clinical trial
protocols. Failure to achieve either of these in any of our programs, including BCX4161 and our second generation HAE product candidates,
could result in delays in our trials or require the performance of additional unplanned trials. This could result in delays in
the development of our product candidates and could result in significant unexpected costs or the termination of programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in"><B><I>If we fail to reach milestones
or to make annual minimum payments or otherwise breach our obligations under our license agreements, our licensors may terminate
our agreements with them and seek additional remedies.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">If we are unable or fail to meet payment
obligations, performance milestones relating to the timing of regulatory filings, or development and commercial diligence obligations,
are unable or fail to make milestone payments or material data use payments in accordance with applicable provisions, or fail to
pay the minimum annual payments under our respective licenses, our licensors may terminate the applicable license or seek other
available remedies. As a result, our development of the respective product candidate or commercialization of the product would
cease.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in"><B><I>If we fail to obtain additional
financing or acceptable partnership arrangements, we may be unable to complete the development and commercialization of our product
candidates or continue operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">As our programs advance, our costs are likely
to increase. Our current and planned discovery, pre-clinical and clinical trials plus the related development, manufacturing, regulatory
approval process requirements, and additional personnel resources and testing required for supporting the development of our product
candidates will consume significant capital resources. Our expenses, revenues and cash utilization rate could vary significantly
depending on many factors, including: our ability to raise additional capital; the development progress of our collaborative agreements
for our product candidates; the amount of funding we receive from NIAID/HHS or other government agencies for BCX4430 or from other
new partnerships with third parties for the development of our product candidates, including BCX4161 and our second generation
HAE product candidates; the amount or profitability of any orders for RAPIVAB (peramivir injection) or BCX4430 by any government
agency or other party; the progress and results of our current and proposed clinical trials for our most advanced  product
candidates, including BCX4161, BCX7353 and our second generation HAE product candidates; the progress made in the manufacturing
of our lead products and the progression of our other programs. We expect that we will be required to enter into one or more acceptable
partnership arrangements in order to complete the development of ulodesine for the treatment of gout.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 27pt">We expect that we will be required to
raise additional capital to complete the development and commercialization of our current product candidates and we may seek to
raise capital at any time. Additional funding, whether through additional sales of securities or collaborative or other arrangements
with corporate partners or from other sources, including governmental agencies in general and from any BARDA/HHS or NIAID/HHS
contract specifically, may not be available when needed or on terms acceptable to us. The issuance of preferred or common stock
or convertible securities, with terms and prices significantly more favorable than those of the currently outstanding common stock,
could have the effect of diluting or adversely affecting the holdings or rights of our existing stockholders. In addition, collaborative
arrangements may require us to transfer certain material rights to such corporate partners. Insufficient funds or lack of an acceptable
partnership may require us to delay, scale-back or eliminate certain of our research and development programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">In order to continue future operations
and continue our drug development programs, we will be required to raise additional capital. In addition to seeking strategic
partnerships, transactions and government funding, we may decide to access the equity or debt markets or seek other sources to
meet liquidity needs. Our ability to raise additional capital may be limited and may greatly depend upon the success of ongoing
development related to our current drug development programs, including post approval studies for peramivir,&nbsp;the progress,
timeline and ultimate outcome of&nbsp;the OPuS-2 clinical trial, progress of our second generation HAE compounds, funding for
and continued successful development of BCX4430, and progress of our early discovery programs. In addition, constriction and volatility
in the equity and debt markets may restrict our future flexibility to raise capital when such needs arise. Furthermore, we have
exposure to many different industries, financing partners and counterparties, including commercial banks, investment banks and
partners (which include investors, licensing partners, and the U.S. Government) which may be unstable or may become unstable in
the current economic and political environment. Any such instability may impact these parties&rsquo; ability to fulfill contractual
obligations to us or they might limit or place burdensome conditions upon future transactions with us. Also, it is possible that
suppliers may be negatively impacted. Any such unfavorable outcomes in our current programs or unfavorable economic conditions
could place severe downward pressure on the stock and credit markets, which could reduce the return available on invested corporate
cash, which if severe and sustained could have a material and adverse impact on our results of operations and cash flows and limit
our ability to continue development of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0 0.25in; text-indent: 0in"><B><I>If NIAID/HHS was to eliminate,
reduce or delay funding from our contract, this would have a significant negative impact on our revenues and cash flows.</I></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">Our projections of revenues and incoming cash
flows are substantially dependent upon NIAID/HHS reimbursement for the costs related to our BCX4430 program. If NIAID/HHS was to
eliminate, reduce or delay the funding for these programs or disallow some of our incurred costs, we would have to obtain additional
funding for continued development or regulatory registration for these product candidates or significantly reduce or stop the development
effort.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">&nbsp;</P>

<!-- Field: Page; Sequence: 17; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">Further, BARDA/HHS and NIAID/HHS may challenge
actions that we have taken or may take under our contracts with them, which could negatively impact our operating results and
cash flows.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">In contracting with BARDA/HHS and NIAID/HHS,
we are subject to various U.S. Government contract requirements, including general clauses for a cost-reimbursement research and
development contract, which may limit our reimbursement or if we are found to be in violation could result in contract termination.
U.S. Government contracts typically contain extraordinary provisions that would not typically be found in commercial contracts.
For instance, government contracts permit unilateral modification by the government, interpretation of relevant regulations (i.e.,
federal acquisition regulation clauses), and the ability to terminate without cause. In addition, U.S. Government contracts are
subject to an in-process review, where the U.S. Government will review the project and its options under the contract. As such,
we may be at a disadvantage as compared to other commercial contracts. U.S. Government contracts are subject to audit and modification
by the government at its sole discretion. If the U.S. Government terminates any of its contracts with us for its convenience, or
if we default by failing to perform in accordance with the contract schedule and terms, significant negative impact on our cash
flows and operations could result.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in"><B><I>Our government contracts with
BARDA/HHS and NIAID/HHS have special contracting requirements, which create additional risks of reduction or loss of funding.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">We have recently completed work under a contract
with BARDA/HHS for the development of our neuraminidase inhibitor, peramivir. We also have entered into a contract with NIAID/HHS
for the development of BCX4430 as a treatment for Marburg virus disease and Ebola virus disease. In contracting with these government
agencies, we are subject to various U.S. Government contract requirements, including general clauses for a cost-reimbursement research
and development contract, which may limit our reimbursement or, if we are found to be in violation, could result in contract termination.
U.S. Government contracts typically contain extraordinary provisions that would not typically be found in commercial contracts.
For instance, government contracts permit unilateral modification by the government, interpretation of relevant regulations (i.e.,
federal acquisition regulation clauses), and the ability to terminate without cause. In addition, U.S. Government contracts are
subject to the in-process review described above. As such, we may be at a disadvantage as compared to competitors that do not rely
on U.S. Government contracts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 27pt">U.S. Government contracts typically contain
unfavorable termination provisions and are subject to audit and modification by the government at its sole discretion, each of
which subjects us to additional risks. These risks include the ability of the U.S. Government to unilaterally:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 5%; text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="width: 95%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">terminate or reduce the scope of our contract; and</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 5%; text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="width: 95%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">audit and object to our contract-related costs and fees, including allocated indirect costs.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">The U.S. Government may terminate its contracts
with us either for its convenience or if we default by failing to perform in accordance with the contract schedule and terms.
Termination for convenience provisions generally enable us to recover only our costs incurred or committed, and settlement expenses
and profit on the work completed prior to termination. Termination does not permit these recoveries under default provisions.
In the event of termination or upon expiration of a contract, the U.S. Government may dispute wind-down and termination costs
and may question prior expenses under the contract and deny payment of those expenses. Should we choose to challenge the U.S.
Government for denying certain payments under a contract, such a challenge could subject us to substantial additional expenses
which we may or may not recover. Further, if the U.S. Government terminates its contracts with us for its convenience, or if we
default by failing to perform in accordance with the contract schedule and terms, significant negative impact on our cash flows
and operations could result.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">As a U.S. Government contractor, we are required
to comply with applicable laws, regulations and standards relating to our accounting practices and are subject to periodic audits
and reviews. As part of any such audit or review, the U.S. Government may review the adequacy of, and our compliance with, our
internal control systems and policies, including those relating to our purchasing, property, estimating, compensation and management
information systems. Audits conducted by the U.S. Government for the BARDA/HHS contract have been performed and concluded through
fiscal 2009; all subsequent fiscal years are still open and auditable. Based on the results of its audits, the U.S. Government
may adjust our contract-related costs and fees, including allocated indirect costs. This adjustment could impact the amount of
revenues reported on a historic basis and could impact our cash flows under the contracts prospectively. In addition, in the event
BARDA/HHS or NIAID/HHS determines that certain costs and fees were unallowable or determines that the allocated indirect cost rate
was higher than the actual indirect cost rate, BARDA/HHS or NIAID/HHS would be entitled to recoup any overpayment from us as a
result. In addition, if an audit or review uncovers any improper or illegal activity, we may be subject to civil and criminal penalties
and administrative sanctions, including termination of our contracts, forfeiture of profits, suspension of payments, fines and
suspension or prohibition from doing business with the U.S. Government. We could also suffer serious harm to our reputation if
allegations of impropriety were made against us. In addition, under U.S. Government purchasing regulations, some of our costs may
not be reimbursable or allowed under our contracts. Further, as a U.S. Government contractor, we are subject to an increased risk
of investigations, criminal prosecution, civil fraud, whistleblower lawsuits and other legal actions and liabilities as compared
to private sector commercial companies</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: 0in"><B><I></I></B></P>

<!-- Field: Page; Sequence: 18; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: 0in"><B><I>If we fail to successfully commercialize
or establish collaborative relationships to commercialize certain of our product candidates or if any partner terminates or fails
to perform its obligations under agreements with us, potential revenues from commercialization of our product candidates could
be reduced, delayed or eliminated.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">Our business strategy is to increase the asset
value of our product candidate portfolio. We believe this is best achieved by retaining full product rights or through collaborative
arrangements with third parties as appropriate. As needed, potential third-party alliances could include preclinical development,
clinical development, regulatory approval, marketing, sales and distribution of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">Currently, we have established collaborative
relationships with Mundipharma for the development and commercialization of forodesine and with each of Shionogi and Green Cross
for the development and commercialization of peramivir, in Japan, Taiwan and South Korea. The process of establishing and implementing
collaborative relationships is difficult, time-consuming and involves significant uncertainty, including:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 5%; text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="width: 95%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">our partners may seek to renegotiate or terminate their relationships with us due to unsatisfactory clinical results, a change in business strategy, a change of control or other reasons;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">our contracts for collaborative arrangements may expire;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">our partners may choose to pursue alternative technologies, including those of our competitors;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"></P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 5%; text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="width: 95%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">we may have disputes with a partner that could lead to litigation or arbitration;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">we do not have day to day control over the activities of our partners and have limited control over their decisions;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">our ability to generate future event payments and royalties from our partners depends upon their abilities to establish the safety and efficacy of our product candidates, obtain regulatory approvals and achieve market acceptance of products developed from our product candidates;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">we or our partners may fail to properly initiate, maintain or defend our intellectual property rights, where applicable, or a party may utilize our proprietary information in such a way as to invite litigation that could jeopardize or potentially invalidate our proprietary information or expose us to potential liability;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">our partners may not devote sufficient capital or resources towards our product candidates; and</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">our partners may not comply with applicable government regulatory requirements.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">If we or our partners fail to fulfill our responsibilities
in a timely manner, or at all, our commercialization efforts related to that collaboration could be reduced, delayed or terminated,
or it may be necessary for us to assume responsibility for activities that would otherwise have been the responsibility of our
partner. If we are unable to establish and maintain collaborative relationships on acceptable terms, we may have to delay or discontinue
further development of one or more of our product candidates, undertake commercialization activities at our own expense or find
alternative sources of funding. Any delay in the development or commercialization of our product candidates would severely affect
our business, because if our product candidates do not progress through the development process or reach the market in a timely
manner, or at all, we may not receive additional future event payments and may never receive milestone, product sales or royalty
payments</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0 27.35pt"><B><I>We do not have a great deal of experience
in commercializing our products or technologies, and our future revenue generation is uncertain.</I></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: 0in"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">We do not have a great deal of experience
in commercializing our products or technologies. We currently have limited marketing
capability, no direct or third-party sales force and limited distribution capabilities. We may be unable to establish or
sufficiently increase these capabilities for products we are, or plan to, commercialize. In addition, our revenue from
collaborative agreements may be dependent upon the status of our preclinical and clinical programs. If we fail to advance
these programs to the point of being able to enter into successful collaborations, we will not receive any potential future
event or other collaborative payments.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">Our ability to receive revenue from products we commercialize presents
several risks, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 5%; text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <TD STYLE="width: 95%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">we or our collaborators may fail to successfully complete clinical trials sufficient to obtain FDA marketing approval;</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-indent: 0in">&nbsp;</td>
    <TD STYLE="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <TD STYLE="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">many competitors are more experienced and have significantly more resources, and their products could reach the market faster, be more cost effective or have a better efficacy or tolerability profile than our product candidates;</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-indent: 0in">&nbsp;</td>
    <TD STYLE="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <TD STYLE="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">we may fail to employ a comprehensive and effective intellectual property strategy, which could result in decreased commercial value of our Company and our products;</font></td></tr>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 19; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="text-indent: 0in; width: 5%">&nbsp;</td>
    <TD STYLE="text-indent: 0in; width: 95%">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <TD STYLE="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">we may fail to employ a comprehensive and effective regulatory strategy, which could result in a delay or failure in commercialization of our products;</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-indent: 0in">&nbsp;</td>
    <TD STYLE="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <TD STYLE="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">our ability to successfully commercialize our products is affected by the competitive landscape, which cannot be fully known at this time;</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-indent: 0in">&nbsp;</td>
    <TD STYLE="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <TD STYLE="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">reimbursement is constantly changing, which could greatly affect usage of our products; and</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-indent: 0in">&nbsp;</td>
    <TD STYLE="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <TD STYLE="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">future revenue from product sales would depend on our ability to successfully complete clinical studies, obtain regulatory approvals, and manufacture, market and commercialize our approved drugs.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in"><B><I>If our development collaborations
with third parties, such as our development partners and contract research organizations, fail, the development of our product
candidates will be delayed or stopped.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 27pt">We rely heavily upon other parties for
many important stages of our product candidate development, including but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 5%; text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="width: 95%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">discovery of compounds that cause or enable biological reactions necessary for the progression of the disease or disorder, called enzyme targets;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in">licensing or designing of enzyme inhibitors for development as product candidates;</td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">execution of some preclinical studies and late-stage development for our compounds and product candidates;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">management of our clinical trials, including medical monitoring and data management;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">execution of additional toxicology studies that may be required to obtain approval for our product candidates; and</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">manufacturing the starting materials and drug substance required to formulate our  products and the product candidates to be used in our clinical trials, toxicology studies and any potential commercial product.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">Our failure to engage in successful
collaborations at any one of these stages would greatly impact our business. If we do not license enzyme targets or
inhibitors from academic institutions or from other biotechnology companies on acceptable terms, our drug development efforts
would suffer. Similarly, if the contract research organizations that conduct our initial or late-stage clinical trials,
conduct our toxicology studies, manufacture our starting materials, drug substance and  product candidates or manage our
regulatory function breached their obligations to us or perform their services inconsistent with industry standards and not
in accordance with the required regulations, this would delay or prevent both the development of our product candidates and
the availability of any potential commercial product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">If we lose our relationship with any one or more
of these parties, we could experience a significant delay in both identifying another comparable provider and then contracting
for its services. We may be unable to retain an alternative provider on reasonable terms, if at all. Even if we locate an alternative
provider, it is likely that this provider may need additional time to respond to our needs and may not provide the same type or
level of service as the original provider. In addition, any provider that we retain will be subject to applicable FDA current Good
Laboratory Practices (&ldquo;cGLP&rdquo;), current Good Manufacturing Practices (&ldquo;cGMP&rdquo;) and current Good Clinical
Practices (&ldquo;cGCP&rdquo;), and comparable foreign standards. We do not have control over compliance with these regulations
by these providers. Consequently, if these practices and standards are not adhered to by these providers, the development and commercialization
of our product candidates could be delayed, and our business, financial condition and results of operations could be materially
adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0 0.25in"><B><I>Commercialization of RAPIVAB is subject to
the potential commercialization risks described herein and numerous additional risks. Any potential revenue benefits to us are
highly speculative. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">Commercialization success of RAPIVAB is uncertain
and is subject to all the risks and uncertainties disclosed in our other risk factors relating to drug development and commercialization.
In addition, commercialization of RAPIVAB is subject to further risks and commercialization may be negatively impacted by a number
of factors, including, but not limited to, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 5%; text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <TD STYLE="width: 95%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">RAPIVAB may not prove to be safe and sufficiently effective for market approval in the major markets other than the United States;</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-indent: 0in">&nbsp;</td>
    <TD STYLE="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <TD STYLE="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">necessary funding for post marketing commitments and further development of RAPIVAB may not be available timely, at all, or in sufficient amounts;</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-indent: 0in">&nbsp;</td>
    <TD STYLE="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <TD STYLE="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">flu prevention or pandemic treatment concerns may not materialize at all, or in the near future;</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-indent: 0in">&nbsp;</td>
    <TD STYLE="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <TD STYLE="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">advances in flu vaccines or other antivirals, including competitive i.v. antivirals, could substantially replace potential demand for RAPIVAB;</font></td></tr>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 20; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="text-indent: 0in; width: 5%">&nbsp;</td>
    <TD STYLE="text-indent: 0in; width: 95%">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <TD STYLE="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">any substantial demand for pandemic or seasonal flu treatments may not exist in the future;</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-indent: 0in">&nbsp;</td>
    <TD STYLE="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <TD STYLE="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">RAPIVAB may not be accepted by patients and physicians as a treatment for seasonal influenza compared to the other currently marketed antiviral drugs, which would limit revenue from non-governmental entities;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 5%; text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="width: 95%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">numerous large and well-established pharmaceutical and biotech companies will be competing to meet the market demand for flu drugs and vaccines;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">the only major markets in which patents relating to RAPIVAB have issued or been allowed are the United States, Canada, Japan, Australia and many contracting and extension states of the European Union, and no patent applications or issued patents for RAPIVAB exist in other potentially significant markets;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">regulatory authorities may not make needed accommodations to accelerate the drug testing and approval process for RAPIVAB outside the United States; </font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">a limited number of governmental entities are expected to be the primary potential stockpiling customers for RAPIVAB and if we are not successful at marketing RAPIVAB to these entities for any reason, we will not receive substantial revenues from stockpiling orders;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">government and third party payors may not provide sufficient coverage or reimbursement which would negatively impact the demand for RAPIVAB; </font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">we may not be able to maintain sufficient and acceptable commercial manufacturing ourselves or through third-party manufacturers; </font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">the commercial demand and acceptance for RAPIVAB by healthcare providers and by patients may not be sufficient
to result in substantial revenues of RAPIVAB;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 95%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&bull;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">effectiveness of our marketing efforts, especially since we have
    no     sales force for RAPIVAB and we have devoted limited resources to  its commercialization;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&bull;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">market satisfaction with existing alternative therapies; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&bull;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">perceived efficacy relative to other available therapies; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&bull;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">disease prevalence; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&bull;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">cost of treatment; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&bull;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">pricing and availability of alternative products; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&bull;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">marketing and sales activities of competitors; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&bull;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">shifts in the medical community to new treatment paradigms or standards of care; and </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&bull;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">relative convenience and ease of administration.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">If any or all of these and other risk factors
occur, we will not attain significant revenues or gross margins from RAPIVAB and our stock price and or cash flows may be adversely
affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt"><B><I>We are subject to various federal and state
laws regulating the marketing of RAPIVAB and, if we do not comply with these regulations, we could face substantial penalties.
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">Our sales, promotion and other activities related
to RAPIVAB, or any of our other products under development following their regulatory approval, are subject to regulatory and law
enforcement authorities in addition to the FDA, including the Federal Trade Commission, the Department of Justice, and state and
local governments. We are subject to various federal and state laws pertaining to health care &ldquo;fraud and abuse,&rdquo; including
both federal and state anti-kickback laws. Although we seek to comply with these statutes, it is possible that our practices, or
those of our distributors, might be challenged under anti-kickback or similar laws. Violations of fraud and abuse laws may be punishable
by civil or criminal sanctions, including fines and civil monetary penalties, and future exclusion from participation in government
healthcare programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">&nbsp;</P>

<!-- Field: Page; Sequence: 21; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">We have a number of
outstanding post-marketing commitments to the FDA, which we may not complete successfully or on time for any number of
reasons, including but not limited to lack of funds to complete the studies or insufficient interest by appropriate sites,
investigators or study subjects. For example, as a condition of the approval of RAPIVAB, we are required to complete a
pediatric patient study of RAPIVAB and to submit the final results of this clinical trial to the FDA. Depending on the
outcome of this clinical trial, we may be unable to expand the indication for RAPIVAB or we may be required to include
specific warnings or limitations on dosing this product, which could negatively impact our sales of RAPIVAB. We may be
subject to penalties if we fail to comply with post-approval legal and regulatory requirements and our products could be
subject to continual recordkeeping and reporting requirements, review and periodic inspections by the FDA and other
regulatory bodies. Regulatory approval of a product may be subject to limitations on the indicated uses for which the product
may be marketed or to the other restrictive conditions of approval that limit our ability to promote, sell or distribute a
product. Furthermore, RAPIVAB, and any other future product candidates&rsquo; approval, may contain requirements for costly
post-marketing testing and surveillance to monitor its  safety or efficacy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">Our advertising and promotion are subject to
stringent FDA rules and oversight. In particular, the claims in our promotional materials and activities must be consistent with
the FDA approvals for our products, and must be appropriately substantiated and fairly balanced with information on the safety
risks and limitations of the products. We must review adverse event information concerning our products and make expedited and
periodic adverse event reports to the FDA and other regulatory authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">In addition, the research, manufacturing,
distribution, sale and promotion of products are potentially subject to regulation by various federal, state and local authorities
in addition to the FDA, including the Centers for Medicare and Medicaid Services, other divisions of the U.S. Department of Health
and Human Services, the U.S. Department of Justice and individual U.S. Attorney offices within the Department of Justice, and state
and local governments. Pricing and rebate programs must comply with the Medicaid rebate requirements of the Omnibus Budget Reconciliation
Act of 1990, as amended, and the Veterans Health Care Act of 1992, as amended. If products are made available to authorized users
of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. All of these activities
are also potentially subject to federal and state consumer protection and unfair competition laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">If our operations are found to be in violation
of any of the healthcare fraud and abuse laws described above or any other governmental regulations that apply to us, we may be
subject to penalties, including civil and criminal penalties, damages, fines and the curtailment or restructuring of our operations.
Any penalties, damages, fines, curtailment or restructuring of our operations could adversely affect our ability to operate our
business and our financial results. Although compliance programs can mitigate the risk of investigation and prosecution for violations
of these laws, the risks cannot be entirely eliminated. Any action against us for violation of these laws, even if we successfully
defend against it, could cause us to incur significant legal expenses and divert our management's attention from the operation
of our business. Moreover, achieving and sustaining compliance with all applicable federal and state fraud and abuse laws may be
costly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in"><B><I>We are subject to new legislation, regulatory
proposals and healthcare payor initiatives that may increase our costs of compliance and adversely affect our ability to market
our products, obtain collaborators and raise capital. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 9pt 0 10pt; text-indent: 17.25pt">In March 2010, the President signed
the Patient Protection and Affordable Care Act, or PPACA, which makes extensive changes to the delivery of health care in the U.S.
The PPACA includes numerous provisions that affect pharmaceutical companies, some of which became effective immediately and others
of which will be taking effect over the next several years. For example, the PPACA seeks to expand health care coverage to the
uninsured through private health insurance reforms and an expansion of Medicaid. The PPACA will also impose substantial costs on
pharmaceutical manufacturers, such as an increase in liability for rebates paid to Medicaid, new drug discounts that must be offered
to certain enrollees in the Medicare prescription drug benefit, an annual fee imposed on all manufacturers of brand prescription
drugs in the U.S., and an expansion of an existing program requiring pharmaceutical discounts to certain types of hospitals and
federally subsidized clinics. The PPACA also contains cost containment measures that could reduce reimbursement levels for health
care items and services generally, including pharmaceuticals. It also will require reporting and public disclosure of payments
and other transfers of value provided by pharmaceutical companies to physicians and teaching hospitals. We cannot predict what
effect the PPACA or other healthcare reform initiatives that may be adopted in the future will have on our business. Further, it
remains unclear whether there will be any changes made to provisions of the PPACA or other health care laws through acts of Congress
in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of health
care services to contain or reduce costs of health care could result in decreased net revenues from our pharmaceutical products
and decrease potential returns from our development efforts. In addition, pharmaceutical and device manufacturers will also be
required to report and disclose investment interests held by physicians and their immediate family members during the preceding
calendar year. &nbsp;Failure to submit required information may result in civil monetary penalties for payments, transfers of value
or ownership or investment interests not reported in an annual submission. Compliance with the PPACA and state laws with similar
provisions is difficult and time consuming, and companies that do not comply with these state laws face civil penalties. Because
of the breadth of these laws and the narrowness of the safe harbors, it is possible that some of our business activities could
be subject to challenge under one or more of such laws. Such a challenge could have a material adverse effect on our business,
financial condition, results of operations and growth prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 10pt; text-indent: 17.3pt"></P>

<!-- Field: Page; Sequence: 22; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 10pt; text-indent: 17.3pt">In addition, there have been a number
of other legislative and regulatory proposals aimed at changing the pharmaceutical industry. In particular, legislation has been
enacted in certain states and proposed at a federal level that requires development of an electronic pedigree to track and trace
each prescription drug at the saleable unit level through the distribution system. Compliance with these electronic pedigree requirements
may increase our operational expenses and impose significant administrative burdens. In addition, our compliance may be deemed
insufficient and we could fact a material adverse effect on our business, financial condition, results of operations and growth
prospects.&nbsp; As a result of these and other new proposals, we may determine to change our current manner of operation, provide
additional benefits or change our contract arrangements, any of which could have a material adverse effect on our business, financial
condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 10pt; text-indent: 0.25in">Managed care organizations are increasingly
challenging the prices charged for medical products and services and, in some cases, imposing restrictions on the coverage of particular
drugs. Many managed care organizations negotiate the price of medical services and products and develop formularies which establish
pricing and reimbursement levels. Exclusion of a product from a formulary can lead to its sharply reduced usage in the managed
care organization&rsquo;s patient population. The process for obtaining coverage can be lengthy and costly, and we expect that
it could take several months before a particular payor initially reviews our product and makes a decision with respect to coverage.
For example, third-party payors may require cost-benefit analysis data from us in order to demonstrate the cost-effectiveness of
RAPIVAB or any other product we might bring to market. For any individual third-party payor, we may not be able to provide data
sufficient to gain reimbursement on a similar or preferred basis to competitive products, or at all which may have a material adverse
effect on our business, financial condition and results of operations.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in"><B><I>There are risks related to the
potential government use or sale of RAPIVAB.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">Government use or sale of RAPIVAB in emergency
situations, or otherwise, may result in the use of RAPIVAB which is outside of its approved use. To the extent that RAPIVAB is
used as a treatment for influenza by any government entity, there can be no assurance that it will prove to be generally safe,
well-tolerated and effective. Such government use of RAPIVAB may create certain liabilities for us. There is no assurance that
we or our manufacturers will be able to fully meet the demand for RAPIVAB in the event of additional orders. Further, we may not
achieve a favorable price for additional orders of RAPIVAB in the United States or in any other country. Our competitors may develop
products that could compete with or replace RAPIVAB. We may face competition in markets where we have no existing intellectual
property protection or are unable to successfully enforce our intellectual property rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">There is no assurance that the non-U.S.
partnerships that we have entered into for RAPIVAB will result in any order for RAPIVAB in those countries. There is no assurance
that RAPIVAB will be approved for any use or will achieve market approval in additional countries. In the event that any emergency
use or market approval is granted, there is no assurance that any order by any non-U.S. partnership or commercialization of RAPIVAB
in other countries will be substantial or will be profitable to us. The sale of RAPIVAB, emergency use or other use of RAPIVAB
in any country may create certain liabilities for us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in"><B><I>Because we have limited
manufacturing experience, we depend on third-party manufacturers to manufacture our product, product candidates and the
materials for our product candidates. If we cannot rely on third-party manufacturers, we will be required to incur
significant costs and potential delays in finding new third-party manufacturers.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">We have limited manufacturing experience
and only a small scale manufacturing facility. We currently rely upon third-party manufacturers to manufacture the materials
required for our product, product candidates and most of the preclinical and clinical quantities of our product candidates.
We depend on these third-party manufacturers to perform their obligations in a timely manner and in accordance with
applicable governmental regulations. Our third-party manufacturers may encounter difficulties with meeting our requirements,
especially for RAPIVAB and BCX4161, including but not limited to problems involving:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 5%; text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="width: 95%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">inconsistent production yields;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">product liability claims;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">difficulties in scaling production to commercial and validation sizes;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">interruption of the delivery of materials required for the manufacturing process;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">scheduling of plant time with other vendors or unexpected equipment failure;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">potential catastrophes that could strike their facilities or have an effect on infrastructure;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">potential impurities in our drug substance or products that could affect availability of product for our clinical trials or future commercialization;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">poor quality control and assurance or inadequate process controls; and</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">lack of compliance or cooperation with regulations and specifications or requests set forth by the FDA or other foreign regulatory agencies, particularly associated with RAPIVAB and planned studies for BCX4161, BCX7353 and BCX4430.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 27pt">For example, our product manufacturer
for RAPIVAB has been issued a Warning Letter and a Form 483 from the FDA. Failure to adequately address the observations
made in the Form 483 and subsequent, timely satisfactory inspections and other necessary FDA processes may result in issues with
future supply of RAPIVAB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt"></P>

<!-- Field: Page; Sequence: 23; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">These contract manufacturers may not be able
to manufacture the materials required for our product candidates at a cost or in quantities necessary to make them commercially
viable. We also have no control over whether third-party manufacturers breach their agreements with us or whether they may terminate
or decline to renew agreements with us. To date, our third-party manufacturers have met our manufacturing requirements, but they
may not continue to do so. Furthermore, changes in the manufacturing process or procedure, including a change in the location where
the drug is manufactured or a change of a third-party manufacturer (including RAPIVAB), may require prior review and approval in
accordance with the FDA&rsquo;s cGMP and comparable foreign requirements. This review may be costly and time-consuming and could
delay or prevent the launch of a product. The FDA or similar foreign regulatory agencies at any time may also implement new standards,
or change their interpretation and enforcement of existing standards for manufacture, packaging or testing of products. If we or
our contract manufacturers are unable to comply, we or they may be subject to regulatory action, civil actions or penalties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">If we are unable to maintain current manufacturing
or other contract relationships, or enter into new agreements with additional manufacturers on commercially reasonable terms, or
if there is poor manufacturing performance or failure to comply with any regulatory agency on the part of any of our third-party
manufacturers, we may not be able to complete development of, seek timely approval of, or market, our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">Our raw materials, drug substances,
and product candidates are manufactured by a limited group of suppliers and some at a single facility. If any of these
suppliers were unable to produce these items, this could significantly impact our supply of product candidate material for
further preclinical testing and clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0 0.25in; text-indent: 0in"><B><I>Royalties and milestone payments
from Shionogi under the Company&rsquo;s license agreement with Shionogi (the &ldquo;Shionogi Agreement&rdquo;) will be required
to be used by Royalty Sub to service its obligations under its PhaRMA Notes, and generally will not be available to us for other
purposes until Royalty Sub has repaid in full its obligations under the PhaRMA Notes.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">In March 2011, our wholly-owned subsidiary
Royalty Sub issued $30.0 million in aggregate principal amount of PhaRMA Notes. The PhaRMA Notes are secured principally by (i)
certain royalty and milestone payments under the Shionogi Agreement, pursuant to which Shionogi licensed from us the rights to
market peramivir in Japan and, if approved for commercial sale, Taiwan, (ii) rights to certain payments under a Japanese yen/U.S.
dollar foreign currency hedge arrangement put into place by us in connection with the issuance of the PhaRMA Notes and (iii) the
pledge by us of our equity interest in Royalty Sub. Payments from Shionogi to us under the Shionogi Agreement will generally not
be available to us for other purposes until Royalty Sub has repaid in full its obligations under the PhaRMA Notes. Accordingly,
these funds will be required to be dedicated to Royalty Sub&rsquo;s debt service and not available to us for product development
or other purposes. As of September 1, 2014, the payments from Shionogi were insufficient for Royalty Sub to service its obligations
under the PhaRMA Notes, resulting in an event of default with respect to the PhaRMA Notes. As a result of this event of default,
the holders of the PhaRMA Notes may be able to pursue acceleration of the PhaRMA Notes and foreclose on the collateral securing
the PhaRMA Notes and our equity interest in Royalty Sub and may&nbsp;exercise other remedies available to them under the indenture
or other documents related to&nbsp;the PhaRMA Notes. In such event, we may not realize the benefit of future royalty payments that
might otherwise accrue to us following repayment of the PhaRMA Notes, we may incur legal costs&nbsp;and we might otherwise be adversely
affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in"><B><I>Because an event of default has
occurred under the PhaRMA Notes, the holders of the PhaRMA Notes may be able to pursue acceleration of the PhaRMA Notes and foreclose
on the collateral securing the PhaRMA Notes and our equity interest in Royalty Sub, in which case we may not realize the benefit
of future royalty payments that might otherwise accrue to us following repayment of the PhaRMA Notes and we could otherwise be
adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23.05pt">Royalty Sub&rsquo;s ability to service
its payment obligations in respect of the PhaRMA Notes, and our ability to benefit from our equity interest in Royalty Sub, is
subject to numerous risks. Peramivir was first approved for marketing and manufacturing in Japan in October 2009 and has been offered
for sale in Japan only since January 2010. As a result, there is limited sales history for peramivir in Japan, and there can
be no assurance that peramivir will gain market acceptance in the Japanese market. In addition, Shionogi&rsquo;s sales of peramivir
are expected to be highly seasonal and vary significantly from year to year, and the market for products to treat or prevent influenza
is highly competitive. Under our license agreement with Shionogi, Shionogi has control over the commercial process for peramivir
in Japan and Taiwan. Royalty Sub&rsquo;s ability to service the PhaRMA Notes may be adversely affected by, among other things,
changes in or any termination of our relationship with Shionogi, reimbursement, regulatory, manufacturing and/or intellectual property
issues, product returns, product recalls, product liability claims and allegations of safety issues, as well as other factors.
As Royalty Sub has been unable to service its obligations under the PhaRMA Notes and an event of default has occurred under the
PhaRMA Notes, the holders of the PhaRMA Notes may be able to pursue acceleration of the PhaRMA Notes and foreclose on the collateral
securing the PhaRMA Notes and our equity interest in Royalty Sub and may&nbsp;exercise other remedies available to them under the
indenture&nbsp;or other documents related to&nbsp;the PhaRMA Notes. In such event, we may not realize the benefit of future royalty
payments that might otherwise accrue to us following repayment of the PhaRMA Notes, we may incur legal costs&nbsp;and we might
otherwise be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt"></P>

<!-- Field: Page; Sequence: 24; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in"><B><I>Shionogi&rsquo;s failure to successfully
market and commercialize peramivir in Japan would have a material adverse effect on Royalty Sub&rsquo;s ability to service its
obligations on the PhaRMA Notes.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">The successful commercialization of peramivir
in Japan depends on the efforts of Shionogi and is beyond the control of us or Royalty Sub. Sales by Shionogi depend on many factors,
including the incidence and severity of seasonal influenza in Japan each year (both of which can vary very significantly from year
to year), the perceived and actual efficacy and safety of peramivir, the experience of physicians and patients with peramivir,
continued market acceptance, continued availability of supply, competition, sales and marketing efforts, governmental regulation,
and pricing and reimbursement in Japan. Shionogi is responsible for the marketing and sale of peramivir in Japan, including with
respect to the pricing of peramivir in that market. There are no minimum royalties, sales levels or other performance measures
required of Shionogi under the Shionogi Agreement and Shionogi could in its sole discretion reduce or cease its sale efforts of
peramivir in Japan, subject to its covenant in the Shionogi Agreement to use diligent efforts to commercialize peramivir in Japan.
If Shionogi is unable to, or fails to, successfully market and commercialize peramivir, it would have a material adverse effect
on Royalty Sub&rsquo;s ability to service its obligations under the PhaRMA Notes and our ability to benefit from our equity interest
in Royalty Sub. To date, Shionogi royalties have been insufficient for Royalty Sub to service annual interest obligations from the
PhaRMA Notes and the PhaRMA Notes are in default<B><I>.</I></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in"><B><I>We may be required to pay significant
premiums under the foreign currency hedge arrangement entered into by us in connection with the issuance of the PhaRMA Notes. In
addition, because our potential obligations under the foreign currency hedge are marked to market, we may experience additional
quarterly volatility in our operating results and cash flows attributable to the foreign currency hedge arrangement.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">In connection with the issuance by Royalty
Sub of the PhaRMA Notes, we entered into a foreign currency hedge arrangement to hedge certain risks associated with changes in
the value of the Japanese yen relative to the U.S. dollar. Under the foreign currency hedge agreement, we may be required to pay
an annual premium in the amount of $2.0 million in each May, provided the foreign currency hedge arrangement remains in effect,
continuing through May 2020. Such payment will be required if, in May of the relevant year, the spot rate of exchange for Japanese
yen-U.S. dollars (determined in accordance with the foreign currency hedge arrangement) is such that the U.S. dollar is worth 100
yen or less. We will be required to mark-to-market our potential obligations under the currency hedge and post cash collateral,
which may cause us to experience additional quarterly volatility in our operating results and cash flows as a result. Additionally,
we may be required to pay significant premiums or a termination fee under the foreign currency hedge agreement entered into by
us in connection with the issuance of the PhaRMA Notes. The Company is required to maintain a foreign currency hedge at 100 yen
per dollar under the agreements governing the PhaRMA Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in"><B><I>If we or our partners do
not obtain and maintain governmental approvals for our product candidates under development, we or our partners will not be
able to sell these potential products, which would significantly harm our business because we will receive no
revenue.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">We or our partners must obtain regulatory approval
before marketing or selling our future product candidates. If we or our partners are unable to receive regulatory approval and do not
market or sell our future product candidates, we will never receive any revenue from such product sales. In the United States, we or
our partners must obtain FDA approval for product candidates that we intend to commercialize. The process of preparing for and obtaining
FDA approval may be lengthy and expensive, and approval is never certain. Products distributed abroad are also subject to foreign
government regulation and export laws of the United States. Because of the risks and uncertainties in biopharmaceutical development,
our product candidates could take a significantly longer time to gain regulatory approval than we expect or may never gain approval.
If the FDA delays regulatory approval of our product candidates, our management&rsquo;s credibility, our  value
and our operating results may suffer. Even if the FDA or foreign regulatory agencies approve a product candidate, the approval
may limit the indicated uses for a product candidate and/or may require post-approval studies.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">The FDA regulates, among other things,
the record keeping and storage of data pertaining to potential pharmaceutical products. We currently store most of our preclinical
research data, our clinical data and our manufacturing data at our facility. While we do store duplicate copies of most of our
clinical data offsite and a significant portion of our data is included in regular backups of our systems, we could lose important
data if our facility incurs damage, or if our vendor data systems fail, suffer damage or are destroyed. If we receive approval
to market our potential products, whether in the United States or internationally, we will continue to be subject to extensive
regulatory requirements. These requirements are wide ranging and govern, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">adverse drug experience reporting regulations;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">product promotion;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">product manufacturing, including good manufacturing practice requirements;&nbsp;and</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">product changes or modifications.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">Our failure to comply with existing or
future regulatory requirements, or our loss of, or changes to, previously obtained approvals, could have a material adverse effect
on our business because we will not receive product or royalty revenues if we or our partners do not receive approval of our products
for marketing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in"><B><I>We face intense competition,
and if we are unable to compete effectively, the demand for our products, if any, may be reduced.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">The biotechnology and pharmaceutical industries
are highly competitive and subject to rapid and substantial technological change. There are many companies seeking to develop products
for the same indications that we are working on. Our competitors in the United States and elsewhere are numerous and include, among
others, major multinational pharmaceutical and chemical companies and specialized biotechnology firms. Most of these competitors
have greater resources than we do, including greater financial resources, larger research and development staffs and more experienced
marketing and manufacturing organizations. In addition, most of our competitors have greater experience than we do in conducting
clinical trials and obtaining FDA and other regulatory approvals. Accordingly, our competitors may succeed in obtaining FDA or
other regulatory approvals of product candidates more rapidly than we do. Companies that complete clinical trials, obtain required
regulatory approvals, and commence commercial sale of their drugs before we do may achieve a significant competitive advantage,
including patent and FDA exclusivity rights that would delay our ability to market products. We face, and will continue to face,
competition in the licensing of desirable disease targets, licensing of desirable product candidates, and development and marketing
of our product candidates from academic institutions, government agencies, research institutions and biotechnology and pharmaceutical
companies. Competition may also arise from, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 25; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">other drug development technologies;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">methods of preventing or reducing the incidence of disease, including vaccines;&nbsp;and</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">new small molecule or other classes of therapeutic agents.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">Developments by others may render our product
candidates or technologies obsolete or noncompetitive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">We and our partners are performing research
on or developing products for the treatment of several disorders including HAE, recurrent/refractory peripheral T-cell lymphoma
and broad spectrum antivirals which may be developed as medical countermeasures. We expect to encounter significant competition
for any of the pharmaceutical products we plan to develop. Companies that complete clinical trials, obtain required funding or
government support, obtain required regulatory approvals and commence commercial sales or stockpiling orders of their products
before their competitors may achieve a significant competitive advantage. Such is the case with Eisai Co. Ltd.&rsquo;s TARGRETIN&reg;
for cutaneous T-cell lymphoma and the current neuraminidase inhibitors marketed by GSK and Roche for influenza and CINRYZE&reg;
and FIRAZYR&reg; for HAE, marketed by Shire Pharmaceuticals, Inc., and KALBITOR&reg; for HAE, marketed by Dyax Corporation. Therapeutic
products with potentially promising data to treat Ebola include Tekmira Pharmaceutical s Corporation&rsquo;s TKM-Ebola (RNAi interference
based) and Mapp Biopharmaceutical, Inc.&rsquo;s ZMapp (antibody-based) both of which have been used in Ebola patients. Further,
several pharmaceutical and biotechnology firms, including major pharmaceutical companies and specialized structure-based drug design
companies, have announced efforts in the field of structure-based drug design and molecules in development in the fields of HAE
and in other therapeutic areas where we have discovery and development efforts ongoing. If one or more of our competitors&rsquo;
products or programs are successful, the market for our products may be reduced or eliminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">Compared to us, many of our competitors
and potential competitors have substantially greater:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">capital resources;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">research and development resources, including personnel and technology;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">regulatory experience;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">preclinical study and clinical testing experience;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">manufacturing and marketing experience;&nbsp;and</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">production facilities.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">Any of these competitive factors could
impede our funding efforts, render technology and product candidates non-competitive or eliminate or reduce demand for our product
candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in"><B><I>If we fail to adequately protect
or enforce our intellectual property rights or secure rights to patents of others, the value of those rights would diminish.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">Our success will depend in part on our ability
and the abilities of our partners to obtain, protect and enforce viable intellectual property rights including but not limited
to trade name, trademark and patent protection for our Company and its products, methods, processes and other technologies we may
license or develop, to preserve our trade secrets, and to operate without infringing the proprietary rights of third parties both
domestically and abroad. The patent position of biotechnology and pharmaceutical companies is generally highly uncertain, involves
complex legal and factual questions and has recently been the subject of much litigation. Neither the United States Patent and
Trademark Office (&ldquo;USPTO&rdquo;), the Patent Cooperation Treaty offices, nor the courts of the United States and other jurisdictions
have consistent policies nor predictable rulings regarding the breadth of claims allowed or the degree of protection afforded under
many biotechnology and pharmaceutical patents. Further, we may not have worldwide patent protection for all of our product candidates
and our intellectual property rights may not be legally protected or enforceable in all countries throughout the world. In some
jurisdictions, some of our product candidates in certain programs, including our HAE program, may have short or no composition
of matter patent life and we may therefore rely on orphan drug exclusivity or data exclusivity. There can be no assurance that
we will obtain orphan drug exclusivity or data exclusivity in every jurisdiction. Further, in some jurisdictions, we may rely on
formulation patents or method of use patents. Both the ability to achieve issuance and the enforcement of formulation and method
of use patents can be highly uncertain and can vary from jurisdiction to jurisdiction, and such patents may therefore not adequately
prevent competitors and potential infringers in some jurisdictions. The validity, scope, enforceability and commercial value of
the rights protected by such patents, therefore, is highly uncertain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 26; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">We also rely on trade secrets to protect technology
in cases when we believe patent protection is not appropriate or obtainable. However, trade secrets are difficult to protect. If
we cannot maintain the confidentiality of our technology and other confidential information in connection with our collaborators
and advisors, our ability to receive patent protection or protect our proprietary information may be imperiled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">Our success depends in part on avoiding the infringement
of other parties&rsquo; patents and other intellectual property rights as well as avoiding the breach of any licenses relating
to our technologies and products. In the United States, patent applications filed in recent years are confidential for 18 months,
while older applications are not published until the patent issues. As a result, avoiding patent infringement may be difficult
and we may inadvertently infringe third-party patents or proprietary rights. These third parties could bring claims against us,
our partners or our licensors that even if resolved in our favor, could cause us to incur substantial expenses and, if resolved
against us, could additionally cause us to pay substantial damages. Further, if a patent infringement suit were brought against
us, our partners or our licensors, we or they could be forced to stop or delay research, development, manufacturing or sales of
any infringing product in the country or countries covered by the patent we infringe, unless we can obtain a license from the patent
holder. Such a license may not be available on acceptable terms, or at all, particularly if the third party is developing or marketing
a product competitive with the infringing product. Even if we, our partners or our licensors were able to obtain a license, the
rights may be nonexclusive, which would give our competitors access to the same intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">If we or our partners are unable or fail
to adequately initiate, protect, defend or enforce our intellectual property rights in any area of commercial interest or in any
part of the world where we wish to seek regulatory approval for our products, methods, processes and other technologies, the value
of the product candidates to produce revenue would diminish. Additionally, if our products, methods, processes, and other technologies
or our commercial use of such products, processes, and other technologies, including but not limited to any trade name, trademark
or commercial strategy infringe the proprietary rights of other parties, we could incur substantial costs. The USPTO and the patent
offices of other jurisdictions have issued to us a number of patents for our various inventions and we have in-licensed several
patents from various institutions. We have filed additional patent applications and provisional patent applications with the USPTO.
We have filed a number of corresponding foreign patent applications and intend to file additional foreign and U.S. patent applications,
as appropriate. We have also filed certain trademark and trade name applications worldwide. We cannot assure you as to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">the degree and range of protection any patents will afford against competitors with similar products;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">if and when patents will issue;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">if patents do issue we cannot be sure that we will be able to adequately defend such patents and whether or not we will be able to adequately enforce such patents;&nbsp;or</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">whether or not others will obtain patents claiming aspects similar to those covered by our patent applications.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">If the USPTO or other foreign patent office
upholds patents issued to others or if the USPTO grants patent applications filed by others, we may have to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">obtain licenses or redesign our products or processes to avoid infringement;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">stop using the subject matter claimed in those patents;&nbsp;or</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">pay damages.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">We may initiate, or others may bring against
us, litigation or administrative proceedings related to intellectual property rights, including proceedings before the USPTO or
other foreign patent office. Any judgment adverse to us in any litigation or other proceeding arising in connection with a patent
or patent application could materially and adversely affect our business, financial condition and results of operations. In addition,
the costs of any such proceeding may be substantial whether or not we are successful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">Our success is also dependent upon
the skills, knowledge and experience, none of which is patentable, of our scientific and technical personnel. To help protect our
rights, we require all employees, consultants, advisors and partners to enter into confidentiality agreements that prohibit the
disclosure of confidential information to anyone outside of our company and require disclosure and assignment to us of their ideas,
developments, discoveries and inventions. These agreements may not provide adequate protection for our trade secrets, know-how
or other proprietary information in the event of any unauthorized use or disclosure or the lawful development by others of such
information, and if any of our proprietary information is disclosed, our business will suffer because our revenues depend upon
our ability to license or commercialize our product candidates and any such events would significantly impair the value of such
product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in"><B><I>We face an inherent risk of liability
in the event that the use or misuse of our products results in personal injury or death and our product liability insurance coverage
may be insufficient.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">If the use or misuse of RAPIVAB or any other
FDA-approved products we may sell in the future harms people, we may be subject to costly and damaging product liability claims
brought against us by consumers, healthcare providers, pharmaceutical companies, third-party payors or others. The use of our product
candidates in clinical trials could also expose us to product liability claims. We cannot predict all of the possible harms or
side effects that may result from the use of our products or the testing of product candidates and, therefore, the amount of insurance
coverage we currently may not be adequate to cover all liabilities or defense costs we might incur. A product liability claim or
series of claims brought against us could give rise to a substantial liability that could exceed our resources. Even if claims
are not successful, the costs of defending such claims and potential adverse publicity could be harmful to our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">&nbsp;</P>

<!-- Field: Page; Sequence: 27; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">We face an inherent risk of product liability
exposure related to the testing of our product candidates in human clinical trials and will face even greater risks upon any commercialization
by us of our product candidates. We have product liability insurance covering our commercial sale of RAPIVAB and our clinical trials.
Clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient
insurance or increase our existing coverage at a reasonable cost to protect us against losses that could have a material adverse
effect on our business. An individual may bring a product liability claim against us if one of our products or product candidates
causes, or is claimed to have caused, an injury or is found to be unsuitable for consumer use. Any product liability claim brought
against us, with or without merit, could result in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">liabilities that substantially exceed our product liability insurance, which we would then be required to pay from other sources, if available;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">an increase of our product liability insurance rates or the inability to maintain insurance coverage in the future on acceptable terms, or at all;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">withdrawal of clinical trial volunteers or patients;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">damage to our reputation and the reputation of our products, resulting in lower sales;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">regulatory investigations that could require costly recalls or product modifications;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">litigation costs;&nbsp;and</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">the diversion of management&rsquo;s attention from managing our business.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in"><B><I>Insurance coverage is increasingly
more costly and difficult to obtain or maintain.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">While we currently have insurance for our business,
property, directors and officers, and our products insurance is increasingly more costly and narrower in scope, and we may be required
to assume more risk in the future. If we are subject to claims or suffer a loss or damage in excess of our insurance coverage,
we will be required to bear any loss in excess of our insurance limits. If we are subject to claims or suffer a loss or damage
that is outside of our insurance coverage, we may incur significant uninsured costs associated with loss or damage that could have
an adverse effect on our operations and financial position. Furthermore, any claims made on our insurance policies may impact our
ability to obtain or maintain insurance coverage at reasonable costs or at all.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in"><B><I>If our facility incurs damage
or power is lost for a significant length of time, our business will suffer.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">We store clinical and stability samples at our
facility that could be damaged if our facility incurs physical damage or in the event of an extended power failure. We have backup
power systems in addition to backup generators to maintain power to all critical functions, but any loss of these samples could
result in significant delays in our drug development process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">In addition, we store most of our
preclinical and clinical data at our facilities. Duplicate copies of most critical data are secured off-site. Any significant degradation
or failure of our computer systems could cause us to inaccurately calculate or lose our data. Loss of data could result in significant
delays in our drug development process and any system failure could harm our business and operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in"><B><I>If we fail to retain our existing
key personnel or fail to attract and retain additional key personnel, the development of our product candidates and commercialization
of our products and the related expansion of our business will be delayed or stopped.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are highly dependent upon our senior
management and scientific team, the unexpected loss of whose services might impede the achievement of our development and commercial
objectives. Competition for key personnel with the experience that we require is intense and is expected to continue to increase.
Our inability to attract and retain the required number of skilled and experienced management, commercial, operational and scientific
personnel will harm our business because we rely upon these personnel for many critical functions of our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in"><B><I>If because of our use of hazardous
materials, we violate any environmental controls or regulations that apply to such materials, we may incur substantial costs and
expenses in our remediation efforts.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">Our research and development involves
the controlled use of hazardous materials, chemicals and various radioactive compounds. We are subject to federal, state and local
laws and regulations governing the use, storage, handling and disposal of these materials and some waste products. Accidental contamination
or injury from these materials could occur. In the event of an accident, we could be liable for any damages that result and any
liabilities could exceed our resources. Compliance with environmental laws and regulations or a violation of such environmental
laws and regulations could require us to incur substantial unexpected costs, which would materially and adversely affect our results
of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>Risks relating to investing in our common stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in"><B><I>Our existing principal stockholders
hold a substantial amount of our common stock and may be able to influence significant corporate decisions, which may conflict
with the interest of other stockholders.</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">Several of our stockholders own greater
than 5% of our outstanding common stock. Our top five stockholders own more than 50% of BioCryst and can individually, and as
a group, influence our operations based upon their concentrated ownership. These stockholders, if they act together, may be able
to influence the outcome of matters requiring approval of the stockholders, including the election of our directors and other corporate
actions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<!-- Field: Page; Sequence: 28; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in"><B><I>Our stock price has been, and
is likely to continue to be, highly volatile, which could result in the value of your investment in our common stock to decline
significantly.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">The market prices for securities of biotechnology
companies in general have been highly volatile and may continue to be highly volatile in the future. Moreover, our stock price
has fluctuated frequently, and these fluctuations are often not related to our financial results. For the twelve months ended December
31, 2014, the 52-week range of the market price of our stock was from $7.29 to $14.62 per share. The following factors, in addition
to other risk factors described in this section, may have a significant impact on the market price of our common stock:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 5%; text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="width: 95%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">announcements of technological innovations or new products by us or our competitors;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">developments or disputes concerning patents or proprietary rights;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">additional dilution through sales of our common stock or other derivative securities;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">status of new or existing licensing or collaborative agreements and government contracts;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">announcements relating to the status of our programs;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">developments and announcements regarding new and virulent strains of influenza;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">we or our partners achieving or failing to achieve development milestones;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">publicity regarding actual or potential medical results relating to products under development by us or our competitors;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">publicity regarding certain public health concerns for which we are or may be developing treatments;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 5%; text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="width: 95%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">regulatory developments in both the United States and foreign countries;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">public concern as to the safety of pharmaceutical products;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">actual or anticipated fluctuations in our operating results;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">changes in financial estimates or recommendations by securities analysts;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">changes in the structure of healthcare payment systems, including developments in price control legislation;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">additions or departures of key personnel or members of our board of directors;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">purchases or sales of substantial amounts of our stock by existing stockholders, including officers or directors;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">economic and other external factors or other disasters or crises; and</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">period-to-period fluctuations in our financial results.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0 11.5pt; text-indent: 0in"><B><I>Future sales and issuances
of securities may dilute the ownership interests of our current stockholders and cause our stock price to decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">Future sales of our common stock by current
stockholders into the public market could cause the market price of our stock to fall. As of January&nbsp;31, 2015, there were
72,320,136 shares of our common stock outstanding. We may from time to time issue securities in relation to a license arrangement,
collaboration, merger or acquisition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">As of January&nbsp;31, 2015, there were
11,067,975 stock options and restricted stock units outstanding, 1,369,593 shares available for issuance under our Amended and
Restated Stock Incentive Plan, and 538,293 shares available for issuance under our Employee Stock Purchase Plan. In addition,
we could also make equity compensation grants outside of our Stock Incentive Plan. The shares underlying existing stock options,
restricted stock units and possible future stock options, stock appreciation rights and stock awards have been registered pursuant
to registration statements on Form S-8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23.05pt"></P>

<!-- Field: Page; Sequence: 29; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23.05pt">If some or all of such shares are sold
or otherwise issued into the public market over a short period of time, our current stockholders&rsquo; ownership interests may
be diluted and the value of all publicly traded shares is likely to decline, as the market may not be able to absorb those shares
at then-current market prices. Additionally, such sales and issuances may make it more difficult for us to sell equity securities
or equity-related securities in the future at a time and price that our management deems acceptable, or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in"><B><I>We have anti-takeover provisions
in our corporate charter documents that may result in outcomes with which you do not agree.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23.05pt">Our board of directors has the authority
to issue up to 4,800,000 shares of undesignated preferred stock and to determine the rights, preferences, privileges and restrictions
of those shares without further vote or action by our stockholders. The rights of the holders of any preferred stock that may
be issued in the future may adversely affect the rights of the holders of common stock. The issuance of preferred stock could
make it more difficult for third parties to acquire a majority of our outstanding voting stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23.05pt">In addition, our certificate of
incorporation provides for staggered terms for the members of the board of directors and supermajority approval of the removal
of any member of the board of directors and prevents our stockholders from acting by written consent. Our certificate also requires
supermajority approval of any amendment of these provisions. These provisions and other provisions of our by-laws and of Delaware
law applicable to us could delay or make more difficult a merger, tender offer or proxy contest involving us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0 0.25in; text-indent: 0in"><B><I>We have never paid dividends
on our common stock and do not anticipate doing so in the foreseeable future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23.05pt">We have never paid cash dividends on our
stock. We currently intend to retain all future earnings, if any, for use in the operation of our business. Accordingly, we do
not anticipate paying cash dividends on our common stock in the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0.25in; text-align: left; margin-bottom: 0"><B>Information
Regarding Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23.05pt">This filing contains forward-looking statements
within the meaning of Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, which are subject to the &ldquo;safe
harbor&rdquo; created in Section&nbsp;21E. All statements other than statements of historical facts contained in this filing are
forward-looking statements. These forward-looking statements can generally be identified by the use of words such as &ldquo;may,&rdquo;
&ldquo;will,&rdquo; &ldquo;intends,&rdquo; &ldquo;plans,&rdquo; &ldquo;believes,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;expects,&rdquo;
&ldquo;estimates,&rdquo; &ldquo;predicts,&rdquo; &ldquo;potential,&rdquo; the negative of these words or similar expressions. Statements
that describe our future plans, strategies, intentions, expectations, objectives, goals or prospects are also forward-looking statements.
Discussions containing these forward-looking statements are principally contained in &ldquo;Business,&rdquo; &ldquo;Risk Factors&rdquo;
and &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations,&rdquo; as well as any amendments
we make to those sections in filings with the SEC. These forward-looking statements include, but are not limited to, statements
about:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">the initiation, timing, progress and results of our preclinical testing, clinical trials, and other research and development efforts;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">the potential funding from our contracts with BARDA/HHS for the development and support of the NDA filing for RAPIVAB and the potential funding from our contract with NIAID/HHS for the development of BCX4430;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the potential for a government stockpiling order or profit from commercial sales of RAPIVAB;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">the potential use of RAPIVAB as a treatment for H1N1, H5N1, and H7N9 or other strains of influenza;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; font-size: 10pt"></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>



<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">the further preclinical or clinical development and commercialization of our product candidates, including our HAE program, RAPIVAB, BCX4430, early stage discovery programs, forodesine, and other PNP inhibitor development programs;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">the implementation of our business model, strategic plans for our business, product candidates and technology;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">our ability to establish and maintain collaborations or out-license rights to our drug candidates;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">plans, programs, progress and potential success of our collaborations, including Mundipharma for forodesine and Shionogi and Green Cross for peramivir in their territories;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">Royalty Sub&rsquo;s ability to service its payment obligations in respect of the PhaRMA Notes, and our ability to benefit from our equity interest in Royalty Sub;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">the foreign currency hedge agreement entered into by us in connection with the issuance by Royalty Sub of the PhaRMA Notes;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">our ability to operate our business without infringing the intellectual property rights of others;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">estimates of our expenses, revenues, capital requirements and our needs for additional financing;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">the timing or likelihood of regulatory filings and approvals;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">our ability to raise additional capital to fund our operations;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">our financial performance;&nbsp;and</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">competitive companies, technologies and our industry.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt"></P>

<!-- Field: Page; Sequence: 30; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">These statements relate to future events
or to our future financial performance and involve known and unknown risks, uncertainties and other important factors that may
cause our actual results, performance or achievements to be materially different from any future results, performance or achievements
expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current
expectations include, among other things, those listed under &ldquo;Risk Factors.&rdquo; Any forward-looking statement reflects
our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating
to our operations, results of operations, industry and future growth. Except as required by law, we assume no obligation to update
or revise these forward-looking statements for any reason, even if new information becomes available in the future.</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 9%; text-indent: 0in"><A NAME="p1i1b"></A><font style="font: 10pt Times New Roman, Times, Serif"><b>&nbsp;ITEM&nbsp;1B.</b></font></td>
    <td style="width: 91%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>UNRESOLVED STAFF COMMENTS</i></b></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">None.</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 9%; text-indent: 0in"><A NAME="p1i2"></A><font style="font: 10pt Times New Roman, Times, Serif"><b>&nbsp;ITEM&nbsp;2.</b></font></td>
    <td style="width: 91%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>PROPERTIES</i></b></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 0.5in">We
lease property in both Durham, North Carolina and Birmingham, Alabama. Our headquarters, including our clinical and regulatory
operations, are based in Durham, while our principal research facilities are located in Birmingham. We lease approximately 15,000
square feet in Durham through June 30, 2020 and lease approximately 35,000 square feet in Birmingham through June&nbsp;30, 2016.
Beginning in October 2015, we will lease an additional approximate 35,000 square feet in Birmingham to house our new research facilities.
We expect to begin construction on our new research facility in 2015. We believe that our facilities are adequate for our current
operations.</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 9%; text-indent: 0in"><A NAME="p1i3"></A><font style="font: 10pt Times New Roman, Times, Serif"><b>&nbsp;ITEM&nbsp;3.</b></font></td>
    <td style="width: 91%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>LEGAL PROCEEDINGS</i></b></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">None.</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 9%; text-indent: 0in"><A NAME="p1i4"></A><font style="font: 10pt Times New Roman, Times, Serif"><b>&nbsp;ITEM&nbsp;4.</b></font></td>
    <td style="width: 91%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>MINE SAFETY DISCLOSURES</i></b></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center; text-indent: 0.5in"><B>PART&nbsp;II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 9%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif"><b><A NAME="i5"></A>&nbsp;ITEM&nbsp;5.</b></font></td>
    <td style="width: 91%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>MARKET FOR REGISTRANT&rsquo;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</i></b></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 0in"><B><U>Market Information</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">Our common stock trades on the NASDAQ Global
Select Market under the symbol BCRX. The following table sets forth the low and high sales prices of our common stock as reported
by the NASDAQ Global Select Market for each quarter in 2014 and 2013:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2014</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2013</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Low</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">High</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Low</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">High</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-align: left">First quarter</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">7.46</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">13.33</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1.12</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2.04</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Second quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7.29</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">12.86</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.26</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.21</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Third quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">9.78</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">14.62</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.51</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7.59</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Fourth quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">9.02</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">13.28</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.55</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7.84</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">The last sale price of the common stock
on January&nbsp;30, 2015 as reported by the NASDAQ Global Select Market was $10.18 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"><B><U>Holders</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">As of January&nbsp;31, 2015, there were
approximately 197 holders of record of our common stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"><B><U>Dividends</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">We have never paid cash dividends and do
not anticipate paying cash dividends in the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"><B><U>Stock Performance Graph</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">This performance graph is not &ldquo;soliciting
material,&rdquo; is not deemed filed with the SEC and is not to be incorporated by reference in any filing by us under the Securities
Act or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in
any such filing. The stock price performance shown on the graph is not necessarily indicative of future price performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-align: center; text-indent: 0in"><B></B></P>

<!-- Field: Page; Sequence: 31; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-align: center; text-indent: 0in"><B>PERFORMANCE GRAPH
FOR BIOCRYST</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Indexed Comparison Since
2009</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="graph.jpg" ALT=""><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Beginning<BR> Investment <BR>12/31/09</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Investment<BR> at 12/31/10</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Investment<BR> at 12/31/11</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Investment<BR> at 12/31/12</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Investment<BR> at 12/31/13</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Investment<BR> at 12/31/14</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 22%; text-align: left">BioCryst Pharmaceuticals, Inc.</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">100.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">80.03</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">38.24</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">21.98</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">117.65</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">188.24</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">The NASDAQ Stock Market</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">117.55</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">117.91</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">137.29</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">183.26</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">206.09</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">NASDAQ&nbsp;Pharmaceutical&nbsp;Stocks</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">102.60</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">120.54</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">137.81</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">186.98</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">227.77</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">The above graph measures the change in
a $100 investment in our common stock based on its closing price of $6.46 on December&nbsp;31, 2009 and its year-end closing price
thereafter. Our relative performance is then compared with the CRSP Total Return Indexes for the NASDAQ Stock Market (U.S.) and
NASDAQ Pharmaceutical Stocks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 0in"><B>Recent Sales of Unregistered Securities:
None.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 0in"><B>Issuer Purchases of Equity Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">There were no repurchases of our common
stock or shares surrendered to satisfy tax obligations during the fourth quarter of 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 32; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 9%; text-indent: 0in"><A NAME="i6"></A><font style="font: 10pt Times New Roman, Times, Serif"><b>&nbsp;ITEM&nbsp;6.</b></font></td>
    <td style="width: 91%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>SELECTED FINANCIAL DATA</i></b></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">The selected Statement of Operations Data
and Balance Sheet data with respect to the years ended December&nbsp;31, 2014, 2013, 2012, 2011, and 2010 set forth below are derived
from our consolidated financial statements. The selected financial data set forth below should be read in conjunction with &ldquo;Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations contained in Item&nbsp;7 below and our consolidated financial
statements and the notes thereto appended to this annual report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="19" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Years Ended December&nbsp;31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2014</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2013</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2012</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2011</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2010</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="19" STYLE="font-weight: bold; text-align: center">(In thousands, except per share amounts)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Statement of Operations Data:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 45%; text-align: left">Total revenues</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">13,608</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">17,331</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">26,293</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">19,643</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">62,381</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Cost of product sold</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">86</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Research and development expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">51,796</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">41,943</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">49,160</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">55,538</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">82,473</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">General and administrative expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,461</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,007</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,130</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,692</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,145</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Royalty expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">121</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">98</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">132</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Restructuring costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,759</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,034</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Loss from operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(45,771</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(30,717</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(33,888</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(49,587</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(34,357</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(45,189</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(30,108</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(39,081</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(56,948</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(33,853</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Basic and diluted net loss per share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.68</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.55</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.79</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1.26</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.76</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Weighted average shares outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">66,773</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">55,216</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">49,474</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45,144</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44,564</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="19" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">As of December&nbsp;31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2014</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2013</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2012</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2011</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2010</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="19" STYLE="font-weight: bold; text-align: center">(In thousands)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Balance Sheet Data:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 45%; text-align: left">Cash, cash equivalents and investments</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">114,038</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">40,788</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">37,058</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">57,725</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">66,341</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Receivables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,490</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,115</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,562</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,831</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,227</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Inventory</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">683</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">263</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">898</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">136,874</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,866</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">57,439</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">82,208</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">109,447</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Long-term deferred revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,552</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,736</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,920</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,103</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,944</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Non-recourse notes payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accumulated deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(467,898</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(422,709</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(392,601</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(353,520</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(296,572</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total stockholders&rsquo; (deficit) equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75,635</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,126</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(454</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,806</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">65,503</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 9%; text-indent: 0in"><A NAME="i7"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ITEM&nbsp;7.</B></FONT></td>
    <td style="width: 91%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</i></b></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt"><I>This Annual Report on Form&nbsp;10-K
contains certain statements of a forward-looking nature relating to future events or the future financial performance of BioCryst.
Such statements are only predictions and the actual events or results may differ materially from the results discussed in the forward-looking
statements. Factors that could cause or contribute to such differences include those discussed below and elsewhere in this report,
as well as those discussed in other filings made by BioCryst with the Securities and Exchange Commission.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt"><I>The following Management&rsquo;s Discussion
and Analysis (&ldquo;MD&amp;A&rdquo;) is intended to help the reader understand our results of operations and financial condition.
MD&amp;A is provided as a supplement to, and should be read in conjunction with, our audited financial statements and the accompanying
notes to the financial statements and other disclosures included in this Annual Report on Form&nbsp;10-K (including the disclosures
under &ldquo;Item&nbsp;1A. Risk Factors&rdquo;).</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"><B>Cautionary Statement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">The
discussion herein contains forward-looking statements within the meaning of Section&nbsp;21E of the Securities Exchange Act of
1934, as amended, which are subject to the &ldquo;safe harbor&rdquo; created in Section&nbsp;21E. Forward looking statements regarding
our financial condition and our results of operations that are based upon our consolidated financial statements, which have been
prepared in accordance with accounting principles generally accepted within the United States (&ldquo;U.S. GAAP&rdquo;), as well
as projections for the future. The preparation of these financial statements requires our management to make estimates and judgments
that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and
liabilities. We evaluate our estimates on an ongoing basis. Our estimates are based on historical experience and on various other
assumptions that are believed to be reasonable under the circumstances. The results of our estimates form the basis for making
judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt"></P>

<!-- Field: Page; Sequence: 33; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">We operate in a highly competitive environment
that involves a number of risks, some of which are beyond our control. We are subject to risks common to biotechnology and biopharmaceutical
companies, including risks inherent in our drug discovery, drug development and commercialization efforts, clinical trials, uncertainty
of regulatory actions and marketing approvals, reliance on collaborative partners, enforcement of patent and proprietary rights,
the need for future capital, competition associated with products, potential competition associated with our product candidates
and retention of key employees. In order for any of our product candidates to be commercialized, it will be necessary for us, or
our collaborative partners, to conduct clinical trials, demonstrate efficacy and safety of the product candidate to the satisfaction
of regulatory authorities, obtain marketing approval, enter into manufacturing, distribution and marketing arrangements, and obtain
market acceptance and adequate reimbursement from government and private insurers. We cannot provide assurance that we will generate
significant revenues or achieve and sustain profitability in the future. In addition, we can provide no assurance that we will
have sufficient funding to meet our future capital requirements. Statements contained in Management&rsquo;s Discussion and Analysis
of Financial Condition and Results of Operations and elsewhere in this report which are not historical facts are, or may constitute,
forward-looking statements. Forward-looking statements involve known and unknown risks that could cause our actual results to differ
materially from expected results. The most significant known risks are discussed in the section entitled &ldquo;Risk Factors.&rdquo;
Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results,
levels of activity, performance or achievements.&nbsp;We caution you not to place undue reliance on any forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">Our revenues are difficult to predict
and depend on numerous factors, including the prevalence and severity of influenza in regions for which peramivir has received
regulatory approval, seasonality of influenza, ongoing discussions with government agencies regarding future RAPIVAB and/or BCX4430
development and stockpiling procurement, as well as entering into, or modifying, licensing agreements for our product candidates.
Furthermore, revenues related to our collaborative development activities are dependent upon the progress toward and the achievement
of developmental milestones by us or our collaborative partners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">Our operating expenses are also difficult
to predict and depend on several factors, including research and development expenses (and whether these expenses are reimbursable
under government contracts), drug manufacturing, and clinical research activities, the ongoing requirements of our development
programs, and the availability of capital and direction from regulatory agencies, which are difficult to predict. Management may
be able to control the timing and level of research and development and general and administrative expenses, but many of these
expenditures will occur irrespective of our actions due to contractually committed activities and/or payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">As a result of these factors, we believe
that period to period comparisons are not necessarily meaningful and you should not rely on them as an indication of future performance.
Due to all of the foregoing factors, it is possible that our operating results will be below the expectations of market analysts
and investors. In such event, the prevailing market price of our common stock could be materially adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"><B><U>Overview</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">We are a biotechnology company that designs,
optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. We focus on
the treatment of rare  diseases in which significant unmet medical needs exist and align with our capabilities and
expertise. We integrate the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and
develop small molecule pharmaceuticals through the process known as structure-guided drug design.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"><B><I>Critical Accounting Policies and
Estimates</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">The accompanying discussion and analysis
of our financial condition and results of operations are based upon our consolidated financial statements and the related disclosures,
which have been prepared in accordance with U.S. GAAP. The preparation of these consolidated financial statements requires us to
make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure
of contingent assets and liabilities. We evaluate our estimates, judgments and the policies underlying these estimates on a periodic
basis, as situations change, and regularly discuss financial events, policies, and issues with members of our audit committee and
our independent registered public accounting firm. We routinely evaluate our estimates and policies regarding revenue recognition,
administration, inventory and manufacturing, taxes, stock-based compensation, research and development, consulting and other expenses
and any associated liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"><B>Recent Corporate Highlights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 0in"><I>RAPIVAB<B> (peramivir injection)</B></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 22.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">RAPIVAB
was approved by the FDA on December 19, 2014</FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">for the treatment of
acute uncomplicated influenza in adult patients who have been symptomatic for no more than two days. We supplied RAPIVAB to our
specialty distributors and made it available to patients on December 26, 2014. We have elected the &ldquo;Sell-Through&rdquo;
revenue recognition and recognized approximately $33,000 of RAPIVAB product sales in 2014. With the approval and commercial availability
of RAPIVAB, we are now moving our focus to obtaining a stock-piling procurement contract with the U.S. Government to realize the
strategic value of this program. The $234.8 million development contract from BARDA/HHS in which peramivir was being developed
expired on June 30, 2014 upon completion of all our responsibilities under the contract. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"><B><I>HAE Program</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 27pt"></P>

<!-- Field: Page; Sequence: 34; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 27pt"><B><I>BCX4161</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 27.35pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 27.35pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.35pt">On December 18, 2014, we announced the
dosing of the first patient in OPuS-2 (Oral ProphylaxiS-2), a blinded, randomized, placebo-controlled clinical trial of orally-administered
BCX4161 in patients with HAE. OPuS-2 is a 12-week, three-arm, parallel cohort design trial to evaluate the efficacy and safety
of two doses of BCX4161, 300 mg and 500 mg, administered three-times daily compared with placebo. This trial is being conducted
in the U.S. and select European countries and is expected to enroll approximately 100 HAE patients. The primary efficacy endpoint
for the trial will be the mean angioedema attack rate for each BCX4161 dose group compared to placebo. In December 2014 and January
2015, the FDA granted BCX4161 Orphan Drug designation and Fast Track designation for the treatment of HAE. In addition, the COMP
of the EMA issued a positive opinion on the application for orphan drug designation for BCX4161 for the treatment of patients
with HAE and the European Commission recently affirmed this designation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 27pt"><B><I>BCX7353 and other 2nd generation
HAE compounds</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">In January 2015, we selected BCX7353,
one of two advanced-stage preclinical optimized plasma kallikrein inhibitors, to advance into Phase 1 development as a
once-daily, oral prophylactic HAE treatment. BXC7353 is structurally different from BCX4161, but has a similar mechanism of
action. BCX7353 has completed all toxicology requirements necessary for testing in healthy human volunteers and we expect it
to enter Phase 1 clinical development in 2015. In addition to BCX7353, we continue to work on multiple other second
generation molecules that are at an earlier stage of preclinical development.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"><B><I>BCX4430</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">On December 15, 2014, we announced the
dosing of the first subject in a randomized, placebo-controlled Phase 1 clinical trial to evaluate i.m. administration of BCX4430
in healthy volunteers. The main goals of this first-in-human study are to evaluate the safety, tolerability and pharmacokinetics
of escalating doses of BCX4430 administered via i.m. injection in healthy subjects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">On December 23, 2014, we announced results
from a successful proof-of-concept study of <FONT STYLE="font: 10pt Times New Roman, Times, Serif">BCX4430 for the treatment of
experimental Ebola virus infection in Rhesus macaques, conducted at USAMRIID. The primary goal of the study was to assess the
effect of BCX4430 treatment on survival through Day 41 in animals infected with Ebola virus. Dosing of&nbsp;placebo or BCX4430
by i.m. injection was initiated 30-120 minutes after virus challenge and continued twice a day for 14 days. The overall survival
rate for BCX4430 treated animals at day 41 was 10 of 12 (83%, p &lt; 0.001 compared to controls). Preliminary evaluation of the
quantity of virus in the blood showed an approximate 3-log reduction in Ebola virus RNA copies/mL of plasma, compared with control
animals. This Rhesus macaques study was conducted following the completion, in November 2014, of a dose-ranging study of BCX4430
for the treatment of cynomolgus macaques infected with Ebola virus. The cynomolgus macaques study was designed to evaluate whether
BCX4430 showed a meaningful benefit for survival in Ebola virus NHP disease models. In this study, BCX4430 demonstrated a statistically
significant prolongation of survival for the animals at the highest dose regimen tested, but no animals survived beyond 21 days.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">On February 12, 2015, NIAID/HHS exercised
an additional option under our BCX4430 development contract which provides an additional $2.7 million to us for i.v. development
and submission of an IND. Exercise of this option yields $25.0 million of obligated option funding under the $29.1 million contact.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"><B><U>Results of Operations</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 0in"><B><I>Year Ended December&nbsp;31, 2014
Compared to 2013</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">Total 2014 revenues decreased to $13.6
million as compared to 2013 revenues of $17.3 million. The 2014 revenue consisted of $3.0 million of royalty revenue from Shionogi
and Green Cross associated with sales of peramivir in Japan and Korea, $9.4 million of reimbursement of collaborative expenses
from BARDA/HHS and NIAID/HHS related to the development of peramivir and BCX4430, and $1.2 million associated with collaborative
revenue amortization from other corporate partnerships. In addition, we recorded approximately $33,000 of RAPIVAB revenue under
the &ldquo;Sell-Through&rdquo; revenue recognition methodology. RAPIVAB was available for commercial sale on December 26, 2014.
The decrease in total revenues was primarily the result of the June 2014 BARDA/HHS peramivir contract expiration associated with
completion of development activities under this contract. The 2013 revenue consisted of $2.6 million of royalty revenue from Shionogi
and Green Cross associated with sales of peramivir in Japan and Korea, $13.5 million of reimbursement of collaborative expenses
from BARDA/HHS related to the development of peramivir and $1.2 million associated with collaborative revenue amortization from
other corporate partnerships. With the expiration of BARDA/HHS peramivir contract, unless we enter into new government contracts,
all significant and future reimbursement of collaborative expenses will be under the NIAID/HHS BCX4430 development contract. In
addition, we expect RAPIVAB product sales to increase in future years when the product is available prior to the beginning of
the influenza season and for a longer period of time within a fiscal year. However, our RAPIVAB product revenue will be difficult
to predict because of volatility in prevalence, timing and severity of influenza season to season in the United States and because
we will not incur substantial commercialization expenses to promote it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">Research and Development (&ldquo;R&amp;D&rdquo;)
expenses increased to $51.8 million in 2014 from $41.9 million in 2013. 2014 R&amp;D expenses, compared with 2013, reflect increased
spending on our HAE and BCX4430 programs which were partially offset by the wind-down of peramivir development activities and the
expiration of the BARDA/HHS development contract. In addition, our 2014 equity compensation expense allocated to R&amp;D increased
due to the vesting of two underlying milestones under previously issued performance-based stock options for the successful outcome
of OPuS-1 and RAPIVAB approval in the U.S. In 2013, we recognized approximately $5.0 million of R&amp;D costs related to a write-off
of deferred collaboration costs associated with our PNP licensing agreement with AECOM/IRL. This write-off, and related R&amp;D
expenses, was allocated to the ulodesine program and represents the majority of 2013 ulodesine expense represented in the table
below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt"></P>

<!-- Field: Page; Sequence: 35; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">The following table summarizes our R&amp;D
expenses for the periods indicated (amounts are in thousands).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2014</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2013</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2012</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">R&amp;D expenses by program:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 61%; text-align: left; padding-left: 10pt">BCX4161</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">19,005</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">15,442</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">8,931</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Peramivir</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,898</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,627</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,799</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Ulodesine</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,866</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,726</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">BCX4430</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,060</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,318</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,248</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">BCX5191</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">448</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,229</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Forodesine</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,148</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">2nd generation HAE compounds</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,681</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.1pt; padding-left: 10pt">Other research, preclinical and development costs</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">5,116</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">3,230</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">6,079</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.75pt; padding-left: 10pt">Total R&amp;D expenses</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">51,796</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">41,943</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">49,160</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">R&amp;D expenses include all direct and
indirect expenses and are allocated to specific programs at the point of development of a lead product candidate. Direct expenses
are charged directly to the program to which they relate and indirect expenses are allocated based upon internal direct labor
hours dedicated to each respective program. Direct expenses consist of compensation for R&amp;D personnel and costs of outside
parties to conduct laboratory studies, develop manufacturing processes, manufacture the product candidates, conduct and manage
clinical trials, as well as other costs related to our clinical and preclinical studies. Indirect R&amp;D expenses consist of
lab supplies and services, facility expenses, depreciation of development equipment and other overhead of our research and development
efforts. R&amp;D expenses vary according to the number of programs in clinical development and the stage of development of our
clinical programs. Later stage clinical programs tend to cost more than earlier stage programs due to the longer length of time
of the clinical trials and the higher number of patients enrolled in these clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">General and administrative (&ldquo;G&amp;A&rdquo;)
expenses increased to $7.5 million in 2014 compared to $6.0 million in 2013. The increase of $1.5 million is primarily due to
RAPIVAB distribution expenses and unrestricted grants awarded to the U.S. and International HAE patient advocacy groups. Although
we do not have plans to incur substantial commercial expenses to promote RAPIVAB in the U.S. in the future, we do expect our future
G&amp;A expenses to increase associated with RAPIVAB distribution expenses and other increases in administrative expenses associated
with corporate growth in preparation for future NDA and other regulatory filings and for product commercialization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">Interest expense, related to the non-recourse
notes issued in conjunction with the peramivir royalty monetization transaction in March 2011, increased slightly to $5.0 million
in 2014 as compared to $4.8 million in 2013. In addition, a mark to market gain of $5.5 million was recognized in 2014 related
to the foreign currency hedge entered into in conjunction with the royalty monetization transaction, compared to a mark to market
gain of $5.3 million in 2013, both resulting from changes in the U.S. dollar/Japanese yen exchange rate during the respective years.
We entered into a foreign Currency Hedge Agreement to hedge changes in the value of the Japanese yen relative to the U.S. dollar.
The currency hedge does not qualify for hedge accounting treatment and therefore mark to market adjustments are recognized in our
Consolidated Statements of Comprehensive Loss. Although we cannot predict the future yen/dollar exchange rate, the applicable foreign
currency rates moved such that we currently have no collateral posted; however, it is possible that collateral will be required
in 2015 or the future. We are unable to predict future changes in the yen/dollar exchange rate or increases/decreases in our hedge
loss associated with the Currency Hedge Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 0in"><B><I>Year Ended December&nbsp;31, 2013
Compared to 2012</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">Total 2013 revenues decreased to $17.3
million as compared to 2012 revenues of $26.3 million. The 2013 revenue consisted of $2.6 million of royalty revenue from Shionogi
and Green Cross associated with sales of peramivir in Japan and Korea, $13.5 million of reimbursement of collaborative expenses
from BARDA/HHS related to the development of i.v. peramivir and $1.2 million associated with collaborative revenue amortization
from other corporate partnerships. The decrease was primarily due to the recognition of $7.8 million of previously deferred forodesine-related
revenue during the first quarter of 2012. The remaining 2012 revenues consisted of $3.3 million of royalty revenue from Shionogi
sales of RAPIACTA, $14.0 million of reimbursement of collaborative expenses from BARDA/HHS related to the development of i.v. peramivir
and $1.2 million associated with collaborative revenue amortization from other corporate partnerships.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">R&amp;D expenses decreased to $41.9 million
in 2013 from $49.2 million in the prior year. The 2013 R&amp;D expenses, compared with 2012, reflect decreased spending on our
ulodesine and BCX5191 programs and reduced R&amp;D infrastructure costs, partially offset by increased expenditures for our BCX4161
and BCX4430 programs. In connection with the Amended and Restated License and Development Agreement with Mundipharma and the Knowledge
Transfer that was completed in the first quarter of 2012, we recognized $1.9 million of deferred expense in 2012. With this amendment,
we did not incur many forodesine-related costs in 2013 and do not expect to incur any significant forodesine costs in the future.
Furthermore, we do not expect to incur significant ulodesine expenses in the future because we do not plan to initiate Phase 3
development of ulodesine without a partner. In 2013, we recognized approximately $5.0 million of R&amp;D costs related to a write-off
of deferred collaboration costs associated with our PNP licensing agreement with AECOM/IRL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">G&amp;A expenses decreased to $6.0 million
in 2013 compared to $9.1 million in the prior year. The decrease of $3.1 million is primarily due to the December 2012 restructuring
that reduced our cost structure and operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt"></P>

<!-- Field: Page; Sequence: 36; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">Interest expense increased slightly to
$4.8 million in 2013 as compared to $4.7 million in 2012. In addition, a mark to market gain of $5.3 million was recognized in
2013 related to the foreign currency hedge compared to a mark to market loss of $0.7 million in the prior year, both resulting
from changes in the U.S. dollar/Japanese yen exchange rate during the respective years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 0in"><B>Restructuring</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">In December 2012, we announced that we
had restructured our operations during the fourth quarter of 2012 to significantly reduce the size and operations of our Company
in order to extend our existing cash runway. We eliminated approximately 50% of our workforce and decreased other costs, which
significantly decreased our 2013 operating expenses and operating cash utilization, as compared to 2012 levels. In connection with
the restructuring, we recorded restructuring charges of approximately $1.8 million for the year ended December&nbsp;31, 2012, which
was reported in a separate line item in our Consolidated Statements of Comprehensive Loss. Significant components of the restructuring
charge were termination benefits for employees impacted by the restructuring and losses associated with leased lab and office space
that became underutilized. We do not expect to incur any additional restructuring changes as a result of our December 2012 restructuring
and there was no restructuring accrual remaining at December&nbsp;31, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">Cash expenditures have exceeded
revenues since our inception and we expect our 2015 operating expenses to exceed our 2015 revenues. Our operations have
principally been funded through public offerings and private placements of equity securities; cash from collaborative and
other research and development agreements, including U.S. Government contracts for peramivir and BCX4430; and to a lesser
extent, the PhaRMA Notes financing. To date, we have been awarded a BARDA/HHS peramivir development contract totaling $234.8
million, which expired on June 30, 2014, and a NIAID/HHS BCX4430 development contract totaling $29.1 million (as of February
12, 2015), which is ongoing. The total amount of NIAID/HHS funding obligated under awarded options (as of February
12, 2015) in the contract is
$25.0&nbsp;million. Most recently, we completed a successful public offering in June 2014 of 11.5 million shares of common
stock at a price of $10.00 per share following the release of our OPuS-1 clinical trial results, which provided net proceeds
to us of approximately $106.6 million. This financing provides us liquidity through the middle of 2016. We retain the ability
to offer for sale approximately $10.0 million of securities, including common stock, preferred stock, debt securities,
depositary shares and warrants from an effective shelf registration statement, which we filed with the SEC on
November&nbsp;6, 2013. In addition to the above, we have received funding from other sources, including other collaborative
and other research and development agreements; government grants; equipment lease financing; facility leases; research
grants; and interest income on our investments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">As of December&nbsp;31, 2014, we had net
working capital of $31.7 million, an increase of approximately $4.8 million from $26.9 million at December&nbsp;31, 2013. The increase
in working capital was principally due to $106.6 million in net proceeds derived from our June 2014 public offering, largely offset
by our normal operating expenses associated with the development of our product candidates and the reclassification of our non-recourse
notes payable to current liabilities. Our principal sources of liquidity at December&nbsp;31, 2014 were approximately $54.7 million
in cash and cash equivalents; approximately $59.3 million in investments considered available-for-sale; approximately $2.8 million
in U.S. Government receivables; and approximately $5.6 million of receivables from product sales of RAPIVAB. We anticipate our
cash and investments will fund our operations through the middle of fiscal 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">We intend to contain costs and reduce cash
flow requirements by closely managing our third party costs and headcount, leasing scientific equipment and facilities, contracting
with other parties to conduct certain research and development projects and using consultants. We expect to incur additional expenses,
potentially resulting in significant losses, as we continue to pursue our research and development activities, primarily related
to our clinical trial activity. We may incur additional expenses related to the filing, prosecution, maintenance, defense and enforcement
of patent and other intellectual property claims and additional regulatory costs as our clinical programs advance through later
stages of development. The objective of our investment policy is to ensure the safety and preservation of invested funds, as well
as maintaining liquidity sufficient to meet cash flow requirements. We place our excess cash with high credit quality financial
institutions, commercial companies, and government agencies in order to limit the amount of our credit exposure. We have not realized
any significant losses on our investments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">We extended or executed additional
lease obligations in 2015 for our Birmingham, Alabama operations which increases the obligation by $5.1 million and for which
these new obligations extend out through 2026. These operating lease obligations encompass future rental obligations of our
Birmingham operating facilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 0in">We plan to finance our needs principally
from the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">lease or loan financing and future public or private equity financing;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">our existing capital resources and interest earned on that capital;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">payments under existing and executing new contracts with the U.S. Government; and</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">payments under collaborative and licensing agreements with corporate partners.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt"></P>

<!-- Field: Page; Sequence: 37; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">As our programs continue to advance, our
costs will increase. Our current and planned clinical trials, plus the related development, manufacturing, regulatory approval
process requirements and additional personnel resources and testing required for the continuing development of our product candidates
will consume significant capital resources and will increase our expenses. Our expenses, revenues and cash utilization rate could
vary significantly depending on many factors, including our ability to raise additional capital, the development progress of our
collaborative agreements for our product candidates, the amount and timing of funding we receive from existing U.S. Government
contracts for peramivir and BCX4430, the amount of funding or assistance, if any, we receive from new U.S. Government contracts
or other new partnerships with third parties for the development and or commercialization of our product candidates, the progress
and results of our current and proposed clinical trials for our most advanced product candidates, the progress made in the manufacturing
of our lead product candidates and the progression of our other programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">With the funds available at
December&nbsp;31, 2014, we believe these resources will be sufficient to fund our operations through the middle of fiscal
2016. Our future liquidity needs, and ability to address those needs, will largely be determined by the success of our
product candidates and key development and regulatory events in the future. In order to continue our operations substantially
beyond the middle of fiscal 2016, we will need to: (1)&nbsp;successfully secure, or increase U.S. Government funding of our
programs, including procurement contracts; (2)&nbsp;out-license rights to certain of our product candidates, pursuant to
which we would receive cash milestones; (3)&nbsp;raise additional capital through equity or debt financings or from other
sources; (4)&nbsp;obtain product candidate regulatory approvals, which would generate revenue and cash flow; (5)&nbsp;reduce
spending on one or more research and development programs; and/or (6)&nbsp;restructure operations. Additionally, we retain
the ability to offer for sale approximately $10.0 million of securities, including common stock, preferred stock, debt
securities, depositary shares and securities warrants from an effective shelf registration statement, which we filed with
the SEC on November&nbsp;6, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">Our long-term capital requirements and
the adequacy of our available funds will depend upon many factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">our ability to perform under our government contracts and receive reimbursement, and receive stockpiling procurement contracts;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">the magnitude of work under our government contracts;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">the progress and magnitude of our research, drug discovery and development programs;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">changes in existing collaborative relationships or government contracts;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">our ability to establish additional collaborative relationships with academic institutions, biotechnology or pharmaceutical companies and governmental agencies or other third parties;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">the extent to which our partners, including governmental agencies, will share in the costs associated with the development of our programs or run the development programs themselves;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">our ability to negotiate favorable development and marketing strategic alliances for certain product candidates or a decision to build or expand internal development and commercial capabilities;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">successful commercialization of marketed products by either us or a partner;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">the scope and results of preclinical studies and clinical trials to identify and develop product candidates;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">our ability to engage sites and enroll subjects in our clinical trials;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">the scope of manufacturing of our product candidates to support our preclinical research and clinical trials;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">increases in personnel and related costs to support the development and commercialization of our product candidates;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">the
    scope of manufacturing of our drug substance and product candidates required for future NDA filings;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">competitive and technological advances;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">the time and costs involved in obtaining regulatory approvals;&nbsp;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">post-approval commitments for RAPIVAB and other products that receive regulatory approval; and</font></td></tr>
<tr>
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in">&nbsp;</td></tr>
<tr>
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">the costs involved in all aspects of intellectual property strategy and protection including the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 38; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">We
expect that we will be required to raise additional capital to complete the development and commercialization of our current product
candidates and we may seek to raise capital in the near future. Additional funding, whether through additional sales of equity
or debt securities, collaborative or other arrangements with corporate partners or from other sources, including governmental agencies
in general and existing government contracts specifically, may not be available when needed or on terms acceptable to us. The issuance
of preferred or common stock or convertible securities, with terms and prices significantly more favorable than those of the currently
outstanding common stock, could have the effect of diluting or adversely affecting the holdings or rights of our existing stockholders.
In addition, collaborative arrangements may require us to transfer certain material rights to such corporate partners. Insufficient
funds may require us to delay, scale back or eliminate certain of our research and development programs. Our future working capital
requirements, including the need for additional working capital, will be largely determined by the advancement of our portfolio
of product candidates as well as rate of reimbursement by U.S. Government agencies of our peramivir and BCX4430 expenses and any
future decisions regarding the future of the peramivir and BCX4430 programs, including those relating to stockpiling procurement.
More specifically, our working capital requirements will be dependent on the number, magnitude, scope and timing of our development
programs; regulatory approval of our product candidates; obtaining funding from collaborative partners; the cost, timing and outcome
of regulatory reviews, regulatory investigations, and changes in regulatory requirements; the costs of obtaining patent protection
for our product candidates; the timing and terms of business development activities; the rate of technological advances relevant
to our operations; the efficiency of manufacturing processes developed on our behalf by third parties; and the level of required
administrative support for our daily operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 0in"><B>Financial Outlook for 2015</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">Based upon our development plans, expected
operations and our awarded government contracts, we expect 2015 operating cash usage to be in the range of $65 to $80 million,
and expect our total 2015 operating expenses to be in the range of $75 to $95 million. Our operating expense range excludes equity-based
compensation expense due to the difficulty in accurately projecting this expense as it is significantly impacted by the volatility
and price of the Company&rsquo;s stock, as well as vesting of the Company&rsquo;s outstanding performance-based stock options.
Our operating cash forecast excludes any impact of our royalty monetization, hedge collateral posted or returned, and any other
non-routine cash outflows or inflows. Our ability to remain within our operating expense and operating cash target ranges is subject
to multiple factors, including unanticipated or additional general development and administrative costs and other factors described
under the Risk Factors located elsewhere in this report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"><B>Off-Balance Sheet Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">As of December&nbsp;31, 2014, we are not
involved in any unconsolidated entities or off&ndash;balance sheet arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"><B>Contractual Obligations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">In the table below, we set forth our enforceable
and legally binding obligations and future commitments and obligations related to all contracts that we are likely to continue
regardless of the fact that they are cancelable as of December&nbsp;31, 2014. Some of the amounts we include in this table are
based on management&rsquo;s estimates and assumptions about these obligations, including their duration, the possibility of renewal,
anticipated actions by third parties, and other factors. Because these estimates and assumptions are necessarily subjective, the
obligations we will actually pay in future periods may vary from those reflected in the table.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="19" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Payments Due by Period<BR> (In thousands)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 1.1pt solid">Contractual Obligations</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Total</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Less&nbsp;Than<BR> 1&nbsp;Year</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">1-3&nbsp;Years</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">3-5&nbsp;Years</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">More&nbsp;Than<BR> 5&nbsp;Years</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; text-align: left">Operating lease obligations</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2,414</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">739</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">767</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">722</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">186</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Purchase obligations(1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31,546</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31,546</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Contingent license obligations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,425</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">575</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,150</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,150</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,550</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.1pt">Non-recourse notes payable(2)</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">60,879</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">10,229</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">8,400</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">8,400</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">33,850</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.75pt">Total</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">101,264</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">43,089</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">10,317</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">10,272</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">37,586</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 4%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">(1)</font></td>
    <td style="width: 96%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">Purchase obligations include commitments related to clinical development, manufacturing and research operations and other purchase commitments.</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">(2)</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">Assumes the PhaRMA Notes will be repaid at maturity and the related interest costs will accrue and be paid annually through maturity. This assumption is based on the unpredictable nature of the royalty payments from Shionogi, which are designated for both principal and interest payments on the PhaRMA Notes.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">Under the Currency Hedge Agreement, we
have the right to purchase dollars and sell yen at a rate of 100 yen per dollar for which we may be required to pay a premium in
each year from 2015 through 2020, provided the Currency Hedge Agreement is still in effect. A payment of $2.0 million will be required
if, during the relevant year, the dollar is worth less than 100 yen. As of December&nbsp;31, 2014, we have no hedge collateral.
Because the posting of additional collateral and payment of annual premiums is contingent on the value of the yen relative to the
dollar and other factors, such payments have been excluded from the foregoing table.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">In addition to the above, we have committed
to make potential future &ldquo;sublicense&rdquo; payments to third-parties as part of in-licensing and development programs. Payments
under these agreements generally become due and payable only upon achievement of certain developmental, regulatory and/or commercial
milestones. Because the achievement of these milestones is neither probable nor reasonably estimable, such contingencies have not
been recorded on our balance sheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"><B>Critical Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">We
have established various accounting policies that govern the application of accounting principles generally accepted in the U.S.,
which were utilized in the preparation of our consolidated financial statements. Certain accounting policies involve significant
judgments and assumptions by management that have a material impact on the carrying value of certain assets and liabilities. Management
considers such accounting policies to be critical accounting policies. The judgments and assumptions used by management are based
on historical experience and other factors, which are believed to be reasonable under the circumstances. Because of the nature
of the judgments and assumptions made by management, actual results could differ from these judgments and estimates, which could
have a material impact on the carrying values of assets and liabilities and the results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt"></P>

<!-- Field: Page; Sequence: 39; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">While our significant accounting policies
are more fully described in Note&nbsp;1 to our consolidated financial statements included in this Annual Report on Form&nbsp;10-K
for the year ended December&nbsp;31, 2014, we believe that the following accounting policies are the most critical to aid you in
fully understanding and evaluating our reported financial results and affect the more significant judgments and estimates that
we use in the preparation of our financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 0in"><B><I>Inventory</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">Our inventories consist of RAPIVAB finished
goods and work in process, which are valued at the lower of cost or market using the first-in, first-out (i.e., FIFO) method. Cost
includes materials, labor, overhead, shipping and handling costs. Our inventories are subject to expiration dating. We regularly
evaluate the carrying value of our inventories and provide valuation reserves for any estimated obsolete, short-dated or unmarketable
inventories. In addition, we may experience spoilage of our raw materials and supplies. Our determination that a valuation reserve
might be required, in addition to the quantification of such reserve, requires us to utilize significant judgment. In connection
with the FDA approval of RAPIVAB in December 2014, the Company began capitalizing costs associated with the production of RAPIVAB
commercial inventories.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"><B><I>Accrued Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">We enter into contractual agreements with
third-party vendors who provide research and development, manufacturing, and other services in the ordinary course of business.
Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. We
record liabilities under these contractual commitments when an obligation has been incurred. This accrual process involves reviewing
open contracts and purchase orders, communicating with our applicable personnel to identify services that have been performed and
estimating the level of service performed and the associated cost when we have not yet been invoiced or otherwise notified of actual
cost. The majority of our service providers invoice us monthly in arrears for services performed. We make estimates of our accrued
expenses as of each balance sheet date based on the facts and circumstances known to us. We periodically confirm the accuracy of
our estimates with the service providers and make adjustments if necessary. Examples of estimated accrued expenses include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">fees paid to Clinical Research Organizations (&ldquo;CROs&rdquo;) in connection with preclinical and toxicology studies and clinical trials;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">fees paid to investigative sites in connection with clinical trials;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">fees
    paid to contract manufacturers in connection with the production of our raw materials, drug substance and product
    candidates;&nbsp;and</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">professional fees.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">We base our expenses related to clinical
trials on our estimates of the services received and efforts expended pursuant to contracts with multiple research institutions
and clinical research organizations that conduct and manage clinical trials on our behalf. The financial terms of these agreements
are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these
contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing
service fees, we estimate the time period over which services will be performed and the level of effort expended in each period.
If the actual timing of the performance of services or the level of effort varies from our estimate, we will adjust the accrual
accordingly. If we do not identify costs that we have begun to incur or if we underestimate or overestimate the level of these
costs, our actual expenses could differ from our estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"><B><I>Revenue Recognition</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">We recognize revenues from collaborative
and other research and development arrangements and product sales. Revenue is realized or realizable and earned when all of the
following criteria are met: (i)&nbsp;persuasive evidence of an arrangement exists; (ii)&nbsp;delivery has occurred or services
have been rendered; (iii)&nbsp;the seller&rsquo;s price to the buyer is fixed or determinable; and (iv)&nbsp;collectability is
reasonably assured.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0 23pt; text-indent: 0in"><I>Collaborative and Other Research
and Development Arrangements and Royalties</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">Revenue from license fees, royalty payments,
event payments, and research and development fees are recognized as revenue when the earnings process is complete and we have no
further continuing performance obligations or we have completed the performance obligations under the terms of the agreement. Fees
received under licensing agreements that are related to future performance are deferred and recognized over an estimated period
determined by management based on the terms of the agreement and the products licensed. In the event a license agreement contains
multiple deliverables, we evaluate whether the deliverables are separate or combined units of accounting. Revisions to revenue
or profit estimates as a result of changes in the estimated revenue period are recognized prospectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">Under certain of our license agreements,
we receive royalty payments based upon our licensees&rsquo; net sales of covered products. We recognize royalty revenues when we
can reliably estimate such amounts and collectability is reasonably assured. Royalty revenue paid by Shionogi on their product
sales is subject to returns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt"></P>

<!-- Field: Page; Sequence: 40; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">Reimbursements
received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the income statement
rather than as a reduction in expenses. Event payments are recognized as revenue upon the achievement of specified events if (1)&nbsp;the
event is substantive in nature and the achievement of the event was not reasonably assured at the inception of the agreement and
(2)&nbsp;the fees are non-refundable and non-creditable. Any event payments received prior to satisfying these criteria are recorded
as deferred revenue. Under our contracts with BARDA/HHS and NIAID/HHS, revenue is recognized as reimbursable direct and indirect
costs are incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"><I>Product Sales</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">We recognize revenue for sales of RAPIVAB
when title and substantially all the risks and rewards of ownership have transferred to the customer, which generally occurs on
the date of shipment from our specialty distributors, utilizing the Sell-Through revenue recognition methodology. Product sales
are recognized when there is persuasive evidence that an arrangement exists, title has passed, the price was fixed and determinable,
and collectability is reasonably assured. Product sales are recognized net of estimated allowances, discounts, sales returns, chargebacks
and rebates. In the United States, we sell RAPIVAB to specialty distributors, who, in turn, sell to physician offices, hospitals
and federal, state and commercial health care organizations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">Sales deductions consist of statutory
rebates to state Medicaid, Medicare and other government agencies and sales discounts (including trade discounts and distribution
service fees). These deductions are recorded as reductions to revenue from RAPIVAB in the same period as the related sales with
estimates of future utilization derived from historical experience adjusted to reflect known changes in the factors that impact
such reserves.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">We utilize data from external sources to
help estimate gross-to-net sales adjustments as they relate to the recognition of revenue for RAPIVAB sold. External sourced data
includes, but is not limited to, information obtained from specialty distributors with respect to their inventory levels and sell-through
to customers, and information from third-party suppliers of market research data to the pharmaceutical industry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">The Company has categorized and described
more fully the following significant sales deductions, all of which involve estimates and judgments, which the Company considers
to be critical accounting estimates, and requires it to use information from external sources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-indent: 0in"><I>Rebates and Chargebacks </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">Statutory rebates to state Medicaid agencies
and Medicare are based on statutory discounts to RAPIVAB&rsquo;s selling price.&nbsp;As it can take up to nine months or more for
information to be received on actual usage of RAPIVAB in Medicaid and other governmental programs, we maintain reserves for amounts
payable under these programs relating to RAPIVAB sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">Chargebacks claimed by specialty distributors
are based on the differentials between product acquisition prices paid by the specialty distributors and lower government contract
pricing paid by eligible customers covered under federally qualified programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.05pt">The amount of the reserve for rebates
and chargebacks is based on multiple qualitative and quantitative factors, including the historical and projected utilization levels,
historical payment experience, changes in statutory laws and interpretations as well as contractual terms, product pricing (both
normal selling prices and statutory or negotiated prices), changes in prescription demand patterns and utilization of our product
through public benefit plans, and the levels of RAPIVAB inventory in the distribution channel. We acquire prescription utilization
data from third-party suppliers of market research data to the pharmaceutical industry. We update our estimates and assumptions
each period and record any necessary adjustments to reserves. Settlements of rebates and chargebacks typically occur within nine
months from point of sale. To the extent actual rebates and chargebacks differ from our estimates, additional reserves may be required
or reserves may need to be reversed, either of which would impact current period product revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-indent: 0in"><I>Discounts and Sales Incentives
</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">Discounts and other sales incentives primarily
consist of Inventory Management Agreement (&ldquo;IMA&rdquo;) Fees. Per contractual agreements with our specialty distributors,
we provide an IMA fee based on a percentage of their purchases of RAPIVAB. The IMA fee rates are set forth in our individual contracts.
We track sales to our specialty distributors each period and accrue a liability relating to the unpaid portion of these fees by
applying contractual rates to such sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-indent: 0in"><I>Product Returns </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">We do not record a product return allowance
as we do not offer the ability to return goods once a bonafide shipment has been accepted by a specialty distributor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 41; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 0in"><B><I>Research and Development Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">Our research and development costs are
charged to expense when incurred. Advance payments for goods or services that will be used or rendered for future research and
development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered
or the related services are performed. Research and development expenses include, among other items, personnel costs, including
salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies,
and overhead allocations consisting of various administrative and facilities related costs. Most of our manufacturing and clinical
and preclinical studies are performed by third-party CROs. Costs for studies performed by CROs are accrued by us over the service
periods specified in the contracts and estimates are adjusted, if required, based upon our on-going review of the level of services
actually performed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">Additionally, we have license agreements
with third parties, such as AECOM, IRL, and UAB, which require fees related to sublicense agreements or maintenance fees. We expense
sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred
and recognized over the related revenue recognition period. We expense maintenance payments as incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">Deferred collaboration expenses represent
sub-license payments paid to our academic partners upon receipt of consideration from various commercial partners, and other consideration
to our academic partners for modification to existing license agreements. These deferred expenses would not have been incurred
without receipt of such payments or modifications from our commercial partners and are being expensed in proportion to the related
revenue being recognized. We believe that this accounting treatment appropriately matches expenses with the associated revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">We group our R&amp;D expenses into two major
categories: direct external expenses and indirect expenses. Direct expenses consist of compensation for R&amp;D personnel and
costs of outside parties to conduct laboratory studies, develop manufacturing processes and manufacture the product candidate,
conduct and manage clinical trials, as well as other costs related to our clinical and preclinical studies. These costs are accumulated
and tracked by program. Indirect expenses consist of lab supplies and services, facility expenses, depreciation of development
equipment and other overhead of our research and development efforts. These costs apply to work on our clinical and preclinical
candidates as well as our discovery research efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"><B><I>Stock-Based Compensation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">All share-based payments, including grants
of stock option awards and restricted stock unit awards, are recognized in our Consolidated Statements of Comprehensive Loss based
on their fair values. Stock-based compensation cost is estimated at the grant date based on the fair value of the award and is
recognized as expense on a straight-line basis over the requisite service period of the award. Determining the appropriate fair
value model and the related assumptions for the model requires judgment, including estimating the life of an award, the stock
price volatility, and the expected term. We utilize the Black-Scholes option-pricing model to value our awards and recognize compensation
expense on a straight-line basis over the vesting periods. The estimation of share-based payment awards that will ultimately vest
requires judgment, and to the extent actual results or updated estimates differ from our current estimates, such amounts will
be recorded as a cumulative adjustment in the period estimates are revised. In addition, we have outstanding performance-based
stock options for which no compensation expense is recognized until &ldquo;performance&rdquo; has occurred. Significant management
judgment is also required in determining estimates of future stock price volatility and forfeitures to be used in the valuation
of the options. Actual results, and future changes in estimates, may differ substantially from our current estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"><B><I>Foreign Currency Hedge</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">In connection with our issuance of the
PhaRMA Notes, we entered into a foreign Currency Hedge Agreement to hedge certain risks associated with changes in the value of
the Japanese yen relative to the U.S.&nbsp;dollar. Under the Currency Hedge Agreement, we have the right to purchase dollars and
sell yen at a rate of 100 yen per dollar for which we may be required to pay a premium in each year from 2015 through 2020, provided
the Currency Hedge Agreement remains in effect. A payment of $2.0&nbsp;million will be required if, on May&nbsp;18 of the relevant
year, the U.S. dollar is worth 100 yen or less as determined in accordance with the Currency Hedge Agreement. In conjunction with
establishing the Currency Hedge Agreement, we will be required to post collateral to the counterparty, which may cause us to experience
additional quarterly volatility in our financial results. We will not be required at any time to post collateral exceeding the
maximum premium payments remaining payable under the Currency Hedge Agreements. In establishing the hedge, we provided initial
funds of approximately $2.0&nbsp;million to support our potential hedge obligations. As of December 31, 2014, the maximum amount
of hedge collateral we may be required to post is $11.7 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">The Currency Hedge Agreement does not
qualify for hedge accounting treatment and therefore mark to market adjustments will be recognized in our Consolidated Statements
of Comprehensive Loss. Cumulative mark to market adjustments for the year ended December&nbsp;31, 2014 resulted in a $5.5 million
gain. Mark to market adjustments are determined by quoted prices in markets that are not actively traded and for which significant
inputs are observable directly or indirectly, representing the Level 2 in the fair value hierarchy as defined by generally accepted
accounting principles. The Company is also required to post collateral in connection with the mark to market adjustments based
on defined thresholds. As of December&nbsp;31, 2014, no collateral was posted under the agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 0in"><B><I>Tax</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">We account for uncertain tax positions
in accordance with accounting principles generally accepted in the U.S. Significant management judgment is required in determining
our provision for income taxes, deferred tax assets and liabilities and any valuation allowance recorded against net deferred tax
assets. We have recorded a valuation allowance against all potential tax assets, due to uncertainties in our ability to utilize
deferred tax assets, primarily consisting of certain net operating losses carried forward, before they expire. The valuation allowance
is based on estimates of taxable income in each of the jurisdictions in which we operate and the period over which our deferred
tax assets will be recoverable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 42; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"><B><I>Impact of Inflation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">We do not believe that our operating results
have been materially impacted by inflation during the past three years. However, we cannot be assured that our operating results
will not be adversely affected by inflation in the future. We will continually seek to mitigate the adverse effects of inflation
on the services that we use through improved operating efficiencies and cost containment initiatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"><B>Recent Accounting Pronouncements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">Note&nbsp;11 to the Consolidated Financial
Statements included in Item&nbsp;8 of this Annual Report on Form&nbsp;10-K discusses accounting pronouncements recently issued
or proposed but not yet required to be adopted.</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 9%; text-indent: 0in"><A NAME="i7a"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ITEM&nbsp;7A.</B></FONT></td>
    <td style="width: 91%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</i></b></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 0in"><I>Interest Rate Risk</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">We are subject to interest rate risk on
our investment portfolio and borrowings under our PhaRMA Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">We invest in marketable securities in
accordance with our investment policy. The primary objectives of our investment policy are to preserve capital, maintain proper
liquidity to meet operating needs and maximize yields. Our investment policy specifies credit quality standards for our investments
and limits the amount of credit exposure to any single issue, issuer or type of investment. We place our excess cash with high
credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of credit exposure.
Some of the securities we invest in may have market risk. This means that a change in prevailing interest rates may cause the principal
amount of the investment to fluctuate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">Our investment exposure to market risk
for changes in interest rates relates to the increase or decrease in the amount of interest income we can earn on our portfolio,
changes in the market value due to changes in interest rates and other market factors as well as the increase or decrease in any
realized gains and losses. Our investment portfolio includes only marketable securities and instruments with active secondary or
resale markets to help ensure portfolio liquidity. A hypothetical 100 basis point drop in interest rates along the entire interest
rate yield curve would not significantly affect the fair value of our interest sensitive financial instruments. We generally have
the ability to hold our fixed-income investments to maturity and therefore do not expect that our operating results, financial
position or cash flows will be materially impacted due to a sudden change in interest rates. However, our future investment income
may fall short of expectations due to changes in interest rates, or we may suffer losses in principal if forced to sell securities
which have declined in market value due to changes in interest rates or other factors, such as changes in credit risk related to
the securities&rsquo; issuers. To minimize this risk, we schedule our investments to have maturities that coincide with our expected
cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, we do not believe that
we have material exposure to interest rate risk arising from our investments. Generally, our investments are not collateralized.
We have not realized any significant losses from our investments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">We do not use interest rate derivative
instruments to manage exposure to interest rate changes. We ensure the safety and preservation of invested principal funds by limiting
default risk, market risk and reinvestment risk. We reduce default risk by investing in investment grade securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"><I>Foreign Currency Risk</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">The majority of our transactions occur in
U.S. dollars and we do not have operating subsidiaries or investments in foreign countries. Therefore, we are not subject to significant
foreign currency exchange risk in our normal operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">In connection with the issuance by Royalty
Sub of the PhaRMA Notes, we entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value
of the Japanese yen relative to the U.S. dollar. Under the Currency Hedge Agreement, we are required to post collateral based on
our potential obligations under the Currency Hedge Agreement as determined by periodic mark to market adjustments. Provided the
Currency Hedge Agreement remains in effect, we may be required to pay an annual premium in the amount of $2.0&nbsp;million from
May&nbsp;2015 through May&nbsp;2020. Such payment will be required if, in May of the relevant year, the spot rate of exchange for
Japanese yen-U.S. dollars (determined in accordance with the Currency Hedge Agreement) is such that the U.S. dollar is worth 100
yen or less.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 43; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"></P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 9%; text-indent: 0in"><A NAME="i8"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ITEM&nbsp;8.</B></FONT></td>
    <td style="width: 91%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</i></b></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0; text-align: center"><B>BIOCRYST PHARMACEUTICALS,
INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 6pt; margin-bottom: 0; text-align: center"><B>CONSOLIDATED BALANCE
SHEETS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>(In thousands, except per
share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">December&nbsp;31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2014</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2013</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center; text-indent: 0in">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; text-align: left">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">54,540</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">21,164</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Restricted cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">150</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">151</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Investments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,232</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,891</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Receivables from collaborations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,849</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,115</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Receivables from product sales</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,641</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Inventory</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">683</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Prepaid expenses and other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,172</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,725</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.1pt">Deferred collaboration expense</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">76</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">75</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">89,343</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">42,121</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Investments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">41,116</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,582</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Furniture and equipment, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">207</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">306</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Deferred collaboration expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">177</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">237</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.1pt">Other assets</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">6,031</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">3,620</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.75pt; padding-left: 10pt">Total assets</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">136,874</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">48,866</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center; text-indent: 0in">LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"><P STYLE="margin: 0pt 0">2,849</P>


</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,174</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0pt 0">11,723</P>


</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,742</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Interest payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,029</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,867</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Deferred collaboration revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,481</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,473</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Deferred product sales revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,605</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.1pt">Non-recourse notes payable</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">30,000</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">57,687</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,256</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Deferred collaboration revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,552</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,736</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Non-recourse notes payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Stockholders&rsquo; equity:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Preferred stock, $0.001 par value; shares authorized&nbsp;&mdash;&nbsp;5,000; no shares outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Common stock, $0.01&nbsp;par value; shares authorized&nbsp;&mdash;&nbsp;200,000; shares issued and outstanding&nbsp;&mdash;&nbsp;71,955 in 2014 and 59,092 in 2013</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">720</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">591</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">542,943</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">420,988</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><P STYLE="margin: 0pt 0">Accumulated other comprehensive (loss) income</P>


</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(130</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.1pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">(467,898</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">(422,709</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.1pt; padding-left: 10pt"><P STYLE="margin: 0pt 0">Total stockholders&rsquo;
equity (deficit)</P>


</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">75,635</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left"></TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">(1,126</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.75pt; padding-left: 10pt">Total liabilities and stockholders&rsquo; equity</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">136,874</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">48,866</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center; text-indent: 0in">See accompanying notes
to consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 44; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0; text-align: center"><B>BIOCRYST PHARMACEUTICALS,
INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 6pt; margin-bottom: 0; text-align: center"><B>CONSOLIDATED STATEMENTS
OF COMPREHENSIVE LOSS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>(In thousands, except per
share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Year Ended December&nbsp;31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2014</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2013</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2012</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Revenues</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 61%; text-align: left; padding-left: 10pt">Product sales, net</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">33</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Royalty revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,025</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,562</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,317</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.1pt; padding-left: 10pt">Collaborative and other research and development</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">10,550</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">14,769</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">22,976</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt">Total revenues</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,608</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,331</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,293</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt"><P STYLE="margin: 0pt 0">Cost of products sold</P>


</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">51,796</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">41,943</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">49,160</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">General and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,461</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,007</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,130</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Royalty</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">121</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">98</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">132</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.1pt; padding-left: 10pt">Restructuring</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">1,759</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.1pt; padding-left: 20pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">59,379</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">48,048</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">60,181</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Loss from operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(45,771</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(30,717</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(33,888</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Interest and other income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">93</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">93</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">222</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,998</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,778</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,666</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.1pt">Gain (loss) on foreign currency derivative</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">5,487</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">5,294</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">(749</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.1pt">Net loss</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">(45,189</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">(30,108</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">(39,081</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Basic and diluted net loss per common share</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">(0.68</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">(0.55</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">(0.79</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Weighted average shares outstanding</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">66,773</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">55,216</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">49,474</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.1pt">Unrealized loss on available for sale investments</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">(134</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">(23</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">(13</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.75pt">Comprehensive loss</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">(45,323</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">)</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">(30,131</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">)</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">(39,094</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">)</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center; text-indent: 0in">See accompanying notes
to consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 45; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center; text-indent: 0in"><B>BIOCRYST PHARMACEUTICALS,
INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: center"><B>CONSOLIDATED STATEMENTS
OF CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>(In thousands, except per
share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Year Ended December&nbsp;31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2014</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2013</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2012</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 61%; text-align: left">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(45,189</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(30,108</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(39,081</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Depreciation, amortization, and impairment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">177</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">304</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">628</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Loss (gain) on disposal of furniture and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(47</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Stock-based compensation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,177</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,368</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,167</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Amortization of debt issuance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">439</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">439</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">439</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Change in fair value of foreign currency derivative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,487</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,294</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">749</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0pt">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt"><P STYLE="margin: 0pt 0">Receivables</P>


</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,375</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,447</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,269</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Inventory</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0pt 0">(683</P>


</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">263</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Prepaid expenses and other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0pt 0">(1,943</P>


</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(620</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(623</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Deferred collaboration expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">59</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,133</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,301</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Accounts payable and accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,818</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,049</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,068</TD><TD STYLE="text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.1pt; padding-left: 10pt"><P STYLE="margin: 0pt 0">Deferred revenue</P>


</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">4,429</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">(1,103</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">(9,577</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 10pt">Net cash used in operating activities:</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right"><P STYLE="margin: 0pt 0">(38,551</P>


</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(26,530</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(37,397</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Investing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Acquisition of furniture and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(106</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(30</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(113</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Proceeds from sale of furniture and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Change in restricted cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">157</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">317</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Purchases of investments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0pt 0">(73,875</P>


</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(23,974</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16,153</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.1pt; padding-left: 10pt">Sales and maturities of investments</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right"><P STYLE="margin: 0pt 0">34,000</P>


</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">20,330</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">40,833</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 10pt">Net cash (used in) provided by investing activities:</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right"><P STYLE="margin: 0pt 0">(39,980</P>


</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(3,467</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">24,884</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Sale of common stock, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">106,600</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,633</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,805</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Exercise of stock options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,997</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,333</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">534</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Employee stock purchase plan sales</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">310</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">124</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">321</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.1pt; padding-left: 10pt">Receipt (payment) of foreign currency derivative collateral</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">5,180</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">(1,700</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 10pt">Net cash provided by financing activities:</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">111,907</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">30,270</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">16,960</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Increase in cash and cash equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33,376</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">273</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,447</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.1pt">Cash and cash equivalents at beginning of year</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">21,164</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">20,891</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">16,444</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.75pt">Cash and cash equivalents at end of year</TD><TD STYLE="font-weight: bold; padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: right">54,540</TD><TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: right">21,164</TD><TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: right">20,891</TD><TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center; text-indent: 0in">See accompanying notes
to consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 46; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0; text-align: center"><B>BIOCRYST PHARMACEUTICALS,
INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 6pt; margin-bottom: 0; text-align: center"><B>CONSOLIDATED STATEMENTS
OF STOCKHOLDERS&rsquo; EQUITY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>(In thousands, except
per share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>


<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Common<BR> Stock</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Additional<BR> Paid-In<BR> Capital</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Accumulated<BR> Other<BR> Comprehensive<BR> (Loss) Income</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Accumulated<BR> Deficit</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Total<BR> Stockholders&rsquo;<BR> Equity&nbsp;(Deficit)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 45%; font-weight: bold; text-align: left">Balance at December&nbsp;31, 2011</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 8%; font-weight: bold; text-align: right">457</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 8%; font-weight: bold; text-align: right">367,829</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 8%; font-weight: bold; text-align: right">40</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 8%; font-weight: bold; text-align: right">(353,520</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 8%; font-weight: bold; text-align: right">14,806</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(39,081</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(39,081</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other comprehensive loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(13</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(13</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Exercise of stock options, 348 shares, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">536</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">539</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Employee stock purchase plan sales, 110&nbsp;shares, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">320</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">321</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Issuance of common stock, 4,774 shares, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,759</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,807</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.1pt; text-indent: -10pt; padding-left: 10pt">Stock-based compensation expense</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">4,167</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">4,167</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.75pt">Balance at December&nbsp;31, 2012</TD><TD STYLE="font-weight: bold; padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: right">509</TD><TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: right">391,611</TD><TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: right">27</TD><TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: right">(392,601</TD><TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: right">(454</TD><TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(30,108</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(30,108</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other comprehensive loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(23</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(23</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Exercise of stock options, 563 shares, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,327</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,333</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Employee stock purchase plan sales, 89&nbsp;shares, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">123</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">124</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Issuance of common stock, 7,547 shares, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,559</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,634</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.1pt; text-indent: -10pt; padding-left: 10pt">Stock-based compensation expense</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">4,368</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">4,368</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.75pt">Balance at December&nbsp;31, 2013</TD><TD STYLE="font-weight: bold; padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: right">591</TD><TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: right">420,988</TD><TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: right">4</TD><TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: right">(422,709</TD><TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: right">(1,126</TD><TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(45,189</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(45,189</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other comprehensive loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(134</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(134</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Exercise of stock options, 1,314 shares, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,984</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,997</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Employee stock purchase plan sales, 49&nbsp;shares, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">309</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">310</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Issuance of common stock, 11,500 shares, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">115</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">106,485</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">106,600</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.1pt; text-indent: -10pt; padding-left: 10pt">Stock-based compensation expense</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">10,177</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">10,177</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.75pt">Balance at December&nbsp;31, 2014</TD><TD STYLE="font-weight: bold; padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: right">720</TD><TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: right">542,943</TD><TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: right">(130</TD><TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: right">(467,898</TD><TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: right">75,635</TD><TD STYLE="border-bottom: Black 2.75pt double; font-weight: bold; text-align: left"></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-bottom: 0; margin-left: 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-bottom: 0; margin-left: 0; text-align: center; text-indent: 0in">See accompanying notes
to consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-bottom: 0; margin-left: 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 47; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; text-align: center; margin-bottom: 0"><B>BIOCRYST PHARMACEUTICALS,
INC.<BR>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(In thousands, except per share amounts)</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 0in"><B>Note&nbsp;1&nbsp;&mdash; Significant
Accounting Policies and Concentrations of Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0 11.5pt; text-indent: 0in"><B><I>The Company</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">BioCryst Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;)
is a biotechnology company that designs, optimizes and develops novel small molecule drugs that block key enzymes involved in
the pathogenesis of diseases. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist
and align with its capabilities and expertise. The Company was incorporated in Delaware in 1986 and its headquarters is located
in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer
modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst
has incurred losses and negative cash flows from operations since inception.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">In the fourth quarter of 2012, the Company
implemented a restructuring plan to significantly reduce its cost structure. Based on its current operating plans, the Company
expects it has sufficient liquidity, with its existing cash and investments of $114,038, to continue its planned operations through
the middle of 2016. The Company&rsquo;s liquidity needs, and ability to address those needs, will largely be determined by the
success of its product candidates and key development and regulatory events in the future. In order to continue its operations
substantially beyond the middle of 2016 it will need to: (1)&nbsp;successfully secure or increase U.S. Government funding of its
programs, including procurement contracts; (2)&nbsp;out-license rights to certain of its product candidates, pursuant to which
the Company would receive cash milestones; (3)&nbsp;raise additional capital through equity or debt financings or from other sources;
(4)&nbsp;obtain product candidate regulatory approvals, which would generate revenue and cash flow; (5)&nbsp;reduce spending on
one or more research and development programs; and/or (6)&nbsp;restructure operations. Additionally, the Company retains the ability
to offer for sale approximately $10,000 of securities, including common stock, preferred stock, debt securities, depositary shares
and securities warrants from its effective shelf registration statement, which it filed with the Securities and Exchange Commission
on November&nbsp;6, 2013. The Company will continue to incur operating losses and negative cash flows until revenues reach a level
sufficient to support ongoing operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0 11.5pt; text-indent: 0in"><B><I>Basis of Presentation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">Beginning in March 2011, the
consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, JPR Royalty Sub LLC
(&ldquo;Royalty Sub&rdquo;). Royalty Sub was formed in connection with a $30,000&nbsp;financing transaction the Company
completed on March&nbsp;9, 2011. See Note 3, Royalty Monetization, for a further description of this transaction. All
intercompany transactions and balances have been eliminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">The Company&rsquo;s consolidated financial
statements have been prepared in accordance with accounting principles generally accepted in the United States. Such consolidated
financial statements reflect all adjustments that are, in management&rsquo;s opinion, necessary to present fairly, in all material
respects, the Company&rsquo;s consolidated financial position, results of operations, and cash flows. There were no adjustments
other than normal recurring adjustments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0 11.5pt; text-indent: 0in"><B><I>Cash and Cash Equivalents</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">The Company generally considers cash equivalents
to be all cash held in commercial checking accounts, money market accounts or investments in debt instruments with maturities of
three months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the
short-term nature of these items.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0 11.5pt; text-indent: 0in"><B><I>Restricted Cash</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">Restricted cash as of December&nbsp;31,
2014 and December 31, 2013 includes $150 that the Company is required to maintain in an interest bearing certificate of deposit
to serve as collateral for a corporate credit card program. At December&nbsp;31, 2013, there is also $1 for royalty receipts received
from Shionogi&nbsp;&amp; Co. Ltd. (&ldquo;Shionogi&rdquo;) designated for interest on the PhaRMA Notes (see Note 3).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0 11.5pt; text-indent: 0in"><B><I>Investments</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">The
Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the
possibility of loss. The objective of the Company&rsquo;s investment policy is to ensure the safety and preservation of invested
funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high
credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit
exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that may consist of U.S. Government
and government agency securities, money market and mutual fund investments, municipal and corporate notes and bonds, commercial
paper and asset or mortgage-backed securities, among others. The Company&rsquo;s investment policy requires it to purchase high-quality
marketable securities with a maximum individual maturity of three years and requires an average portfolio maturity of no more than
18 months. Some of the securities the Company invests in may have market risk. This means that a change in prevailing interest
rates may cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments
with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity
date. Accordingly, the Company does not believe it has a material exposure to interest rate risk arising from its investments.
Generally, the Company&rsquo;s investments are not collateralized. The Company has not realized any significant losses from its
investments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23pt"></P>

<!-- Field: Page; Sequence: 48; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; text-align: center; margin-bottom: 0"><B>BIOCRYST PHARMACEUTICALS,
INC.<BR>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(In thousands, except per share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23pt">The Company classifies all of its investments
as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss
is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically
reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances
indicate that the carrying amount of an asset may not be recoverable. The Company believes the individual unrealized losses represent
temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other
income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions
recorded on a settlement date basis. Investments with original maturities at date of purchase beyond three months and which mature
at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from
the balance sheet date are classified as long-term. At December&nbsp;31, 2014, the Company believes that the costs of its investments
are recoverable in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">The following tables summarize the fair
value of the Company&rsquo;s investments by type. The estimated fair value of the Company&rsquo;s fixed income investments are
classified as Level 2 in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and
indirect inputs, primarily quoted prices of similar, but not identical, instruments in active markets or quoted prices for identical
or similar instruments in markets that are not active. These fair values are obtained from independent pricing services which utilize
Level 2 inputs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="19" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">December 31, 2014</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Amortized<BR> Cost</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Accrued<BR> Interest</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Gross<BR> Unrealized<BR> Gains</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Gross<BR> Unrealized<BR> Losses</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Estimated<BR> Fair Value</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 45%; text-align: left; text-indent: -10pt; padding-left: 10pt">Obligations of U.S. Government and its agencies</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">20,307</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">22</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">(23</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">20,306</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Corporate debt securities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,152</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">151</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(47</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,261</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.1pt">Certificates of deposit</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">11,838</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">6</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">(63</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">11,781</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.75pt">Total investments</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">59,297</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">179</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">5</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">(133</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">)</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">59,348</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="19" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">December&nbsp;31, 2013</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Amortized<BR> Cost</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Accrued<BR> Interest</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Gross<BR> Unrealized<BR> Gains</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Gross<BR> Unrealized<BR> Losses</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Estimated<BR> Fair Value</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 45%; text-align: left; text-indent: -10pt; padding-left: 10pt">Obligations of U.S. Government and its agencies</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">4,899</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">1</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">1</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">4,901</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Corporate debt securities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,528</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,576</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.1pt">Commercial paper</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">5,994</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">2</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">5,996</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.75pt">Total investments</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">19,421</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">48</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">5</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">(1</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">)</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">19,473</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">The following table summarizes the scheduled
maturity for the Company&rsquo;s investments at December&nbsp;31, 2014 and 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2014</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2013</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left">Maturing in one year or less</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">18,232</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">16,891</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Maturing after one year through two years</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,459</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,582</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.1pt">Maturing after two years</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">15,657</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.75pt">Total investments</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">59,348</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">19,473</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 49; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B><I><BR></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; text-align: center; margin-bottom: 0"><B>BIOCRYST PHARMACEUTICALS,
INC.<BR>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(In thousands, except per share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B><I>Receivable from Collaborations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">Receivables from collaborations are recorded
for amounts due to the Company related to reimbursable research and development costs from the U.S. Department of Health and Human
Services or royalty receivables from Shionogi&nbsp;&amp; Co. Ltd. These receivables are evaluated to determine if any reserve
or allowance should be established at each reporting date. At December&nbsp;31, 2014 and 2013, the Company had the following receivables.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">December&nbsp;31, 2014</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Billed</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Unbilled</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Total</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%; text-align: left">U.S. Department of Health and Human Services</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">2,778</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">2,778</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.1pt">Shionogi&nbsp;&amp; Co. Ltd.</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">1,071</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">1,071</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.75pt">Total receivables</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">1,071</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">2,778</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">3,849</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">December&nbsp;31, 2013</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Billed</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Unbilled</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Total</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%; text-align: left">U.S. Department of Health and Human Services</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">90</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">1,573</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">1,663</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.1pt">Shionogi&nbsp;&amp; Co. Ltd.</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">452</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">452</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.75pt">Total receivables</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">542</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">1,573</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">2,115</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">Monthly invoices are submitted to the
U.S. Department of Health and Human Services related to reimbursable research and development costs. The Company is also entitled
to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&rsquo;s calculations
of its indirect cost rates are subject to audit by the U.S. Government.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0 11.5pt; text-indent: 0in"><B><I>Receivables from Product
Sales</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 22.5pt">Receivables from product sales are recorded
for amounts due to the Company related to sales of RAPIVAB. There receivables are evaluated to determine if any reserve or allowance
should be established at each reporting date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0 11.5pt; text-indent: 0in"><B><I>Inventory</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">At December&nbsp;31, 2014 and 2013, the
Company&rsquo;s inventory consisted of RAPIVAB finished goods inventory and work in process. Inventory is stated at the lower of
cost, determined under the first-in, first-out (&ldquo;FIFO&rdquo;) method, or market. The Company expenses costs related to the
production of inventories as research and development expenses in the period incurred until such time it is believed that future
economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory
approval, the Company will capitalize subsequent costs related to the production of inventories.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">During 2014, in connection with the FDA
approval of RAPIVAB, the Company began capitalizing costs associated with the production of RAPIVAB inventories.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">The Company&rsquo;s inventory consisted
of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">As of December&nbsp;31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2014</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2013</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left">Supplies</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">263</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Work in process</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">267</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Finished goods</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">416</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,980</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.1pt">Reserve for finished goods and supplies</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">(4,243</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.75pt">Net inventories</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">683</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0 11.5pt; text-indent: 0in"><B><I></I></B></P>

<!-- Field: Page; Sequence: 50; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-bottom: 0"><B>BIOCRYST PHARMACEUTICALS, INC.</B><BR>
<B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<BR>
(In thousands, except per share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0 11.5pt; text-indent: 0in"><B><I>Furniture and Equipment</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">Furniture and equipment are recorded at
cost. Depreciation is computed using the straight-line method with estimated useful lives of five and seven years. Laboratory equipment,
office equipment, and software are depreciated over a life of five years. Furniture and fixtures are depreciated over a life of
seven years. Leasehold improvements are amortized over their estimated useful lives or the remaining lease term, whichever is less.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">In accordance with generally accepted
accounting principles, the Company periodically reviews its furniture and equipment for impairment when events or changes in circumstances
indicate that the carrying amount of such assets may not be recoverable. Determination of recoverability is based on an estimate
of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash
flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated
fair values. Furniture and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to
sell.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 11.5pt; text-indent: 0in"><B><I>Patents and Licenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">The Company seeks patent protection on
all internally developed processes and products. All patent related costs are expensed to general and administrative expenses when
incurred as recoverability of such expenditures is uncertain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0 11.5pt; text-indent: 0in"><B><I>Accrued Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">The Company generally enters into contractual
agreements with third-party vendors who provide research and development, manufacturing, and other services in the ordinary course
of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period
of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred,
regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with
applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed
and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost.
The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of
accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically
confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued
expenses include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">fees paid to Clinical Research Organizations (&ldquo;CROs&rdquo;) in connection with preclinical and toxicology studies and clinical trials;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">fees paid to investigative sites in connection with clinical trials;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">fees paid to contract manufacturers in connection with the production of our raw materials, drug substance and drug products;&nbsp;and</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&bull;</font></td>
    <td style="vertical-align: top; width: 1%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">professional fees.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">The Company bases its expenses related to
clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions
and CROs that conduct and manage clinical trials on the Company&rsquo;s behalf. The financial terms of these agreements are subject
to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts
depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service
fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period.
If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the
accrual accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 24.5pt">Accrued expenses were  comprised of
the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2014</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2013</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left">Compensation and benefits</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">2,105</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">1,527</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Development costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,232</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,210</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Inventory</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">397</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Professional fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">238
</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Duties and taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">90</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">4,676
</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">1,867</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">11,723</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">5,742</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">As of December 31, 2014 and 2013,
the carrying value of accrued expenses approximates their fair value due to their short-term settlement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"></P>

<!-- Field: Page; Sequence: 51; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-bottom: 0"><B>BIOCRYST PHARMACEUTICALS, INC.</B><BR>
<B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<BR>
(In thousands, except per share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0 11.5pt; text-indent: 0in"><B><I>Income Taxes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">The liability method is used in the Company&rsquo;s
accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between
financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected
to be in effect when the differences are expected to reverse.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0 11.5pt; text-indent: 0in"><B><I>Accumulated Other Comprehensive
(Loss) Income</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">Accumulated other comprehensive (loss)
income is comprised of unrealized gains and losses on investments available-for-sale and is disclosed as a separate component of
stockholders&rsquo; equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0 11.5pt; text-indent: 0in"><B><I>Revenue Recognition</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">The Company recognizes revenues from collaborative
and other research and development arrangements and product sales when realized or realizable and earned. Revenue is realized or
realizable and earned when all of the following criteria are met: (i)&nbsp;persuasive evidence of an arrangement exists; (ii)&nbsp;delivery
has occurred or services have been rendered; (iii)&nbsp;the seller&rsquo;s price to the buyer is fixed or determinable; and (iv)&nbsp;collectability
is reasonably assured.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0 11.5pt; text-indent: 0in"><I>Collaborative and Other Research
and Development Arrangements and Royalties</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">Revenue
from license fees, royalty payments, event payments, and research and development fees are recognized as revenue when the earnings
process is complete and the Company has no further continuing performance obligations or the Company has completed the performance
obligations under the terms of the agreement. Fees received under licensing agreements that are related to future performance are
deferred and recognized over an estimated period determined by management based on the terms of the agreement and the products
licensed. In the event a license agreement contains multiple deliverables, the Company evaluates whether the deliverables are separate
or combined units of accounting. Revisions to revenue or profit estimates as a result of changes in the estimated revenue period
are recognized prospectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23pt">Under certain of our license agreements, the
Company receives royalty payments based upon our licensees&rsquo; net sales of covered products. The Company recognizes royalty
revenues when it can reliably estimate such amounts and collectability is reasonably assured.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">Royalty revenue paid by Shionogi on their
product sales is subject to returns. Prior to the third quarter of 2012, the Company did not have sufficient historical experience
to reasonably estimate product returns and therefore could not reasonably record the underlying revenue. Up to the second quarter
of 2012, the Company deferred recognition of all RAPIACTA&reg; royalty revenue from Shionogi sales. During the third quarter of
2012, and after the completion of the 2011/2012 flu season in Japan, the Company obtained sufficient historical information to
reasonably estimate product returns and recognized royalty revenue of $2,848, net of an allowance for estimated returns. During
the fourth quarter of 2012, the Company recognized royalty revenue of $469, for a total of $3,317 in 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">Reimbursements received for direct out-of-pocket
expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss
rather than as a reduction in expenses. Event payments are recognized as revenue upon the achievement of specified events if (1)&nbsp;the
event is substantive in nature and the achievement of the event was not reasonably assured at the inception of the agreement and
(2)&nbsp;the fees are non-refundable and non-creditable. Any event payments received prior to satisfying these criteria are recorded
as deferred revenue. Under the Company&rsquo;s contracts with BARDA/HHS and NIAID/HHS, revenue is recognized as reimbursable direct
and indirect costs are incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0 11.5pt; text-indent: 0in"><I>Product Sales</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">The Company recognizes revenue for sales
of RAPIVAB when title and substantially all the risks and rewards of ownership have transferred to the customer, which generally
occurs on the date of shipment from our specialty distributors, utilizing the Sell-Through revenue recognition methodology. Product
sales are recognized when there is persuasive evidence that an arrangement exists, title has passed, the price was fixed and determinable,
and collectability is reasonably assured. Product sales are recognized net of estimated allowances, discounts, sales returns, chargebacks
and rebates. In the United States, the Company sells RAPIVAB to specialty distributors, who in turn, sell to physician offices,
hospitals and federal, state and commercial health care organizations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">Sales deductions consist of statutory
rebates to state Medicaid, Medicare and other government agencies and sales discounts (including trade discounts and distribution
service fees). These deductions are recorded as reductions to revenue from RAPIVAB in the same period as the related sales with
estimates of future utilization derived from historical experience adjusted to reflect known changes in the factors that impact
such reserves.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"></P>

<!-- Field: Page; Sequence: 52; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-bottom: 0"><B>BIOCRYST PHARMACEUTICALS, INC.</B><BR>
<B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<BR>
(In thousands, except per share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">The Company utilizes data from external
sources to help it estimate gross-to-net sales adjustments as they relate to the recognition of revenue for RAPIVAB sold. External
sourced data includes, but is not limited to, information obtained from specialty distributors with respect to their inventory
levels and their sell-through to customers, as well as information from third-party suppliers of market research data to the pharmaceutical
industry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">The Company accounts for these sales
deductions in accordance with authoritative guidance on revenue recognition when consideration is given by a vendor to a customer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">The Company has categorized and described more
fully the following significant sales deductions, all of which involve estimates and judgments, which the Company considers to
be critical accounting estimates, and requires it to use information from external sources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-indent: 0in"><I>Rebates and Chargebacks </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">Statutory rebates to state Medicaid agencies
and Medicare are based on statutory discounts to RAPIVAB&rsquo;s selling price.&nbsp;As it can take up to nine months or more for
information to be received on actual usage of RAPIVAB in Medicaid and other governmental programs, the Company maintains reserves
for amounts payable under these programs relating to RAPIVAB sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">Chargebacks claimed by specialty
distributors are based on the differentials between product acquisition prices paid by the  specialty distributors and lower
government contract pricing paid by eligible customers covered under federally qualified programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23.05pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.05pt">The amount of the reserve for rebates
and chargebacks is based on multiple qualitative and quantitative factors, including the historical and projected utilization
levels, historical payment experience, changes in statutory laws and interpretations as well as contractual terms, product pricing
(both normal selling prices and statutory or negotiated prices), changes in prescription demand patterns and utilization of the
Company&rsquo;s product through public benefit plans, and the levels of RAPIVAB inventory in the distribution channel. The Company
acquires prescription utilization data from third-party suppliers of market research data to the pharmaceutical industry. The
Company updates its estimates and assumptions each period and records any necessary adjustments to its reserves. Settlements of
rebates and chargebacks typically occur within nine months from point of sale. To the extent actual rebates and chargebacks differ
from the Company&rsquo;s estimates, additional reserves may be required or reserves may need to be reversed, either of which would
impact current period product revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-indent: 0in"><I>Discounts and Sales Incentives </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">Discounts and other sales incentives primarily
consist of Inventory Management Agreement (&ldquo;IMA&rdquo;) Fees. Per contractual agreements with the Company&rsquo;s specialty
distributors, the Company provides an IMA fee based on a percentage of their purchases of RAPIVAB. The IMA fee rates are set forth
in individual contracts. The Company tracks sales to these distributors each period and accrues a liability relating to the unpaid
portion of these fees by applying the contractual rates to such product sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-indent: 0in"><I>Product Returns </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">The Company does not record a product return
allowance as it does not offer the ability to return goods once a bonafide shipment has been accepted by a specialty distributor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-indent: 0in"><I>Advertising</I>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23.05pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.05pt">The Company engages in very limited distribution
and direct-response advertising when promoting RAPIVAB. Advertising and promotional costs are expensed as the costs are incurred.
Advertising and product promotion expenses were $290 for the year ended December&nbsp;31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 0in">The Company recorded the following revenues
for the years ended December&nbsp;31:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2014</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2013</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2012</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%; text-align: left">Product sales, net</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">33</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Royalty revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,025</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,562</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,317</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Collaborative and other research and development revenues:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">U.S. Department of Health and Human Services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,366</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,585</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,026</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Shionogi (Japan)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,184</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,184</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,184</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.1pt; padding-left: 10pt">Mundipharma (United Kingdom)</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">7,766</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.1pt">Total collaborative and other research and development revenues</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">10,550</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">14,769</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">22,976</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.75pt">Total revenues</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">13,608</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">17,331</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">26,293</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0 11.5pt; text-indent: 0in"><B><I></I></B></P>

<!-- Field: Page; Sequence: 53; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-bottom: 0"><B>BIOCRYST PHARMACEUTICALS, INC.</B><BR>
<B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<BR>
(In thousands, except per share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0 11.5pt; text-indent: 0in"><B><I>Research and Development
Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">The Company&rsquo;s research and development
costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs
related to the development of the Company&rsquo;s portfolio of product candidates. Advance payments for goods or services that
will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized
as expense when the related goods are delivered or the related services are performed. Research and development expenses include,
among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology
services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities
related costs. Most of the Company&rsquo;s manufacturing and clinical and preclinical studies are performed by third-party CROs.
Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts and estimates
are adjusted, if required, based upon the Company&rsquo;s on-going review of the level of services actually performed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">Additionally, the Company has license
agreements with third parties, such as Albert Einstein College of Medicine of Yeshiva University (&ldquo;AECOM&rdquo;), Industrial
Research, Ltd. (&ldquo;IRL&rdquo;), and the University of Alabama at Birmingham (&ldquo;UAB&rdquo;), which require fees related
to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues
that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The
Company expenses maintenance payments as incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">Deferred collaboration expenses represent
sub-license payments, paid to the Company&rsquo;s academic partners upon receipt of consideration from various commercial partners,
and other consideration paid to our academic partners for modification to existing license agreements. These deferred expenses
would not have been incurred without receipt of such payments or modifications from the Company&rsquo;s commercial partners and
are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately
matches expenses with the associated revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 11.5pt; text-indent: 0in"><B><I>Stock-Based Compensation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">All share-based payments, including grants
of stock option awards and restricted stock unit awards, are recognized in the Company&rsquo;s Consolidated Statements of Comprehensive
Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model.
The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation
cost is recognized as expense on a straight-line basis over the requisite service period of the award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0 11.5pt; text-indent: 0in"><B><I>Interest Expense and Deferred
Financing Costs</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">Interest expense for the years ended December&nbsp;31,
2014, 2013 and 2012 was $4,998, $4,778 and $4,666, respectively, and relates to the issuance of the PhaRMA Notes. Costs directly
associated with the issuance of the PhaRMA Notes have been capitalized and are included in other non-current assets on the Consolidated
Balance Sheets. These costs are being amortized to interest expense over the term of the PhaRMA Notes using the effective interest
rate method. Amortization of deferred financing costs included in interest expense was $439 for each of the years ended December&nbsp;31,
2014, 2013 and 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0 11.5pt; text-indent: 0in"><B><I>Currency Hedge Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">In connection with the issuance by Royalty
Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in
the value of the Japanese yen relative to the U.S. dollar. The Currency Hedge Agreement does not qualify for hedge accounting treatment;
therefore mark to market adjustments are recognized in the Company&rsquo;s Consolidated Statements of Comprehensive Loss. Cumulative
mark to market adjustments for the years ended December&nbsp;31, 2014 and 2013 resulted in gains of $5,487 and $5,294, respectively.
Cumulative mark to market adjustments for the year ended December&nbsp;31, 2012 resulted in a loss of $749. Mark to market adjustments
are determined by a third party pricing model which uses quoted prices in markets that are not actively traded and for which significant
inputs are observable directly or indirectly, representing Level 2 in the fair value hierarchy as defined by generally accepted
accounting principles. The Company is also required to post collateral in connection with the mark to market adjustments based
on defined thresholds. As of December 31, 2014 and December&nbsp;31, 2013, no hedge collateral was posted under the agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0 11.5pt; text-indent: 0in"><B><I>Restructuring Activities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">During the fourth quarter of 2012, the
Company announced a restructuring plan in response to setbacks in its development programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt"></P>

<!-- Field: Page; Sequence: 54; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-bottom: 0"><B>BIOCRYST PHARMACEUTICALS, INC.</B><BR>
<B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<BR>
(In thousands, except per share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">The following table sets forth activity
in the restructuring liability for the years ended December&nbsp;31, 2013 and 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.1pt"></TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Employee<BR> separation<BR> costs</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Facilities<BR> related<BR> charges</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Total</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Balance at December&nbsp;31, 2011</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 55%; text-align: left; padding-left: 10pt">Accruals</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">1,662</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">97</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">1,759</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.1pt; padding-left: 10pt">Payments</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">(58</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">(58</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Balance at December&nbsp;31, 2012</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,604</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">97</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,701</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Accruals</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(97</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(97</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.1pt; padding-left: 10pt">Payments</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">(1,604</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">(1,604</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.75pt">Balance at December&nbsp;31, 2013</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0 11.5pt; text-indent: 0in"><B><I>Net Loss Per Share</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">Net loss per share is based upon the weighted
average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share
for all periods presented herein because common equivalent shares from unexercised stock options, outstanding warrants, and common
shares expected to be issued under the Company&rsquo;s employee stock purchase plan were anti-dilutive. The calculation of diluted
earnings per share for the years ended December&nbsp;31, 2014, 2013, and 2012 does not include 5,279, 2,109 and 1,026 respectively,
of potential common shares as their impact would be anti-dilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0 11.5pt; text-indent: 0in"><B><I>Use of Estimates</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">The preparation of financial statements
in conformity with accounting principles generally accepted in the United States (&ldquo;U.S. GAAP&rdquo;) requires the Company
to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from
those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 13.5pt"><B>Significant Customers and Other Risks </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23.05pt"><I>Significant Customers</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">The Company relies primarily on three
specialty distributors to purchase and supply the majority of RAPIVAB. These three pharmaceutical  specialty distributors
accounted for greater than 90% of all RAPIVAB<I> </I>product sales in the year ended December&nbsp;31, 2014 and accounted for
predominantly all of the Company&rsquo;s outstanding <FONT STYLE="font: 10pt Times New Roman, Times, Serif">receivables from
product sales as of December&nbsp;31, 2014. The loss of one or more of these specialty distributors as a customer
could negatively impact the commercialization of RAPIVAB.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">The Company&rsquo;s primary source of
revenue that has an underlying cash flow stream is the reimbursement of peramivir and BCX4430 development expenses, which was
earned under a cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS, respectively. The Company relies on BARDA/HHS and
NIAID/HHS to reimburse predominantly all of the development costs for its peramivir and BCX4430 programs. Accordingly,
reimbursement of these expenses represents a significant portion of the Company&rsquo;s collaborative and other research and
development revenues. The completion, as with the June 30, 2014 BARDA/HHS peramivir development contract, or termination of
the NIAID/HHS BCX4430 programs/collaboration could negatively impact the Company&rsquo;s future Consolidated Statements of
Comprehensive Loss and Cash Flows. In addition, the Company also recognizes royalty revenue from the net sales of RAPIACTA;
however, the underlying cash flow from these royalty payments goes directly to pay the interest, and then the principal, on
the Company&rsquo;s non-recourse notes payable. Payment of the interest and the ultimate repayment of principal of these
notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. The Company&rsquo;s drug
development activities are performed by a limited group of third party vendors. If any of these vendors were unable to
perform their services, this could significantly impact the Company&rsquo;s ability to complete its drug development
activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt; text-indent: 0in"><I>Risks from Third Party Manufacturing
and Distribution Concentration </I>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23.05pt">The Company relies on single source
manufacturers for API and finished product manufacturing of RAPIVAB. Additionally, the Company relies upon a single third party
to provide warehousing and distribution services for RAPIVAB. Delays in the manufacture or distribution of any product could adversely
impact the commercial revenue and future procurement stockpiling of RAPIVAB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0 11.5pt; text-indent: 0in"><B><I>Credit Risk</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">Cash equivalents and investments are financial
instruments which potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance
Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances may exceed the amount
of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative
to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest
rates, the Company maintains a portfolio of investments with an average maturity of approximately 18 months or less. Other than
product sale receivables discussed above, the majority of the Company&rsquo;s receivables from collaborations are due from the
U.S. Government, for which there is no assumed credit risk.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"><B></B></P>

<!-- Field: Page; Sequence: 55; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-bottom: 0"><B>BIOCRYST PHARMACEUTICALS, INC.</B><BR>
<B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<BR>
(In thousands, except per share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"><B>Note&nbsp;2&nbsp;&mdash; Furniture
and Equipment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">Furniture and equipment consisted of the
following at December&nbsp;31:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2014</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2013</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left">Furniture and fixtures</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">542</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">600</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Office equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,115</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,266</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Software</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,423</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,448</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Laboratory equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,786</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,721</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Leased equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">63</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">63</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.1pt">Leasehold improvements</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">5,303</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">5,316</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,232</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,414</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.1pt">Less accumulated depreciation and amortization</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">(14,025</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">(14,108</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.75pt">Furniture and equipment, net</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">207</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">306</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">Depreciation and amortization expense
for the years ended December&nbsp;31, 2014, 2013 and 2012 was $177, $304 and $628, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"><B>Note 3&mdash; Royalty Monetization</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 0in"><I>Overview</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">On March&nbsp;9, 2011, the Company completed
a $30,000&nbsp;financing transaction to monetize certain future royalty and milestone payments under the Shionogi Agreement, pursuant
to which Shionogi licensed from the Company the rights to market RAPIACTA in Japan and, if approved for commercial sale, Taiwan.
The Company received net proceeds of $22,691&nbsp;from the transaction after transaction costs of $4,309&nbsp;and the establishment
of a $3,000&nbsp;interest reserve account by Royalty Sub, available to help cover interest shortfalls in the future. All of the
interest reserve account has been fully utilized with the September 2012 interest payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">As part of the transaction, the Company
entered into a purchase and sale agreement dated as of March&nbsp;9, 2011 with Royalty Sub, whereby the Company transferred to
Royalty Sub, among other things, (i)&nbsp;its rights to receive certain royalty and milestone payments from Shionogi arising under
the Shionogi Agreement, and (ii)&nbsp;the right to receive payments under a Japanese yen/US dollar foreign currency hedge arrangement
(as further described below, the &ldquo;Currency Hedge Agreement&rdquo;) put into place by the Company in connection with the transaction.
Royalty payments will be paid by Shionogi in Japanese yen and milestone payments will paid in U.S. dollars. The Company&rsquo;s
collaboration with Shionogi was not impacted as a result of this transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><I>Non-Recourse Notes Payable</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">On March&nbsp;9, 2011, Royalty Sub completed
a private placement to institutional investors of $30,000 in aggregate principal amount of its PhaRMA Senior Secured 14.0% Notes
due 2020 (the &ldquo;PhaRMA Notes&rdquo;). The PhaRMA Notes were issued by Royalty Sub under an Indenture, dated as of March&nbsp;9,
2011 (the &ldquo;Indenture&rdquo;), by and between Royalty Sub and U.S. Bank National Association, as Trustee. Principal and interest
on the PhaRMA Notes issued are payable from, and are secured by, the rights to royalty and milestone payments under the Shionogi
Agreement transferred by the Company to Royalty Sub and payments, if any, made to Royalty Sub under the Currency Hedge Agreement.
The PhaRMA Notes bear interest at 14%&nbsp;per annum, payable annually in arrears on September&nbsp;1st of each year (the &ldquo;Payment
Date&rdquo;). The Company remains entitled to receive any royalties and milestone payments related to sales of peramivir by Shionogi
following repayment of the PhaRMA Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">Royalty Sub&rsquo;s obligations to pay
principal and interest on the PhaRMA Notes are obligations solely of Royalty Sub and are without recourse to any other person,
including the Company, except to the extent of the Company&rsquo;s pledge of its equity interests in Royalty Sub in support of
the PhaRMA Notes. The Company may, but is not obligated to, make capital contributions to a capital account that may be used to
redeem, or on up to one occasion pay any interest shortfall on, the PhaRMA Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt"></P>

<!-- Field: Page; Sequence: 56; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-bottom: 0"><B>BIOCRYST PHARMACEUTICALS, INC.</B><BR>
<B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<BR>
(In thousands, except per share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">In September&nbsp;2013, Royalty Sub paid
$1,844 of interest on the PhaRMA Notes from royalty payments received from RAPIACTA &reg; sales from the preceding four calendar
quarters. This payment resulted in an obligation shortfall of approximately $2,356 associated with accrued interest due September&nbsp;3,
2013. As stipulated under the PhaRMA Notes Indenture, if the amount available for payment on any Payment Date is insufficient
to pay all of the interest due on a Payment Date, the shortfall in interest will accrue interest at the interest rate applicable
to the PhaRMA Notes compounded annually. Accordingly, commencing in September&nbsp;2013, the Company began accruing interest at
14%&nbsp;per annum on the interest shortfall of $2,356.  In March, June and August of 2014, Royalty Sub paid additional interest of $446, $1,882 and $70, respectively, bringing
the 2013 shortfall down to $222 as of September 30, 2014. Under the terms of the Indenture, Royalty Sub&rsquo;s inability to pay
the full amount of interest payable in September&nbsp;2013 by the next succeeding Payment Date for the PhaRMA Notes, which was
September&nbsp;1, 2014, constituted an event of default. Accordingly, the PhaRMA Notes and related accrued interest have been
classified as current liabilities on the December 31, 2014 balance sheet. As a result of the event of default under the PhaRMA
Notes, the holders of the PhaRMA Notes may pursue acceleration of the PhaRMA Notes, may foreclose on the collateral securing the
PhaRMA Notes and the equity interest in Royalty Sub and exercise other remedies available to them under the Indenture in respect
of the PhaRMA Notes. In such event, the Company may not realize the benefit of future royalty payments that might otherwise accrue
to it following repayment of the PhaRMA Notes and it might otherwise be adversely affected. Due to the non-recourse nature of
the PhaRMA Notes, in the event of any potential acceleration or foreclosure, the primary impact to the Company would be the loss
of future royalty payments from Shionogi and legal costs associated with retiring the PhaRMA Notes. In addition, the Company may
incur costs associated with liquidating the related Currency Hedge Agreement, which would no longer be required in the event of
foreclosure, or if the PhaRMA Notes cease to be outstanding. As the PhaRMA Notes are the obligation of Royalty Sub and non-recourse
to the Company, the event of default of the PhaRMA Notes is not expected to have a significant impact on the Company&rsquo;s future
results of operations or cash flows. In addition to the 2013 interest shortfall, Royalty Sub was unable to make the 2014 interest
payment of $4,200 on the September 1, 2014 Payment Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">The Indenture does not contain any financial
covenants. The Indenture includes customary representations and warranties of Royalty Sub, affirmative and negative covenants of
Royalty Sub, Events of Default and related remedies, and provisions regarding the duties of the Trustee, indemnification of the
Trustee, and other matters typical for indentures used in structured financings of this type.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">As of December&nbsp;31, 2014, the aggregate
fair value of the PhaRMA Notes was estimated to be approximately 50% of its carrying value of $30,000. The estimated fair value
of the PhaRMA Notes is classified as Level 2 in the fair value hierarchy as defined in U.S. GAAP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">The PhaRMA Notes are redeemable at
the option of Royalty Sub at any time at a redemption price equal to the outstanding principal balance of the PhaRMA Notes being
redeemed plus accrued and unpaid interest through the redemption date on the PhaRMA Notes being redeemed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"><I>Foreign Currency Hedge</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">In connection with the issuance by Royalty
Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in
the value of the Japanese yen relative to the U.S. dollar. Under the Currency Hedge Agreement, the Company has the right to purchase
dollars and sell yen at a rate of 100 yen per dollar for which the Company may be required to pay a premium in each year from
2015 through 2020, provided the Currency Hedge Agreement remains in effect. A payment of $1,950&nbsp;will be required if, on May&nbsp;18
of the relevant year, the U.S. dollar is worth 100 yen or less as determined in accordance with the Currency Hedge Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">The
Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore mark to market adjustments are recognized in
the Company&rsquo;s Consolidated Statement of Comprehensive Loss. Cumulative mark to market adjustments in 2014, 2013 and 2012
resulted in a gain of $5,487, $5,294 and a loss of $749, respectively. The Company is also required to post collateral in connection
with the mark to market adjustments based on defined thresholds. As of December&nbsp;31, 2014 and 2013, no collateral was posted
under the Currency Hedge Agreement. The Company will not be required at any time to post collateral exceeding the maximum premium
payments remaining payable under the Currency Hedge Agreement. As of December 31, 2014, the maximum amount of hedge collateral
the Company may be required to post is $11.7 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>Note&nbsp;4&nbsp;&mdash; Lease Obligations
and Other Contingencies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">The Company has the following minimum payments
under operating lease obligations that existed at December&nbsp;31, 2014:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 85%; text-align: left">2015</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">739</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">383</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">384</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">356</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">366</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.1pt">Thereafter</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">186</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.75pt">Total minimum payments</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">2,414</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt"></P>

<!-- Field: Page; Sequence: 57; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-bottom: 0"><B>BIOCRYST PHARMACEUTICALS, INC.</B><BR>
<B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<BR>
(In thousands, except per share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">The obligations in the preceding table are
primarily related to the Company&rsquo;s leases for buildings in Birmingham, Alabama and Durham, North Carolina. The lease for
the Company&rsquo;s headquarters in Durham, North Carolina expires June&nbsp;30, 2020. The lease for the existing facility in
Alabama expires June&nbsp;30, 2016; however, in October 2015, the Company will lease an additional approximate 35 square feet
in Birmingham to house its new research facilities. The Company expects to begin construction on its new research facility in
2015 and this lease obligates the Company for $5,148 through 2026. Rent expense for operating leases was $633, $526, and $629
in 2014, 2013, and 2012, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"><B>Note&nbsp;5&nbsp;&mdash; Stockholders&rsquo;
Equity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt"><B><I>Sales of Common Stock </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">On November&nbsp;6, 2013, the Company filed
a $125,000 shelf registration statement on Form S-3 with the SEC. This shelf registration statement was declared effective in November
2013 and allows us to sell securities, including common stock, preferred stock, depository shares, stock purchase contracts, warrants
and units, from time to time at prices and on terms to be determined at the time of sale. On June 3, 2014, the Company issued 11,500
shares of common stock for gross proceeds of $115,000 under this $125,000 shelf registration statement. Net proceeds were approximately
$106,600 after deducting underwriting discounts and offering expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">In August 2013, the Company completed
a public offering of 4,600 shares of its common stock at a price of $4.40 per share, which included the underwriters&rsquo;
over-allotment allocation of an additional 600 shares. Net proceeds were approximately $18,500 after deducting underwriting
discounts and offering expenses. Shares of common stock in this offering were sold under the $70,000 shelf registration
statement declared effective in July 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">In June 2011, the Company entered into
an At Market Issuance Sales Agreement (the &ldquo;ATM Agreement&rdquo;) with McNicoll, Lewis&nbsp;&amp; Vlak (&ldquo;MLV&rdquo;)
pursuant to which the Company was able to sell $70,000 in shares of its common stock at current market prices under a Form S-3
registration statement with MLV acting as the sales agent. During 2012, the Company sold an aggregate of 4,516 shares of common
stock at an average per share price of $4.08 pursuant to the ATM Agreement for net proceeds of $17,805. During 2013, the Company
sold an aggregate of 2,883 shares of common stock at an average per share price of $1.85 pursuant to the Agreement for net proceeds
of $5,218.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt"><B><I>Annual Incentive Award Paid in Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">On March&nbsp;15, 2012, the Company issued
193 shares of restricted common stock in lieu of a cash payment to employees as payment for their annual incentive award earned
in 2011. The number of shares issued was based on the total value of the annual incentive earned in 2011 of $1,542, less $535 in
withholding taxes paid in cash on the employees&rsquo; behalf, divided by the closing common stock price on March&nbsp;15, 2012
of $5.23 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"><B>Note&nbsp;6&nbsp;&mdash; Stock-Based
Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0 11.5pt; text-indent: 0in"><B><I>Stock Incentive Plan</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">As of December&nbsp;31, 2014, the Company
had two stock-based employee compensation plans, the Stock Incentive Plan (&ldquo;Incentive Plan&rdquo;) and the Employee Stock
Purchase Plan (&ldquo;ESPP&rdquo;), both which were amended and restated in March 2014 and approved by the Company&rsquo;s stockholders
in May 2014. Stock-based compensation expense of $10,177 ($9,963 of expense related to the Incentive Plan, $214 of expense related
to the ESPP) was recognized during 2014, while $4,368 ($4,253 of expense related to the Incentive Plan, $115 of expense related
to the ESPP) was recognized during 2013, and $4,167 ($4,010 of expense related to the Incentive Plan, $157 of expense related to
the ESPP) was recognized during 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">The Company accounts for stock-based compensation
in accordance with FASB authoritative guidance regarding share-based payments. Total stock-based compensation was allocated as
follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Year Ended December&nbsp;31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2014</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2013</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2012</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%; text-align: left">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">8,906</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">3,664</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">3,511</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.1pt">General and administrative</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">1,271</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">704</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">656</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.75pt">Total stock-based compensation expense</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">10,177</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">4,368</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">4,167</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">The Company grants stock option awards and restricted stock
unit awards to its employees, directors, and consultants under the Incentive Plan. Under the Incentive Plan, stock option awards
are granted with an exercise price equal to the market price of the Company&rsquo;s stock at the date of grant. Commencing March&nbsp;1,
2011, stock option awards granted to employees generally vest 25% each year until fully vested after four years. In January 2013,
the Company made retention grants of stock option awards and restricted stock units. These awards vest 50% each year until fully
vested after two years. In August 2013 and December 2014, the Company issued 1,032 and 1,250 performance-based stock options,
respectively. These awards vest upon successful completion of specific development milestones. As of December 31, 2014, 50% of
the August 2013 grants have vested based upon achievement of two milestones (1) successful completion of the OPuS-1 clinical trial
for which vesting occurred in the second quarter of 2014, and 2) FDA approval of RAPIVAB for which vesting occurred in the fourth
quarter of 2014.) Thus, as of December&nbsp;31, 2014, 50% of the August 2013 performance-based grants and 100% of the December
2014 performance-based grants remain unvested and no compensation expense has been recognized for these portions of the previously
issued performance-based grants. Stock option awards granted to non-employee directors of the Company generally vest monthly over
one year. All stock option awards have contractual terms of 5 to 10&nbsp;years. The vesting exercise provisions of all awards
granted under the Incentive Plan are subject to acceleration in the event of certain stockholder-approved transactions, or upon
the occurrence of a change in control as defined in the Incentive Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23pt"></P>

<!-- Field: Page; Sequence: 58; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-bottom: 0"><B>BIOCRYST PHARMACEUTICALS, INC.</B><BR>
<B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<BR>
(In thousands, except per share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23pt">Related activity under the Incentive Plan is
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Awards<BR> Available</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Options<BR> Outstanding</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Weighted<BR> Average<BR> Exercise<BR> Price</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%; text-align: left">Balance at December&nbsp;31, 2011</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">2,009</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">7,858</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">6.21</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Plan amendment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,700</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Restricted stock awards granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(415</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Restricted stock awards cancelled</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">86</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Stock option awards granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,617</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,617</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.65</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Stock option awards exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(350</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.58</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.1pt; padding-left: 10pt">Stock option awards cancelled</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">1,052</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">(1,052</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.26</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Balance at December&nbsp;31, 2012</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,815</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,073</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.09</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Restricted stock awards granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(310</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Restricted stock awards cancelled</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">53</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Stock option awards granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,277</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,277</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.05</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Stock option awards exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(563</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.37</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.1pt; padding-left: 10pt">Stock option awards cancelled</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">1,801</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">(1,801</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.22</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Balance at December&nbsp;31, 2013</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,082</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,986</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.99</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Plan amendment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,750</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Restricted stock awards granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(593</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Restricted stock awards cancelled</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Stock option awards granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,965</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,965</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10.99</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Stock option awards exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,258</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.78</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.1pt; padding-left: 10pt">Stock option awards cancelled</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">88</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">(88</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.83</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.75pt">Balance at December&nbsp;31, 2014</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">2,362</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">9,605</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.21</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">For stock option awards granted under the
Incentive Plan during 2014, 2013 and 2012, the fair value was estimated on the date of grant using a Black-Scholes option pricing
model and the assumptions noted in the table below. The weighted average grant date fair value of these awards granted during
2014, 2013 and 2012 was $8.02, $1.28, and $3.24, respectively. The fair value of the stock option awards is amortized to expense
over the vesting periods using a straight-line expense attribution method. The following explanations describe the assumptions
used by the Company to value the stock option awards granted during 2014, 2013, and 2012. The expected life is based on the average
of the assumption that all outstanding stock option awards will be exercised at full vesting and the assumption that all outstanding
stock option awards will be exercised at the midpoint of the current date (if already vested) or at full vesting (if not yet vested)
and the full contractual term. The expected volatility represents the volatility over the most recent period corresponding with
the expected life. The Company has assumed no expected dividend yield, as dividends have never been paid to stockholders and will
not be for the foreseeable future. The weighted average risk-free interest rate is the implied yield currently available on zero-coupon
government issues with a remaining term equal to the expected term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"><B>Weighted Average Assumptions for Stock
Option Awards Granted under the Incentive Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2014</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2013</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2012</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%; text-align: left">Expected Life</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">5.5</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">4.7</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">5.4</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected Volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">87</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">84</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">87</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Expected Dividend Yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.0</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.0</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.0</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Risk-Free Interest Rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.6</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.7</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.9</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt"></P>

<!-- Field: Page; Sequence: 59; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-bottom: 0"><B>BIOCRYST PHARMACEUTICALS, INC.</B><BR>
<B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<BR>
(In thousands, except per share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">The total intrinsic value of stock option
awards exercised under the Incentive Plan was $8,522 during 2014, $738 during 2013, $877 and during 2012. The intrinsic value represents
the total proceeds (fair market value at the date of exercise, less the exercise price, times the number of stock option awards
exercised) received by all individuals who exercised stock option awards during the period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23pt">The following table summarizes, at December&nbsp;31,
2014, by price range: (1)&nbsp;for stock option awards outstanding under the Incentive Plan, the number of stock option awards
outstanding, their weighted average remaining life and their weighted average exercise price; and (2)&nbsp;for stock option awards
exercisable under the Plan, the number of stock option awards exercisable and their weighted average exercise price:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD>
    <TD COLSPAN="4">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD COLSPAN="9" STYLE="border-bottom: black 1.1pt solid; text-align: center; text-indent: 0in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Outstanding</B></FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD COLSPAN="5" STYLE="border-bottom: black 1.1pt solid; text-align: center; text-indent: 0in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exercisable</B></FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="padding-bottom: 1.1pt"><B><U>Range</U></B></TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1.1pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: center; text-indent: 0in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Number</B></FONT></TD><TD STYLE="border-bottom: black 1.1pt solid; text-align: center; text-indent: 0in">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1.1pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: center; text-indent: 0in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Weighted<BR>
Average</B></FONT><BR>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Remaining</B></FONT><BR>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Life</B></FONT></TD><TD STYLE="border-bottom: black 1.1pt solid; text-align: center; text-indent: 0in">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1.1pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: center; text-indent: 0in"><B>Weighted<BR>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Average<BR>
Exercise</B></FONT><BR>
Price</B></TD><TD STYLE="border-bottom: black 1.1pt solid; text-align: center; text-indent: 0in">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1.1pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: center; text-indent: 0in"><B>Number</B></TD><TD STYLE="border-bottom: black 1.1pt solid; text-align: center; text-indent: 0in">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1.1pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: center; text-indent: 0in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Weighted</B></FONT><BR>
Average</B></FONT><BR>
<B>Exercise</B></FONT><BR>
<B>Price</B></TD><TD STYLE="border-bottom: black 1.1pt solid; text-align: center; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 3%"><B>$</B></TD><TD STYLE="width: 2%; font-weight: bold; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>0</B></FONT></TD>
    <TD STYLE="width: 6%; text-align: center"><B>to</B></TD>
    <TD STYLE="width: 27%"><B>3</B></TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2,236</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">7.2</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1.52</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,145</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1.59</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD>
    <TD><B>&nbsp;</B></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>3</B></FONT></TD>
    <TD STYLE="text-align: center"><B>to</B></TD>
    <TD><B>6</B></TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,214</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.8</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.59</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,955</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.35</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD>
    <TD><B>&nbsp;</B></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>6</B></FONT></TD>
    <TD STYLE="text-align: center"><B>to</B></TD>
    <TD><B>9</B></TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,380</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.2</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.12</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,197</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.11</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD>
    <TD><B>&nbsp;</B></TD><TD STYLE="font-weight: bold; text-align: right">9<FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>
</B></FONT></TD>
    <TD STYLE="text-align: center"><B>to</B></TD>
    <TD><B>12</B></TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,315</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.9</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11.16</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">554</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11.62</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD>
    <TD><B>&nbsp;</B></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>12</B></FONT></TD>
    <TD STYLE="text-align: center"><B>to</B></TD>
    <TD><B>15</B></TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">456</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.2</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12.69</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">365</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12.53</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD>
    <TD><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>15
                   </B></FONT></TD>
    <TD STYLE="text-align: center"><B>to</B></TD>
    <TD><B>18</B></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: black 1.1pt solid; text-align: right">4</TD><TD STYLE="border-bottom: black 1.1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.0</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: right">15.45</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: black 1.1pt solid; text-align: right">4</TD><TD STYLE="border-bottom: black 1.1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: right">15.45</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD>
    <TD><B>$</B></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: right">0<FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></TD>
    <TD STYLE="text-align: center"><B>to</B></TD>
    <TD><B>18</B></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">9,605</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.8</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: right">$</TD><TD STYLE="text-align: right">6.21</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">5,220</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: right">$</TD><TD STYLE="text-align: right">5.73</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23pt">The weighted average remaining contractual life
of stock option awards exercisable under the Incentive Plan at December&nbsp;31, 2014 was 5.2 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">The aggregate intrinsic value of stock
option awards outstanding and exercisable under the Incentive Plan at December&nbsp;31, 2014 was $33,698. The aggregate intrinsic
value represents the value (the period&rsquo;s closing market price, less the exercise price, times the number of in-the-money
stock option awards) that would have been received by all stock option award holders under the Incentive Plan had they exercised
their stock option awards at the end of the year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">The total fair value of the stock option
awards vested under the Incentive Plan was $2,844 during 2014, $3,483 during 2013, and $3,373 during 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">As of December&nbsp;31, 2014, the number
of stock option awards vested and expected to vest under the Incentive Plan is 8,580. The weighted average exercise price of these
stock option awards is $6.27 and their weighted average remaining contractual life is 6.6&nbsp;years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">The following table summarizes the changes
in the number and weighted-average grant-date fair value of non-vested stock option awards during 2014:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Non-Vested<BR> Stock
    Option<BR> Awards</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Weighted Average<BR>
    Grant-Date Fair<BR> Value</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left">Balance December&nbsp;31, 2013</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">4,209</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">1.50</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Stock option awards granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,965</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.76</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Stock option awards vested</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,789</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.59</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.1pt">Stock option awards forfeited</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.75pt">Balance December&nbsp;31, 2014</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right"><P STYLE="margin: 0pt 0">4,385</P>


</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.27</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23pt">As of December&nbsp;31, 2014, there was approximately
$9,987 of total unrecognized compensation cost related to non-vested employee stock option awards and restricted stock units granted
by the Company. That cost is expected to be recognized as follows: $4,101 in 2015, $2,968 in 2016, $2,502 in 2017, and $416 in
2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0 11.5pt; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 60; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-bottom: 0"><B>BIOCRYST PHARMACEUTICALS, INC.</B><BR>
<B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-bottom: 0"><B>(In thousands, except per share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0 11.5pt; text-indent: 0in"><B><I>Employee Stock Purchase
Plan</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">The Company has reserved a total of 1,475&nbsp;shares
of common stock to be purchased under the ESPP, of which 538&nbsp;shares remain available for purchase at December&nbsp;31, 2014.
Eligible employees may authorize up to 15% of their salary to purchase common stock at the lower of 85% of the beginning or 85%
of the ending price during six-month purchase intervals. No more than 3 shares may be purchased by any one employee at the six-month
purchase dates and no employee may purchase stock having a fair market value at the commencement date of $25 or more in any one
calendar year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">There were 49, 89 and 110 shares of common
stock purchased under the ESPP in 2014, 2013, and 2012, respectively, at a weighted average price per share of $6.29, $1.39, and
$2.93, respectively. Expense of $214, $115, and $157, related to the ESPP was recognized during 2014, 2013, and 2012, respectively.
Compensation expense for shares purchased under the ESPP related to the purchase discount and the &ldquo;look-back&rdquo; option
were determined using a Black-Scholes option pricing model. The weighted average grant date fair values of shares granted under
the ESPP during 2014, 2013, and 2012, were $4.41, $1.27, and $1.48, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>Note&nbsp;7&nbsp;&mdash; Income Taxes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">The Company has incurred net losses since
inception and, consequently, has not recorded any U.S.&nbsp;Federal and state income tax expense or benefit. The differences between
the Company&rsquo;s effective tax rate and the statutory tax rate in 2014, 2013, and 2012 are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2014</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2013</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2012</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%; text-align: left">Income tax benefit at federal statutory rate (35%)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(15,816</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(10,538</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(13,678</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">State and local income taxes net of federal tax benefit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,286</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(839</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,470</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Permanent items</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">258</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">738</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">754</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Rate change</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,892</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,147</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Expiration of attribute carryforwards</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">373</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">242</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,135</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Research and development tax credits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(748</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,206</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">829</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(115</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,144</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">281</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.1pt">Change in valuation allowance</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">17,312</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">8,567</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">7,002</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.75pt">Income tax expense</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">The Company recognizes the impact of a
tax position in its financial statements if it is more likely than not that the position will be sustained on audit based on the
technical merits of the position. The Company has concluded that it has an uncertain tax position pertaining to its research and
development credit carryforwards. The Company has established these credits based on information and calculations it believes are
appropriate and the best estimate of the underlying credit. Any changes to the Company&rsquo;s unrecognized tax benefits are offset
by an adjustment to the valuation allowance and there would be no impact on the Company&rsquo;s financial statements. The Company
does not expect its unrecognized tax benefits to change significantly over the next 12 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">A reconciliation of the beginning and
ending amount of unrecognized tax benefits is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2014</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2013</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left">Balance at January&nbsp;1,</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">284</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Additions to current year tax positions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">176</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Additions to tax positions of prior years</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">241</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.1pt">Reductions for tax provisions of prior years</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.75pt">Balance at December&nbsp;31,</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">472</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">284</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">Additionally, utilization of the Company&rsquo;s
net operating loss carryforwards could be subject to a substantial annual limitation due to ownership change limitations as described
in Section&nbsp;382 of the Internal Revenue Code and similar state provisions. The Company has performed an analysis as of December&nbsp;31,
2014, and has determined that it has incurred changes in control as defined under Section&nbsp;382. These ownership changes may
limit the amount of net operating losses that can be utilized annually to offset future taxable income and tax.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt"></P>

<!-- Field: Page; Sequence: 61; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-bottom: 0"><B>BIOCRYST PHARMACEUTICALS, INC.</B><BR>
<B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<BR>
(In thousands, except per share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">Significant components of the Company&rsquo;s
deferred tax assets and liabilities are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2014</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2013</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Deferred tax assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; text-align: left; padding-left: 10pt">Net federal and state operating losses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">135,922</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">119,940</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Research and development credits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,096</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37,348</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Fixed assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,073</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,119</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Reserve for inventories</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,612</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Deferred revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,798</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,151</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,086</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,282</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.1pt; padding-left: 10pt">Other</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">1,178</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">311</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total deferred tax assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">187,153</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">167,763</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><P STYLE="margin: 0">Deferred tax liabilities:</P>


</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Foreign currency derivative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.1pt solid">(2,285</TD><TD STYLE="text-align: left; border-bottom: Black 1.1pt solid">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.1pt solid">(207</TD><TD STYLE="text-align: left; border-bottom: Black 1.1pt solid">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total deferred tax liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.1pt solid">(2,285</TD><TD STYLE="text-align: left; border-bottom: Black 1.1pt solid">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.1pt solid">(207</TD><TD STYLE="text-align: left; border-bottom: Black 1.1pt solid">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.1pt">Valuation allowance</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">(184,868</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: right">(167,556</TD><TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.75pt">Net deferred tax assets</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.75pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 2.75pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23pt">The majority of the Company&rsquo;s deferred
tax assets relate to net operating loss and research and development carryforwards that can only be realized if the Company is
profitable in future periods. It is uncertain whether the Company will realize any tax benefit related to these carryforwards.
Accordingly, the Company has provided a full valuation allowance against the net deferred tax assets due to uncertainties as to
their ultimate realization. The valuation allowance will remain at the full amount of the deferred tax assets until it is more
likely than not that the related tax benefits will be realized. The Company&rsquo;s valuation allowance increased by $17,312 in
2014, $8,567 in 2013, and $7,002 in 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23pt">As of December&nbsp;31, 2014, the Company had federal operating loss carryforwards of
$356,686, state operating loss carryforwards of $361,572, and research and development credit carryforwards of $38,096, which
will expire at various dates from 2015 through 2034. The federal losses begin to expire in 2018, the state losses begin to expire
in 2015 and the research and development contracts begin to expire in 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">The Company&rsquo;s federal and state
operating loss carryforwards include $7,890 of excess tax benefits related to a deduction from the exercise of stock options. The
tax benefit of these deductions has not been recognized in deferred tax assets. If utilized, the benefits from these deductions
will be recorded as adjustments to additional paid-in capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">Tax years 2011-2013 remain open to examination
by the major taxing jurisdictions to which the Company is subject. Additionally, years prior to 2011 are also open to examination
to the extent of loss and credit carryforwards from those years. The Company recognizes interest and penalties accrued related
to unrecognized tax benefits as components of its income tax provision. However, there were no provisions or accruals for interest
and penalties in 2014, 2013, and 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"><B>Note&nbsp;8&nbsp;&mdash; Employee
401(k) Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">In January 1991, the Company adopted an
employee retirement plan (&ldquo;401(k) Plan&rdquo;) under Section&nbsp;401(k) of the Internal Revenue Code covering all employees.
Employee contributions may be made to the 401(k) Plan up to limits established by the Internal Revenue Service. Company matching
contributions may be made at the discretion of the Board of Directors. The Company made matching contributions of $361, $313, and
$418, in 2014, 2013, and 2012, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"><B>Note&nbsp;9&nbsp;&mdash; Collaborative
and Other Research and Development Contracts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt"><I>U.S.&nbsp;Department of Health and Human
Services (&ldquo;BARDA/HHS&rdquo;).</I> In January 2007, the U.S.&nbsp;Department of Health and Human Services (&ldquo;BARDA/HHS&rdquo;)
awarded the Company a $102,661, four-year contract for the advanced development of peramivir for the treatment of influenza. During
2009, peramivir clinical development shifted to focus on intravenous delivery and the treatment of hospitalized patients. To support
this focus, a September 2009 contract modification was awarded to extend the i.v. peramivir program and to increase funding by
$77,191. On February&nbsp;24, 2011, the Company announced that BARDA/HHS had awarded it a $55,000 contract modification, intended
to fund completion of the Phase 3 development of i.v. peramivir for the treatment of patients hospitalized with influenza. That
contract modification brought the total contract award from BARDA/HHS to $234,852 and provided funding to support the filing of
a NDA to seek regulatory approval for i.v. peramivir in the U.S. In December 2013, BioCryst submitted an NDA filing for i.v. peramivir
to the FDA and the NDA was approved in December 2014. The BARDA/HHS contract expired on June 30, 2014 upon completion of all responsibilities
under the contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt"><I></I></P>

<!-- Field: Page; Sequence: 62; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-bottom: 0"><B>BIOCRYST PHARMACEUTICALS, INC.</B><BR>
<B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<BR>
(In thousands, except per share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt"><I>National Institute of Allergy and Infectious
Diseases (&ldquo;NIAID/HHS&rdquo;).</I> In September 2013, NIAID/HHS contracted with the Company for the development of BCX4430
as a treatment for Marburg virus disease. NIAID/HHS, part of the National Institutes of Health, made an initial award of $5,000
to the Company. The total funding under this contract as of December 31, 2014 could be up to $28,717, if all contract options
are exercised by NIAID/HHS, over a five year period. The goals of this contract are to file IND applications for intravenous i.v.
and i.m. BCX4430 for the treatment of Marburg virus disease, and to conduct an initial Phase 1 human clinical trial. The aggregate
$28,717 contract and option funding supports the appropriate IND-enabling program and the initial clinical trial. As of December&nbsp;31,
2014, a total of $22,302 has been awarded under exercised options within the contract. BCX4430 is the lead compound in the Company&rsquo;s
BSAV research program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">The contracts with BARDA/HHS and NIAID/HHS
are cost-plus-fixed-fee contracts. That is, the Company is entitled to receive reimbursement for all costs incurred in accordance
with the contracts provisions that are related to the development of peramivir and BCX4430 plus a fixed fee, or profit. BARDA/HHS
and NIAID/HHS will make periodic assessments of progress and the continuation of the contract is based on the Company&rsquo;s performance,
the timeliness and quality of deliverables, and other factors. The government has rights under certain contract clauses to terminate
these contracts. These contracts are terminable by the government at any time for breach or without cause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt"><I>Shionogi&nbsp;&amp; Co., Ltd. (&ldquo;Shionogi&rdquo;).</I>
In February 2007, the Company entered into an exclusive license agreement with Shionogi to develop and commercialize peramivir
in Japan for the treatment of seasonal and potentially life-threatening human influenza. Under the terms of the agreement, Shionogi
obtained rights to injectable formulations of peramivir in Japan. The Company developed peramivir under a license from UAB and
will owe sublicense payments to them on any future milestone payments and/or royalties received by the Company from Shionogi. In
October 2008, the Company and Shionogi amended the license agreement to expand the territory covered by the agreement to include
Taiwan and to provide rights for Shionogi to perform a Phase&nbsp;3 clinical trial in Hong Kong. Shionogi has commercially launched
peramivir under the commercial name RAPIACTA in Japan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt"><I>Green Cross Corporation (&ldquo;Green
Cross&rdquo;).</I> In June 2006, the Company entered into an agreement with Green Cross to develop and commercialize peramivir
in Korea. Under the terms of the agreement, Green Cross will be responsible for all development, regulatory, and commercialization
costs in Korea. The Company received a one-time license fee of $250. The license also provides that the Company will share in profits
resulting from the sale of peramivir in Korea, including the sale of peramivir to the Korean government for stockpiling purposes.
Furthermore, Green Cross will pay the Company a premium over its cost to supply peramivir for development and any future marketing
of peramivir products in Korea.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt"><I>Mundipharma International Holdings
Limited (&ldquo;Mundipharma&rdquo;).</I> In February 2006, the Company entered into an exclusive, royalty bearing right and license
agreement with Mundipharma for the development and commercialization of forodesine, a Purine Nucleoside Phosphorylase (&ldquo;PNP&rdquo;)
inhibitor, for use in oncology (the &ldquo;Original Agreement&rdquo;). Under the terms of the Original Agreement, Mundipharma obtained
rights to forodesine in markets across Europe, Asia, and Australasia in exchange for a $10,000 up-front payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">The Company deferred revenue recognition
of the $10,000 up-front payment that was received from Mundipharma in February&nbsp;2006 because the Company was involved in the
continued development of forodesine. Amortization of this revenue commenced in February&nbsp;2006 and was initially scheduled to
end in October&nbsp;2017, which is the date of expiration for the last-to-expire patent covered by the agreement. The Company also
deferred revenue recognition of a $5,000 payment received from Mundipharma in connection with the initiation of a clinical trial
in 2007. Amortization of this deferred revenue commenced in 2007 and was initially scheduled to end in October&nbsp;2017. Under
its agreement with AECOM/IRL, the Company paid sublicense payments related to these upfront cash payments received from Mundipharma.
Expense recognition of these sublicense payments was deferred and recognized under the same term as the related deferred revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">On November&nbsp;11, 2011, the Company
entered into the Amended and Restated License and Development Agreement (the &ldquo;Amended and Restated Agreement&rdquo;) with
Mundipharma, amending and restating the Original Agreement. Under the terms of the Amended and Restated Agreement, Mundipharma
obtained worldwide rights to forodesine. Commencing on November&nbsp;11, 2011, Mundipharma controls the development and commercialization
of forodesine and assumes all future development and commercialization costs. The Amended and Restated Agreement provides for the
possibility of future event payments totaling $15,000 for achieving specified regulatory events for certain indications and tiered
royalties ranging from mid to high single-digit percentages of net product sales in each country where forodesine is sold by Mundipharma.
These royalties are subject to downward adjustments based on the then-existing patent coverage and/or the availability of generic
compounds in each country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">The Amended and Restated Agreement is
a multiple element arrangement for accounting purposes, in which the Company is required to deliver to Mundipharma both the worldwide
rights to forodesine in the field of oncology and the transfer of product data and know-how to permit Mundipharma to develop and
commercialize forodesine (the &ldquo;Knowledge Transfer&rdquo;). The Company accounted for these elements as a combined unit of
accounting as they do not have stand-alone value to Mundipharma. The worldwide license rights were granted to Mundipharma on November&nbsp;11,
2011 and the Knowledge Transfer was completed during the first quarter of 2012. Completion of the Knowledge Transfer concluded
the Company&rsquo;s obligations under the Amended and Restated Agreement and resulted in the recognition of the unamortized deferred
revenue and expense of $7,766 and $1,864, respectively, in the Consolidated Statements of Comprehensive Loss for the year ended
December&nbsp;31, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt"></P>

<!-- Field: Page; Sequence: 63; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-bottom: 0"><B>BIOCRYST PHARMACEUTICALS, INC.</B><BR>
<B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<BR>
(In thousands, except per share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt"><I>Albert Einstein College of Medicine
of Yeshiva University and Industrial Research, Ltd. (&ldquo;AECOM&rdquo; and &ldquo;IRL&rdquo; respectively).</I> In June 2000,
the Company licensed a series of potent inhibitors of PNP from AECOM and IRL, (collectively, the &ldquo;Licensors&rdquo;). The
lead product candidates from this collaboration are forodesine and ulodesine. The Company has obtained worldwide exclusive rights
to develop and ultimately distribute these, or any other, product candidates that might arise from research on these inhibitors.
The Company has the option to expand the Agreement to include other inventions in the field made by the investigators or employees
of the Licensors. The Company agreed to use commercially reasonable efforts to develop these drugs. In addition, the Company has
agreed to pay certain milestone payments for each licensed product (which range in the aggregate from $1,400 to almost $4,000&nbsp;per
indication) for future development of these inhibitors, single digit royalties on net sales of any resulting product made by the
Company, and to share approximately one quarter of future payments received from other third-party partners, if any. In addition,
the Company has agreed to pay annual license fees, which can range from $150 to $500, that are creditable against actual royalties
and other payments due to the Licensors. This agreement may be terminated by the Company at any time by giving 60&nbsp;days advance
notice or in the event of material uncured breach by the Licensors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23pt">In May 2010, the Company amended the licensee
agreement through which the Company obtained worldwide exclusive rights to develop and ultimately distribute any product candidates
that might arise from research on a series of PNP inhibitors, including forodesine and ulodesine. Under the terms of the amendment,
the Licensors agreed to accept a reduction of one-half in the percentage of future payments received from third-party sub licensees
of the licensed PNP inhibitors that must be paid to the Licensors. This reduction does not apply to (i)&nbsp;any milestone payments
the Company may receive in the future under its license agreement dated February&nbsp;1, 2006 with Mundipharma and (ii)&nbsp;royalties
received from its sub licensees in connection with the sale of licensed products, for which the original payment rate will remain
in effect. The rate of royalty payments to the Licensors based on net sales of any resulting product made by the Company remains
unchanged.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">In consideration for these modifications
in 2010, the Company issued to the Licensors shares of its common stock with an aggregate value of $5,911 and paid the Licensors
$90 in cash. Additionally, at the Company&rsquo;s sole option and subject to certain agreed upon conditions, any future non-royalty
payments due to be paid by it to the Licensors under the license agreement may be made either in cash, in shares of its common
stock, or in a combination of cash and shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">On November&nbsp;17, 2011, the Company
further amended its agreements with the Licensors whereby the Licensors agreed to accept a reduction of one-half in the percentage
of Net Proceeds (as defined) received by the Company under its Amended and Restated Agreement with Mundipharma that will be paid
to AECOM/IRL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">On June&nbsp;19, 2012, the Company further
amended its agreements with AECOM/IRL whereby the parties clarified the definition of the field with respect to PNP inhibition
and AECOM/IRL agreed to exclusive worldwide license of BCX4430 to BioCryst for any antiviral use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">At its sole option and subject to certain
agreed upon conditions, any future non-royalty payments due to be paid by the Company to AECOM/IRL under the license agreement
may be made either in cash, in shares of the Company&rsquo;s common stock, or in a combination of cash and shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt"><I>The University of Alabama at Birmingham
(&ldquo;UAB&rdquo;).</I> The Company currently has agreements with UAB for influenza neuraminidase and complement inhibitors. Under
the terms of these agreements, UAB performed specific research for the Company in return for research payments and license fees.
UAB has granted the Company certain rights to any discoveries in these areas resulting from research developed by UAB or jointly
developed with the Company. The Company has agreed to pay single digit royalties on sales of any resulting product and to share
in future payments received from other third-party partners. The Company has completed the research under the UAB agreements. These
two agreements have initial 25-year terms, are automatically renewable for five-year terms throughout the life of the last patent
and are terminable by the Company upon three months notice and by UAB under certain circumstances. Upon termination both parties
shall cease using the other parties&rsquo; proprietary and confidential information and materials, the parties shall jointly own
joint inventions and UAB shall resume full ownership of all UAB licensed products. There is currently no activity between the Company
and UAB on these agreements, but when the Company licenses this technology, such as in the case of the Shionogi and Green Cross
agreements, or commercializes products related to these programs, the Company will owe sublicense fees or royalties on amounts
it receives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"><B>Note&nbsp;10&nbsp;&mdash; Quarterly
Financial Information (Unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">First</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Second</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Third</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Fourth</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">2014 Quarters</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 40%; text-align: left; padding-left: 10pt">Revenues</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">3,458</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">1,466</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">3,238</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">5,446</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Net Loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,137</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(14,649</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,731</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,672</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Basic and diluted net loss per share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.17</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.23</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.12</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.16</TD><TD STYLE="text-align: left">)</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; width: 40%">2013 Quarters</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 12%">&nbsp;</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 12%">&nbsp;</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 12%">&nbsp;</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 12%">&nbsp;</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Revenues</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,554</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">821</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,389</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10,567</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Net Loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,506</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12,172</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,001</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,429</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Basic and diluted net loss per share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.09</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.23</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.14</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.09</TD><TD STYLE="text-align: left">)</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"><B></B></P>

<!-- Field: Page; Sequence: 64; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-bottom: 0"><B>BIOCRYST PHARMACEUTICALS, INC.</B><BR>
<B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<BR>
(In thousands, except per share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"><B>Note&nbsp;11&nbsp;&mdash; Recent Accounting
Pronouncements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">In August 2014, the Financial Accounting Standards
Board (&ldquo;FASB&rdquo;) issued ASU No. 2014-15 &ndash; <I>Presentation of Financial Statements - Going Concern (Subtopic 205-40):
Disclosure of Uncertainties about an Entity&rsquo;s Ability to Continue as a Going Concern,</I> which defines management&rsquo;s
responsibility to evaluate, at each annual and interim reporting period, whether there are conditions or events that raise substantial
doubt about an entity&rsquo;s ability to continue as a going concern within one year after the date the financial statements are
issued and to provide related footnote disclosures in certain circumstances. In connection with each annual and interim period,
management must assess if there is substantial doubt about the company&rsquo;s ability to continue as a going concern within one
year after the issuance date.&nbsp; Disclosures are required if conditions give rise to substantial doubt.&nbsp; This standard
is effective for all companies in the first annual period ending after December 15, 2016, and interim periods thereafter, with
early adoption permitted. The Company is currently evaluating the impact of the adoption of this standard on its financial statements
and disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">In May 2014, the FASB issued Accounting Standard
Update (&quot;ASU&quot;) 2014-09 &ndash; <I>Revenue from Contracts with Customers</I>, which provides a single, comprehensive revenue
recognition model for all contracts with customers. The core principal of this ASU is that an entity should recognize revenue when
it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to
be entitled in exchange for those goods or services. This ASU also requires additional disclosure about the nature, amount, timing
and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments
and assets recognized from costs incurred to obtain or fulfill a contract. This ASU is effective for annual periods, and interim
periods within those annual periods, beginning after December 15, 2016. Early adoption is not permitted and companies can transition
to the new standard under the full retrospective method or the modified retrospective method. The Company is currently evaluating
the impact this ASU will have on its consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">In June 2014, the FASB issued ASU 2014-12
&ndash; <I>Compensation &ndash; Stock Compensation: Accounting for Share-Based Payments When the Terms of an Award Provide That
a Performance Target Could be Achieved after the Requisite Service Period,</I> which provides explicit guidance for the accounting
treatment for these types of awards. The ASU requires that a performance target that affects vesting and that could be achieved
after the requisite service period be treated as a performance condition. As such, the performance target should not be reflected
in estimating the grant-date fair value of the award. This update is effective for annual periods and interim periods within those
annual periods beginning after December 15, 2014. Early adoption is permitted. The Company does not expect this ASU will have
a material impact on its consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 65; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-bottom: 0; margin-left: 0; text-align: center; text-indent: 0in"><B>Report of Independent
Registered Public Accounting Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Board of Directors and Stockholders</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BioCryst Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">We have audited the consolidated
balance sheets of BioCryst Pharmaceuticals, Inc. as of December 31, 2014 and 2013, and the related consolidated statements of
comprehensive loss, stockholders&rsquo; equity and cash flows for each of the three years in the period ended
December&nbsp;31, 2014. These financial statements are the responsibility of the Company&rsquo;s management. Our
responsibility is to express an opinion on these financial statements based on our audits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">We conducted our audits in accordance with
the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform
the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes
examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial
statement presentation. We believe that our audits provide a reasonable basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">In our opinion, the financial statements
referred to above present fairly, in all material respects, the consolidated financial position of BioCryst Pharmaceuticals, Inc.
at December&nbsp;31, 2014 and 2013, and the consolidated results of its operations and its cash flows for each of the three years
in the period ended December&nbsp;31, 2014, in conformity with U.S.&nbsp;generally accepted accounting principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">We also have audited, in accordance with
the standards of the Public Company Accounting Oversight Board (United States), BioCryst Pharmaceuticals, Inc.&rsquo;s internal
control over financial reporting as of December&nbsp;31, 2014, based on criteria established in <I>Internal Control-Integrated
Framework</I> issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework) and our report dated
March&nbsp;2, 2015 expressed an unqualified opinion thereon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">/s/&nbsp;Ernst&nbsp;&amp; Young LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 328.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Raleigh, North Carolina&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">March 2, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 66; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="background-color: yellow"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-bottom: 0; margin-left: 0; text-align: center; text-indent: 0.5in"><B>Report of Independent
Registered Public Accounting Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Board of Directors and Stockholders</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BioCryst Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">We have audited BioCryst Pharmaceuticals,
Inc.&rsquo;s internal control over financial reporting as of December&nbsp;31, 2014, based on criteria established in <I>Internal
Control-Integrated Framework</I> issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework)
(the COSO criteria). BioCryst Pharmaceuticals, Inc.&rsquo;s management is responsible for maintaining effective internal control
over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting included in
the accompanying Management&rsquo;s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion
on the Company&rsquo;s internal control over financial reporting based on our audit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">We conducted our audit in accordance with
the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform
the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all
material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk
that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the
assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit
provides a reasonable basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">A company&rsquo;s internal control over financial
reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation
of financial statements for external purposes in accordance with generally accepted accounting principles. A company&rsquo;s internal
control over financial reporting includes those policies and procedures that (1)&nbsp;pertain to the maintenance of records that,
in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2)&nbsp;provide
reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with
generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with
authorizations of management and directors of the company; and (3)&nbsp;provide reasonable assurance regarding prevention or timely
detection of unauthorized acquisition, use, or disposition of the company&rsquo;s assets that could have a material effect on the
financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">Because of its inherent limitations, internal
control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness
to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree
of compliance with the policies or procedures may deteriorate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">In our opinion, BioCryst Pharmaceuticals,
Inc. maintained, in all material respects, effective internal control over financial reporting as of December&nbsp;31, 2014, based
on the COSO criteria.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">We also have audited, in accordance with
the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheets of BioCryst Pharmaceuticals,
Inc. as of December&nbsp;31, 2014 and 2013, and the related consolidated statements of comprehensive loss, stockholders&rsquo;
equity, and cash flows for each of the three years in the period ended December&nbsp;31, 2014 of BioCryst Pharmaceuticals, Inc.
and our report dated March&nbsp;2, 2015 expressed an unqualified opinion thereon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">/s/&nbsp;Ernst&nbsp;&amp; Young LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 328.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Raleigh, North Carolina</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">March 2, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 67; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 9%; text-indent: 0in"><A NAME="i9"></A><font style="font: 10pt Times New Roman, Times, Serif"><b>ITEM&nbsp;9.</b></font></td>
    <td style="width: 91%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</i></b></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">None.</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 9%; text-indent: 0in"><A NAME="i9a"></A><font style="font: 10pt Times New Roman, Times, Serif"><b>ITEM&nbsp;9A.</b></font></td>
    <td style="width: 91%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>CONTROLS AND PROCEDURES</i></b></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 0in"><B>Evaluation of Disclosure Controls and
Procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">We maintain a set of disclosure controls
and procedures that are designed to ensure that information relating to BioCryst Pharmaceuticals, Inc. required to be disclosed
in our periodic filings under the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), is recorded, processed,
summarized and reported in a timely manner under the Exchange Act of 1934. We carried out an evaluation as required by paragraph
(b)&nbsp;of Rule&nbsp;13a-15 or Rule&nbsp;15d-15 under the Exchange Act, under the supervision and with the participation of management,
including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure
controls and procedures (as defined in Rule&nbsp;13a-15(e) or Rule&nbsp;15d-15 under the Exchange Act). Based upon that evaluation,
the Chief Executive Officer and Chief Financial Officer concluded that, as of December&nbsp;31, 2014, our disclosure controls
and procedures are effective. We believe that our disclosure controls and procedures will ensure that information required to
be disclosed in the reports filed or submitted by us under the Exchange Act is recorded, processed, summarized and reported within
the time periods specified in the rules and forms of the Securities and Exchange Commission, and include controls and procedures
designed to ensure that information required to be disclosed by us in such reports is accumulated and communicated to our management,
including our Chairman and Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding
required disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-indent: 0in"><B>Management&rsquo;s Report on Internal
Control Over Financial Reporting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">Management of BioCryst Pharmaceuticals,
Inc. is responsible for establishing and maintaining adequate internal control over financial reporting and for the assessment
of the effectiveness of internal control over financial reporting. As defined by the Securities and Exchange Commission, internal
control over financial reporting is a process designed by, or under the supervision of our principal executive and principal financial
officers and effected by our Board of Directors, management and other personnel, to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of the financial statements in accordance with U.S.&nbsp;generally accepted
accounting principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">Our internal control over financial reporting
is supported by written policies and procedures that (1)&nbsp;pertain to the maintenance of records that, in reasonable detail,
accurately and fairly reflect our transactions and dispositions of our assets; (2)&nbsp;provide reasonable assurance that transactions
are recorded as necessary to permit preparation of the financial statements in accordance with generally accepted accounting principles,
and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and
(3)&nbsp;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition
of our assets that could have a material effect on the financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">Because of its inherent limitations, internal
control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness
to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree
of compliance with the policies or procedures may deteriorate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">In connection with the preparation of our
annual financial statements, management has undertaken an assessment of the effectiveness of our internal control over financial
reporting as of December&nbsp;31, 2014, based on criteria established in Internal Control&nbsp;&mdash; Integrated Framework issued
by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework) (the COSO Framework). Management&rsquo;s
assessment included an evaluation of the design of our internal control over financial reporting and testing of the operational
effectiveness of those controls.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">Based on this assessment, management has
concluded that as of December&nbsp;31, 2014, our internal control over financial reporting was effective. Management believes our
internal control over financial reporting will provide reasonable assurance regarding the reliability of financial reporting and
the preparation of financial statements for external purposes in accordance with U.S.&nbsp;generally accepted accounting principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">Ernst&nbsp;&amp; Young LLP, the independent
registered public accounting firm that audited our financial statements included in this report, has issued an attestation report
on the Company&rsquo;s internal control over financial reporting, a copy of which appears on page&nbsp;67 of this annual report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Changes in Internal Control over Financial Reporting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">There
have been no changes in our internal control over financial reporting that occurred during the quarter ended December&nbsp;31,
2014 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 9%; text-indent: 0in"><A NAME="i9b"></A><font style="font: 10pt Times New Roman, Times, Serif"><b>ITEM&nbsp;9B.</b></font></td>
    <td style="width: 91%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>OTHER INFORMATION</i></b></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 68; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-bottom: 0; margin-left: 0; text-align: center; text-indent: 0in"><B>PART&nbsp;III</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 9%; text-indent: 0in"><A NAME="i10"></A><font style="font: 10pt Times New Roman, Times, Serif"><b>ITEM&nbsp;10.</b></font></td>
    <td style="width: 91%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</i></b></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt">The information required by this item is
set forth under the captions <I>&ldquo;Items to be Voted on&nbsp;&mdash; 1. Election of Directors,&rdquo; &ldquo;Executive Officers,&rdquo;
&ldquo;Section&nbsp;16(a) Beneficial Ownership Reporting Compliance&rdquo;</I> and <I>&ldquo;Corporate Governance&rdquo;</I> in
our definitive Proxy Statement for the 2015 Annual Meeting of Stockholders and incorporated herein by reference.</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 9%; text-indent: 0in"><A NAME="i11"></A><font style="font: 10pt Times New Roman, Times, Serif"><b>ITEM&nbsp;11.</b></font></td>
    <td style="width: 91%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>EXECUTIVE COMPENSATION</i></b></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">The information required by this item
is set forth under the captions <I>&ldquo;Compensation Discussion and Analysis,&rdquo; &ldquo;Summary Compensation Table,&rdquo;
&ldquo;Grants of Plan-Based Awards in 2014,&rdquo; &ldquo;Outstanding Equity Awards at December&nbsp;31, 2014,&rdquo; &ldquo;2014
Option Exercises and Stock Vested,&rdquo; &ldquo;Potential Payments Upon Termination or Change in Control,&rdquo; &ldquo;2014 Director
Compensation,&rdquo; &ldquo;Compensation Committee Interlocks and Insider Participation&rdquo;</I> and <I>&ldquo;Compensation Committee
Report&rdquo;</I> in our definitive Proxy Statement for the 2015 Annual Meeting of Stockholders and incorporated herein by reference.</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 9%; text-indent: 0in"><A NAME="i12"></A><font style="font: 10pt Times New Roman, Times, Serif"><b>ITEM&nbsp;12.</b></font></td>
    <td style="width: 91%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</i></b></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">The information required by this item is
set forth under the captions <I>&ldquo;Equity Compensation Plan Information&rdquo;</I> and &ldquo; <I>Security Ownership of Certain
Beneficial Owners and Management&rdquo;</I> in our definitive Proxy Statement for the 2015 Annual Meeting of Stockholders and
incorporated herein by reference.</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 9%; text-indent: 0in"><A NAME="i13"></A><font style="font: 10pt Times New Roman, Times, Serif"><b>ITEM&nbsp;13.</b></font></td>
    <td style="width: 91%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</i></b></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">The information required by this item is
set forth under the captions <I>&ldquo;Certain Relationships and Related Transactions&rdquo;</I> and &ldquo; <I>Corporate Governance&rdquo;
</I>in our definitive Proxy Statement for the 2015 Annual Meeting of Stockholders and incorporated herein by reference.</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 9%; text-indent: 0in"><A NAME="i14"></A><font style="font: 10pt Times New Roman, Times, Serif"><b>ITEM&nbsp;14.</b></font></td>
    <td style="width: 91%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>PRINCIPAL ACCOUNTING FEES AND SERVICES</i></b></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 23pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">The information required by this item is
set forth under the caption <I>&ldquo;2. Ratification of Appointment of Independent Registered Public Accountants&rdquo;</I> in
our definitive Proxy Statement for the 2015 Annual Meeting of Stockholders and incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 69; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-bottom: 0; margin-left: 0; text-align: center; text-indent: 0in"><B>PART&nbsp;IV</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 9%; text-indent: 0in"><A NAME="i15"></A><font style="font: 10pt Times New Roman, Times, Serif"><b>ITEM&nbsp;15.</b></font></td>
    <td style="width: 91%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>EXHIBITS, FINANCIAL STATEMENT SCHEDULES</i></b></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0 11.5pt; text-indent: 0in"><I>(a)&nbsp;Financial Statements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 0in">The following financial statements appear
in Item&nbsp;8 of this Form&nbsp;10-K:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Page&nbsp;in<BR> Form&nbsp;10-K</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left">Consolidated Balance Sheets at December&nbsp;31, 2014 and 2013</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">44</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Consolidated Statements of Comprehensive Loss for the years ended December&nbsp;31, 2014, 2013 and 2012</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Consolidated Statements of Cash Flows for the years ended December&nbsp;31, 2014, 2013 and 2012</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">46</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Consolidated Statements of Stockholders&rsquo; Equity for the years ended December&nbsp;31, 2014, 2013 and 2012</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Notes to Consolidated Financial Statements</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Report of Independent Registered Public Accounting Firm on Consolidated Financial Statements</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">65</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Report of Independent Registered Public Accounting Firm on Internal Control</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">66</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">No financial statement schedules are included
because the information is either provided in the consolidated financial statements or is not required under the related instructions
or is inapplicable and such schedules therefore have been omitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">(b)&nbsp; <I>Exhibits.</I> See Index of
Exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 70; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-bottom: 0; margin-left: 0; text-align: center; text-indent: 0in"><A NAME="sign"></A><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">Pursuant to the requirements of Section&nbsp;13
or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized on March 2, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="RIGHT" STYLE="width: 40%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">BIOCRYST PHARMACEUTICALS, INC.</font></td></tr>
<tr>
    <td style="text-indent: 0in">&nbsp;</td>
    <td colspan="2" style="text-indent: 0in">&nbsp;</td></tr>
<tr>
    <TD STYLE="text-indent: 0in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT>By:</td>
    <td style="vertical-align: bottom; text-indent: 0in"></td>
    <td style="vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in; border-bottom: black 1.1pt solid">/s/&nbsp;Jon
        P. Stonehouse</P></td></tr>
<tr>
    <td style="vertical-align: top; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: bottom; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">Jon P. Stonehouse</font></td></tr>
<tr>
    <td style="vertical-align: top; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: bottom; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif"><i>Chief Executive Officer</i></font></td></tr>
</table><BR STYLE="clear: both">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 23pt">Pursuant to the requirements of the Securities
Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities
indicated on March 2, 2015:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 35%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: bottom; width: 2%; text-indent: 0in">&nbsp;</td>
    <td style="width: 31%; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: bottom; width: 2%; text-indent: 0in">&nbsp;</td>
    <td style="width: 30%; text-indent: 0in">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD STYLE="text-align: center">
        <P STYLE="text-indent: 0in"><B><U>Signature</U></B></P></td>
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in">&nbsp;</td>
    <TD STYLE="text-align: center">
        <P STYLE="text-indent: 0in"><B><U>Title(s)</U></B></P></td></tr>
<tr>
    <td style="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in; border-bottom: black 1.1pt solid">/s/&nbsp;Jon
        P. Stonehouse</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.75pt 0.8pt 0 0; text-indent: 0in">(Jon P. Stonehouse)</P></td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-align: center; text-indent: 0in">President, Chief
        Executive Officer and Director</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-align: center; text-indent: 0in">(Principal Executive
        Officer)</P></td></tr>
<tr>
    <td style="text-indent: 0in">&nbsp;</td>
    <td colspan="2" style="text-indent: 0in">&nbsp;</td>
    <td colspan="2" style="text-indent: 0in">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in; border-bottom: black 1.1pt solid">/s/&nbsp;Thomas
        R. Staab II</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.75pt 0.8pt 0 0; text-indent: 0in">(Thomas R. Staab II)</P></td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-align: center; text-indent: 0in">Senior Vice President,
        Chief Financial Officer and Treasurer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-align: center; text-indent: 0in">(Principal Financial
        Officer and Principal Accounting Officer)</P></td></tr>
<tr>
    <td style="text-indent: 0in">&nbsp;</td>
    <td colspan="2" style="text-indent: 0in">&nbsp;</td>
    <td colspan="2" style="text-indent: 0in">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in; border-bottom: black 1.1pt solid">/s/ George
        B. Abercrombie</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.75pt 0.8pt 0 0; text-indent: 0in">(George B. Abercrombie)</P></td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">Director</font></td></tr>
<tr>
    <td style="text-indent: 0in">&nbsp;</td>
    <td colspan="2" style="text-indent: 0in">&nbsp;</td>
    <td colspan="2" style="text-indent: 0in">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in; border-bottom: black 1.1pt solid">/s/&nbsp;Fred
        E. Cohen</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.75pt 0.8pt 0 0; text-indent: 0in">(Fred E. Cohen, M.D., D. Phil)</P></td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">Director</font></td></tr>
<tr>
    <td style="text-indent: 0in">&nbsp;</td>
    <td colspan="2" style="text-indent: 0in">&nbsp;</td>
    <td colspan="2" style="text-indent: 0in">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in; border-bottom: black 1.1pt solid">/s/ Stanley
        C. Erck</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.75pt 0.8pt 0 0; text-indent: 0in">(Stanley C. Erck)</P></td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">Director</font></td></tr>
<tr>
    <td style="text-indent: 0in">&nbsp;</td>
    <td colspan="2" style="text-indent: 0in">&nbsp;</td>
    <td colspan="2" style="text-indent: 0in">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in; border-bottom: black 1.1pt solid">/s/ Nancy Hutson</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.75pt 0.8pt 0 0; text-indent: 0in">(Nancy Hutson, Ph.D.)</P></td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">Director</font></td></tr>
<tr>
    <td style="text-indent: 0in">&nbsp;</td>
    <td colspan="2" style="text-indent: 0in">&nbsp;</td>
    <td colspan="2" style="text-indent: 0in">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in; border-bottom: black 1.1pt solid">/s/ Peder K.
        Jensen</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.75pt 0.8pt 0 0; text-indent: 0in">(Peder K. Jensen, M.D.)</P></td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">Director</font></td></tr>
<tr>
    <td style="text-indent: 0in">&nbsp;</td>
    <td colspan="2" style="text-indent: 0in">&nbsp;</td>
    <td colspan="2" style="text-indent: 0in">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in; border-bottom: black 1.1pt solid">/s/&nbsp;Kenneth
        B. Lee, Jr.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.75pt 0.8pt 0 0; text-indent: 0in">(Kenneth B. Lee, Jr.)</P></td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">Director</font></td></tr>
<tr>
    <td style="text-indent: 0in">&nbsp;</td>
    <td colspan="2" style="text-indent: 0in">&nbsp;</td>
    <td colspan="2" style="text-indent: 0in">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in; border-bottom: black 1.1pt solid">/s/&nbsp;Charles
        A. Sanders</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.75pt 0.8pt 0 0; text-indent: 0in">(Charles A. Sanders,&nbsp;M.D.)</P></td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: bottom; text-indent: 0in">&nbsp;</td>
    <td style="vertical-align: top; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">Director</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 71; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-bottom: 0; margin-left: 0; text-align: center; text-indent: 0in"><A NAME="exh"></A><B>INDEX TO EXHIBITS</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: right"><B><U>Number</U></B></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: center"><B><U>Description</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.1</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Third Restated Certificate
of Incorporation of Registrant. Incorporated by reference to Exhibit 3.1 to the Company&rsquo;s Form 8-K filed December 22, 2006.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.2</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certificate of Amendment to
the Third Restated Certificate of Incorporation of Registrant. Incorporated by reference to Exhibit 3.1 to the Company&rsquo;s
Form 8-K filed July 24, 2007.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.4</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certificate of Amendment to
the Third Restated Certificate of Incorporation of Registrant. Incorporated by reference to Exhibit 3.1 to the Company&rsquo;s
Form 8-K filed May 8, 2014.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.5</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certificate of Increase of
Authorized Number of Shares of Series B Junior Participating Preferred Stock. Incorporated by reference to Exhibit 3.1 to the
Company&rsquo;s Form 8-K filed November 4, 2008.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.6</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certificate of Increase of
Authorized Number of Shares of Series B Junior Participating Preferred Stock. Incorporated by reference to Exhibit 3.2 to the
Company&rsquo;s Form 8-K filed May 8, 2014.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.7</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amended and Restated Bylaws
of Registrant effective October 29, 2008. Incorporated by reference to Exhibit 3.2 to the Company&rsquo;s Form 8-K filed November
4, 2008.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.3</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Indenture, dated as of March
9, 2011 by and between JPR Royalty Sub LLC and U.S. Bank National Association, as trustee. Incorporated by reference to Exhibit
4.3 of the Company&rsquo;s Form 10-Q filed May&nbsp;6, 2011.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.1&amp;</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Amended
and Restated Stock Incentive Plan dated March 29, 2012. Incorporated by reference to Exhibit 10.1 of the Company&rsquo;s Form
8-K, filed May 25, 2012.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.2&amp;</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Amended
and Restated Stock Incentive Plan dated March 8, 2014. Incorporated by reference to Exhibit 10.1 to the Company&rsquo;s Form 8-K
filed May 5, 2014.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.3&amp;</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Amended
and Restated Employee Stock Purchase Plan dated March 29, 2012. Incorporated by reference to the Company&rsquo;s Form 8-K, filed
May 25, 2012.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.4&amp;</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Amended
and Restated Employee Stock Purchase Plan dated March 8, 2014. Incorporated by reference to Exhibit 10.2 to the Company&rsquo;s
Form 8-K filed May 5, 2014.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.5</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Notice of Grant of
Non-Employee Director Automatic Stock Option and Stock Option Agreement. Incorporated by reference to Exhibit 10.4 of the Company&rsquo;s
Form 10-K filed March 4, 2008.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.6&amp;</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form
of Notice of Grant of Stock Option and Stock Option Agreement. Incorporated by reference to Exhibit 10.5 of the Company&rsquo;s
Form 10-K filed March 4, 2008.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(10.7)&amp;</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Form
of Notice of Grant of Stock Option and Stock Option Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(10.8)&amp;</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form
of Notice of Grant of Restricted Stock Unit Award and Restricted Stock Unit Agreement.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.9&amp;</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Annual
Incentive Plan. Incorporated by reference to Exhibit 10.1 of the Company&rsquo;s Form 8-K filed March 12, 2012.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.10&amp;</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Executive
Relocation Policy. Incorporated by reference to Exhibit 10.2 of the Company&rsquo;s Form&nbsp;10-K filed March 4, 2008.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.11&amp;</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amended
and Restated Employment Letter Agreement dated February 14, 2007, by and between the Company and Jon P. Stonehouse. Incorporated
by reference to Exhibit 10.12 to the Company&rsquo;s Form 10-K for the year ended December 31, 2006, filed March 14, 2007.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.12&amp;</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Employment
Letter Agreement between BioCryst Pharmaceuticals, Inc. and Thomas R. Staab II, dated May 23, 2011. Incorporated by reference
to Exhibit 10.1 of the Company&rsquo;s Form 8-K filed May 25, 2011.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.13&amp; </FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Employment
Letter Agreement between BioCryst Pharmaceuticals, Inc. and William P. Sheridan dated June 12, 2008. Incorporated by reference
to Exhibit 10.27 of the Company&rsquo;s Form 10-Q filed August 8, 2008.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.14&amp; </FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Employment
Letter Agreement between BioCryst Pharmaceuticals, Inc. and Yarlagadda S. Babu dated April 27, 2012.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.15&amp;</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Employment
Letter Agreement between BioCryst Pharmaceuticals, Inc. and Alane P. Barnes dated August 8, 2013.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(10.16)&amp;</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Employment
Letter Agreement between BioCryst Pharmaceuticals, Inc. and Lynne Powell dated December 30, 2015.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 72; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.17#</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Agreement dated January 3,
2007, between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services, as amended by Amendment number 1
dated January 3, 2007 and Amendment number 2 dated May 11, 2007. Incorporated by reference to Exhibit 10.3 to the Company&rsquo;s
Form 10-Q filed August 9, 2007. (Portions omitted pursuant to request for confidential treatment.)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.18</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment #3 to the Agreement
between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services, dated October 2, 2007. Incorporated by
reference to Exhibit 10.6 of the Company&rsquo;s Form 10-K filed March 4, 2008.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.19</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment #4 to the Agreement
between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services dated April 3, 2008. Incorporated by reference
to Exhibit 10.29 of the Company&rsquo;s Form 10-Q filed August 8, 2008.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.20</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment #5 to the Agreement
between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services dated July 2, 2008. Incorporated by reference
to Exhibit 10.30 of the Company&rsquo;s Form 10-Q filed August 8, 2008.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.21</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment #6 to the Agreement
between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services dated August&nbsp;18, 2008. Incorporated
by reference to Exhibit 10.1 of the Company&rsquo;s Form 8-K filed November&nbsp;7, 2008.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.22</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment #7 to the Agreement
between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services dated November&nbsp;17, 2008. Incorporated
by reference to Exhibit 10.12 of the Company&rsquo;s Form 10-K filed March&nbsp;6, 2009.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.23</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment #8 to the Agreement
between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services dated March 13, 2009. Incorporated by reference
to Exhibit&nbsp;10.13 of the Company&rsquo;s Form 10-K filed March 9, 2010.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.24</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment #9 to the Agreement
between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services dated September 18, 2009. Incorporated
by reference to Exhibit 10.1 of the Company&rsquo;s Form 10-Q filed November 6, 2009.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.25</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment #10 to the Agreement
between the Company and the U.S. Department of Health &amp; Human Services, dated October 15, 2009. Incorporated by reference
to Exhibit 10.2 of the Company&rsquo;s Form 10-Q filed November 6, 2009.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.26</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment #11 to the Agreement
between the Company and the U.S. Department of Health &amp; Human Services, dated February 23, 2011. Incorporated by reference
to Exhibit 10.25 of the Company&rsquo;s Form 10-K filed March 15, 2011.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.27</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Stop-Work Order from U.S. Department
of Health and Human Services, dated March 26, 2013, relating to Agreement dated January 3, 2007 between the Company and the U.S.
Department of Health and Human Services. Incorporated by reference to Exhibit 10.1 of the Company&rsquo;s Form 10-Q filed May
9, 2013.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.28</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment #13 to the Agreement
between the Company and the U.S. Department of Health &amp; Human Services, dated February 15, 2012.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.29</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment #14 to the Agreement
between the Company and the U.S. Department of Health &amp; Human Services, dated June 4, 2013. Incorporated by reference to Exhibit
10.1 of the Company&rsquo;s Form 10-Q filed June 5, 2013.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.30#</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment #15 to the Agreement
between the Company and the U.S. Department of Health &amp; Human Services, dated September 5, 2013. Incorporated by reference
to Exhibit 10.1 of the Company&rsquo;s Form 10-Q filed November 8, 2013. (Portions omitted pursuant to request for confidential
treatment.)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.31</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment #16 to the Agreement
between the Company and the U.S. Department of Health &amp; Human Services, dated December 17, 2013. Incorporated by reference
to Exhibit 10.1 of the Company&rsquo;s Form 8-K filed December 23, 2013.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.32</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment #17 to the Agreement
between the Company and the U.S. Department of Health &amp; Human Services, dated February 21, 2014. Incorporated by reference
to Exhibit 10.1 of the Company&rsquo;s Form 8-K filed February 26, 2014.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.33</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Order for Supplies or Services
from the U.S. Department of Health &amp; Human Services, dated November 4, 2009. Incorporated by reference to Exhibit 10.16 of
the Company&rsquo;s Form 10-K filed March 9, 2010.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.34</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment #18 to the Agreement
between BioCryst Pharmaceuticals, Inc. and the U.S. Department of Health and Human Services, dated March 28, 2014. Incorporated
by reference to Exhibit 10.1 to the Company&rsquo;s Form 8-K filed April 3, 2014.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.35</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment #19 to the Agreement
between BioCryst Pharmaceuticals, Inc. and the U.S. Department of Health and Human Services, dated April 29, 2014. Incorporated
by reference to Exhibit 10.1 to the Company&rsquo;s Form 8-K filed May 2, 2014.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.36</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment #20 to the Agreement
to the Agreement between BioCryst Pharmaceuticals, Inc. and the U.S. Department of Health and Human Services, dated May 30, 2014.
. Incorporated by reference to Exhibit 10.1 to the Company&rsquo;s Form 8-K filed June 5, 2014.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 73; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.37#</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">License, Development and Commercialization
Agreement dated as of February 28, 2007, by and between the Company and Shionogi &amp; Co., Ltd. Incorporated by reference to
Exhibit 10.4 to the Company&rsquo;s Form 10-Q filed May 10, 2007. (Portions omitted pursuant to request for confidential treatment.)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.38#</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">First Amendment to License,
Development and Commercialization Agreement, effective as of September 30, 2008, between the Company and Shionogi &amp; Co., Ltd.
Incorporated by reference to Exhibit 10.19 to the Company&rsquo;s Form 10-K filed March 6, 2009. (Portions omitted pursuant to
request for confidential treatment.)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.39</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Riverchase Business Park Warehouse
Lease dated July 12, 2000 between RBP, LLC an Alabama Limited Liability Company and the Registrant for office/warehouse space.
Incorporated by reference to Exhibit 10.8 to the Company&rsquo;s Form 10-Q for the second quarter ending June 30, 2000 filed August
8, 2000.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.40</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Third Amendment to Lease Agreement
dated August 7, 2007, by and between Riverchase Capital LLC, a Florida limited liability company, Stow Riverchase, LLC, a Florida
limited liability company, as successor landlord to RBP, LLC and the Company. Incorporated by reference to Exhibit 10.4 of the
Company&rsquo;s Form 10-Q filed August 9, 2007.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.41</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Fourth Amendment to the Lease
Agreement dated February 1, 2012, by and between Riverchase Capital LLC, a Florida limited liability company, Stow Riverchase,
LLC, a Florida limited liability company, as successor landlord to RBP, LLC and the Company. Incorporated by reference to Exhibit
10.27 of the Company&rsquo;s Form 10-K filed March 11, 2013.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(10.42)</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Fifth Amendment to Lease Agreement
dated January 15, 2015, by and between Riverchase Capital LLC, a Florida limited liability company, Stow Riverchase, LLC, a Florida
limited liability company, as successor landlord to RBP, LLC and the Company.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.43</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Stock and Warrant Purchase
Agreement dated as of August 6, 2007, by and among BioCryst Pharmaceuticals, Inc. and each of the Investors identified on the
signature pages thereto. Incorporated by reference to Exhibit 4.1 of the Company&rsquo;s Form 8-K filed August 7, 2007.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.44</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Stock Purchase Agreement, dated
as of February&nbsp;17, 2005, by and among BioCryst Pharmaceuticals, Inc., Baker Bros. Investments, L.P., Baker Biotech Fund II,
L.P., Baker Bros. Investments II, L.P., Baker Biotech Fund&nbsp;II (Z), L.P., Baker/Tisch Investments, L.P., Baker Biotech Fund
III, L.P., Baker Biotech Fund&nbsp;I, L.P., Baker Biotech Fund&nbsp;III (Z), L.P. and 14159, L.P. Incorporated by reference to
Exhibit 4.1 to the Company&rsquo;s Form 8-K filed February&nbsp;17, 2005.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.45#</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Development and License Agreement
dated as of February 1, 2006, by and between BioCryst Pharmaceuticals, Inc. and Mundipharma International Holdings Limited. Incorporated
by reference to Exhibit 10.2 to the Company&rsquo;s Form 8-K/A filed May 2, 2006. (Portions omitted pursuant to request for confidential
treatment.)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.46#</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amended and Restated Development
and License Agreement, dated as of November 11, 2011, by and between BioCryst Pharmaceuticals, Inc. and Mundipharma International
Corporation Limited. Incorporated by reference to Exhibit 10.32 to the Company&rsquo;s Form 10-K filed March 6, 2012. (Portions
omitted pursuant to request for confidential treatment.)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.47#</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">License Agreement dated as
of June 27, 2000, by and among Albert Einstein College of Medicine, Industrial Research, Ltd. and BioCryst Pharmaceuticals, Inc.,
as amended by the First Amendment Agreement dated as of July 26, 2002 and the Second Amendment Agreement dated as of April 15,
2005. Incorporated by reference to Exhibit 10.1 to the Company&rsquo;s Form 8-K filed November 30, 2005. (Portions omitted pursuant
to request for confidential treatment.)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.48#</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Third Amendment Agreement by
and among Albert Einstein College of Medicine, Industrial Research, Ltd. and BioCryst Pharmaceuticals, Inc., dated as of December&nbsp;11,
2009. Incorporated by reference to Exhibit 10.33 to the Company&rsquo;s Form 10-K filed March&nbsp;9, 2010. (Portions omitted
pursuant to request for confidential treatment.)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.49#</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Fourth Amendment Agreement
by and among Albert Einstein College of Medicine, Industrial Research, Ltd. and BioCryst Pharmaceuticals, Inc., dated as of May
5, 2010. Incorporated by reference to Exhibit 10.1 to the Company&rsquo;s Form 10-Q filed August 6, 2010. (Portions omitted pursuant
to request for confidential treatment.)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.50#</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Fifth Amendment Agreement by
and among Albert Einstein College of Medicine, Industrial Research, Ltd. and BioCryst Pharmaceuticals, Inc., dated as of November
17, 2011. Incorporated by reference to Exhibit 10.36 to the Company&rsquo;s Form 10-K filed March 6, 2012. (Portions omitted pursuant
to request for confidential treatment.)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.51#</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Sixth Amendment Agreement by
and among Albert Einstein College of Medicine, Industrial Research, Ltd. and BioCryst Pharmaceuticals, Inc., dated as of June
19, 2012. Incorporated by reference to Exhibit 10.1 to the Company&rsquo;s Form 10-Q filed August 8, 2012. (Portions omitted pursuant
to request for confidential treatment.)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.52</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Purchase and Sale Agreement,
dated as of March 9, 2011 between BioCryst Pharmaceuticals, Inc. and JPR Royalty Sub LLC. Incorporated by reference to Exhibit
10.1 of the Company&rsquo;s Form 10-Q filed May 6, 2011.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.53</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pledge and Security Agreement,
dated as of March 9, 2011 between BioCryst Pharmaceuticals, Inc. and U.S. Bank National Association, as trustee. Incorporated
by reference to Exhibit 10.2 of the Company&rsquo;s Form 10-Q filed May 6, 2011.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.54</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Confirmation of terms and conditions
of ISDA Master Agreement, dated as of March 7, 2011, between Morgan Stanley Capital Services Inc. and BioCryst Pharmaceuticals,
Inc. dated as of March 9, 2011. Incorporated by reference to Exhibit 10.3 of the Company&rsquo;s Form 10-Q filed May 6, 2011.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 74; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.55#</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Agreement, dated as of September&nbsp;12,
2013, between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases. Incorporated by reference
to Exhibit 10.2 of the Company&rsquo;s Form 10-Q filed November&nbsp;8, 2013. (Portions omitted pursuant to request for confidential
treatment.)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.56#</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment #1 to the Agreement
between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated December 26, 2013.&nbsp;&nbsp;Incorporated
by reference to Exhibit 10.51 to the Company&rsquo;s Form 10-K filed on March 10, 2014.&nbsp;&nbsp;(Portions omitted pursuant
to request for confidential treatment.)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.57#</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment #2 to the Agreement
between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated January 24, 2014.&nbsp;&nbsp;Incorporated
by reference to Exhibit 10.52 to the Company&rsquo;s Form 10-K filed on March 10, 2014.&nbsp;&nbsp;(Portions omitted pursuant
to request for confidential treatment.)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.58#</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment #3 to the Agreement
between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated June 17, 2014. Incorporated
by reference to Exhibit 10.5 to the Company&rsquo;s Form 10-Q filed on August 8, 2014.&nbsp;&nbsp;&nbsp;&nbsp;(Portions omitted
pursuant to request for confidential treatment.)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.59#</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment #4 to the Agreement
between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated June 17, 2014. Incorporated
by reference to Exhibit 10.6 to the Company&rsquo;s Form 10-Q filed on August 8, 2014.&nbsp;&nbsp;(Portions omitted pursuant to
request for confidential treatment.)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.60#</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment #5 to the Agreement
between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated August 11, 2014. Incorporated
by reference to Exhibit 10.1 to the Company&rsquo;s Form 10-Q filed on November 7, 2014.&nbsp;&nbsp;(Portions omitted pursuant
to request for confidential treatment.)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.61#</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment #6 to the Agreement
between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated August 27, 2014.&nbsp;&nbsp;Incorporated
by reference to Exhibit 10.2 to the Company&rsquo;s Form 10-Q filed on November 7, 2014.&nbsp;&nbsp;(Portions omitted pursuant
to request for confidential treatment.)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.62#</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment #8 to the Agreement
between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated September 17, 2014.&nbsp;&nbsp;Incorporated
by reference to Exhibit 10.3 to the Company&rsquo;s Form 10-Q filed on November 7, 2014.&nbsp;&nbsp;(Portions omitted pursuant
to request for confidential treatment.)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.63#</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment #9 to the Agreement
between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated October 29, 2014.&nbsp;&nbsp;Incorporated
by reference to Exhibit 10.4 to the Company&rsquo;s Form 10-Q filed on November 7, 2014.&nbsp;&nbsp;(Portions omitted pursuant
to request for confidential treatment.)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(21)</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Subsidiaries of the Registrant.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(23)</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Consent of Ernst &amp; Young,
LLP, Independent Registered Public Accounting Firm.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(31.1)</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certification of the Chief
Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(31.2)</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certification of the Chief
Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(32.1)</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certification pursuant to 18&nbsp;U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(32.2)</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certification pursuant to 18&nbsp;U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(101)</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Financial statements from the
Annual Report on Form 10-K of BioCryst Pharmaceuticals, Inc. for the year ended December 31, 2014, formatted in XBRL: (i) Consolidated
Balance Sheets, (ii) Consolidated Statements of Comprehensive Loss, (iii) Consolidated Statements of Cash Flows, (iv) Consolidated
Statements of Stockholders&rsquo; Equity and (v) Notes to Consolidated Financial Statements.</FONT></TD>
</TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 4%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">#</font></td>
    <td style="width: 96%; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">Confidential treatment granted.</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&amp;</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">Management contracts.</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">(&nbsp;)</font></td>
    <td style="text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">Filed herewith.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">75</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 3pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
